Synthesis of Novel Zwitterionic Polymers: From Functional Surfactants to Therapeutics by Skinner, Matthew
University of Massachusetts Amherst 
ScholarWorks@UMass Amherst 
Doctoral Dissertations Dissertations and Theses 
March 2018 
Synthesis of Novel Zwitterionic Polymers: From Functional 
Surfactants to Therapeutics 
Matthew Skinner 
Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2 
 Part of the Polymer Chemistry Commons 
Recommended Citation 
Skinner, Matthew, "Synthesis of Novel Zwitterionic Polymers: From Functional Surfactants to 
Therapeutics" (2018). Doctoral Dissertations. 1195. 
https://scholarworks.umass.edu/dissertations_2/1195 
This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at 
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized 
administrator of ScholarWorks@UMass Amherst. For more information, please contact 
scholarworks@library.umass.edu. 
  
 
 
 
 
 
 
SYNTHESIS OF NOVEL ZWITTERIONIC POLYMERS: 
FROM FUNCTIONAL SURFACTANTS TO THERAPEUTICS 
 
 
 
 
 
 
 
 
A Dissertation Presented 
 
by 
 
MATTHEW W. SKINNER 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School of the 
University of Massachusetts Amherst in partial fulfillment 
of the requirements for the degree of 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
February 2018 
 
 
Polymer Science and Engineering 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by Matthew W. Skinner 2018 
 
All Rights Reserved 
 
 
 
 
  
 
 
 
 
SYNTHESIS OF NOVEL ZWITTERIONIC POLYMERS: 
FROM FUNCTIONAL SURFACTANTS TO THERAPEUTICS 
 
 
 
 
 
 
 
A Dissertation Presented 
 
by 
 
MATTHEW W. SKINNER 
 
 
 
 
 
Approved as to style and content by: 
 
 
 ____________________________________ 
Todd Emrick, Chair 
 
 
 ____________________________________ 
Ryan Hayward, Member 
 
 
 ____________________________________ 
Sarah Perry, Member 
 
 
 
 
 
 __________________________________  
E. Bryan Coughlin, Department Head 
Polymer Science and Engineering 
 
  
  
DEDICATION 
 
 
To my loving, patient, and devoted parents.
v 
ACKNOWLEDGMENTS 
 I would like to thank my thesis advisor, Todd Emrick, for his guidance and support 
throughout my doctoral research, and for continuously challenging me to develop a 
comprehensive understanding of organic and polymer chemistry, an organized and creative 
approach to solving research problems, and an impactful rhetoric for communicating 
scientific findings.  I would also like to thank the members of my committee, Ryan 
Hayward and Sarah Perry, for their guidance and advice, as well as for pushing me to 
thoroughly probe and comprehend the physical properties and behavior of materials 
synthesized throughout my doctoral research.  This guidance has enriched my dissertation, 
and has given me an understanding of polymer physics which will continue to serve me in 
future research endeavors.  I also wish to express my gratitude to Bryan Coughlin for his 
mentorship and support throughout this process. 
 I wish to acknowledge the funding sources which supported the research 
comprising this dissertation, including the National Science Foundation (NSF) Materials 
Research Science & Engineering Center (MRSEC) on Polymers (DMR-0820506), the 
National Institutes of Health (NIH) under award number R21 CA167674, and the U.S. 
Department of Education Graduate Assistance in Areas of National Need (GAANN) under 
award number P200A150276. 
 I am grateful to Samantha McRae Page, Ryan Selhorst, Sarah Ward, Dr. Banishree 
Saha, Dr. Kaitlyn Wong, Dr. Maria Mora, Dr. Giovanna Crisi, Dr. Richard Arenas, Dr. 
Sallie Schneider, and Yalin Liu for collaborating and enhancing my dissertation research.  
I also thank the faculty and staff of the Polymer Science and Engineering Department for 
vi 
supporting and enriching my research, as well as for providing invaluable guidance 
throughout my graduate studies. 
 Thank you to the members of the Emrick group for providing constructive criticism 
and inciteful evaluation of my work, as well as for establishing an encouraging, engaging, 
and entertaining research environment.  I would like to acknowledge members of The 
Drunken Chickens softball team and the memories we shared; summer softball was an 
experience I looked forward to every year.  I am especially grateful for friends and 
colleagues, including Marcus Cole, Ryan Selhorst, Sarah Ward, Rachel Letteri, Samantha 
McRae Page, Zak Page, Stephen Rosa, Stephen Strassburgh, Adam Hauser, Ned Burnett, 
Ari Shapell, Adam Merzel, Andy Webb, John Brody, and Chris Adams.  I also wish to 
express my gratitude to my parents, Kevin and Susan Skinner, my brother Paul Skinner, 
and my sister-in-law Stephanie Skinner.  Your love, support, and willingness to listen was 
critical to me enduring, enjoying, and ultimately completing this dissertation.  I am 
especially grateful to my parents for helping me realize the importance of scientific 
pursuits.  I wish to acknowledge and thank Finn for greeting me with a smiling face every 
day and always cheering me up after long days in the lab; you are a blessing.  Finally, I 
would like to thank Katherine Brooks.  Thank you for providing me the unwavering love, 
support, and friendship which allowed me to complete my dissertation and helped me 
discover a new sense of pride and confidence. 
 
 
  
vii 
ABSTRACT 
SYNTHESIS OF NOVEL ZWITTERIONIC POLYMERS: 
FROM FUNCTIONAL SURFACTANTS TO THERAPEUTICS 
 
FEBRUARY 2018 
 
MATTHEW W. SKINNER, B.A., WASHINGTON UNIVERSITY IN ST. LOUIS 
 
M.A., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Todd Emrick 
 
 
 This dissertation describes the synthesis, characterization, and investigation of 
novel zwitterionic polymers containing phosphorylcholine (PC), sulfobetaine (SB), and 
functional choline phosphate (CP) zwitterions for use as surfactants, self-assembled 
nanomaterials, and therapeutics.  Facile, reproducible, and modular chemistries were 
utilized for incorporating zwitterions into a range of polymer backbones, and strategies 
were developed for overcoming difficult challenges encountered in zwitterionic polymer 
synthesis, especially related to the varying solubility of zwitterions, hydrophobic polymers, 
and functional comonomers.  Synthetic strategies utilized in this work give access to well-
defined materials with narrow molecular weight distributions, tunable compositions and 
architectures, and versatile chemical functionality.    
 Chapter 2 describes the synthesis of water-soluble PC- and SB-functionalized 
siloxane polymers.  PC- and SB-siloxane homopolymers and block copolymers were 
synthesized using thiol-ene ‘click’ chemistry, and their assembly in water and at oil-water 
interfaces was investigated. 
viii 
 Chapter 3 describes the preparation of zwitterionic block copolymer analogues of 
commercial Pluronic® surfactants.  PC-containing triblock copolymers were prepared with 
tunable zwitterion content (5-47 mole percent) and relatively narrow molecular weight 
distributions.  These block copolymer amphiphiles readily formed nanoparticles in water 
and served as novel surfactants.  Through the copolymerization of PC- and CP-
methacrylate monomers, functional mimics of conventional Pluronic structures became 
amenable to crosslinking and the successful synthesis of nanomaterials and robust gels. 
 Chapter 4 presents the in vivo evaluation of poly(2-methacryloyloxyethyl 
phosphorylcholine)-doxorubicin (polyMPC-Dox) prodrugs for treating human ovarian 
tumors (SKOV-3).  In human ovarian tumor-bearing mice, polyMPC-Dox prodrugs with 
an approximate Dox loading of 19 weight percent accumulated in tumor tissue at twice the 
level of free Dox, and animals treated with polyMPC-Dox exhibited enhanced survival and 
retarded tumor growth compared to conventional Dox treatment. 
 Finally, Chapter 5 augments the polyMPC prodrug concept with the development 
of polymer-temozolomide (TMZ) conjugates intended for glioblastoma treatment.  
PolyMPC-TMZ prodrugs were prepared by the controlled free radical copolymerization of 
MPC and novel TMZ-methacrylate monomers, affording copolymers with random and 
block architectures.  Polymer conjugation significantly improved the solution stability of 
TMZ, and the antitumor activity of polyMPC-TMZ prodrugs was demonstrated in TMZ-
sensitive (U87MG) and TMZ-resistant (T98G) glioblastoma cell lines.  The impact of drug 
loading, polymer architecture, and adjuvant co-delivery on the cytotoxicity of polyMPC-
TMZ conjugates was investigated. 
ix 
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CHAPTER 1 
 
POLYMER ZWITTERIONS: SYNTHESIS, SOLUTION PROPERTIES, AND 
THEIR USE IN SURFACTANTS AND THERAPEUTICS 
1.1 Introduction 
 Polymer zwitterions are hydrophilic polymers utilized in numerous applications, 
including as commercial surfactants and detergents,1,2 biocompatible surfaces and 
matrices,3-5 antifouling coatings,6-9 and scaffolds or encapsulants for sustained drug 
delivery.10-14  Composed of covalently tethered anion-cation pairs (i.e. zwitterions) 
distributed as pendent groups along or within polymer backbones, zwitterionic polymers 
are charge-neutral materials which demonstrate excellent aqueous dispersibility, extensive 
 
Figure 1.1: (A) Examples of zwitterions found in Nature; (B) synthesis of 
phosphorylcholine (PC), sulfobetaine (SB), and choline phosphate (CP) zwitterions. 
cellular membrane
lipid bilayer
(A)
(B)
choline phosphate (CP)
sulfobetaine (SB)
NMe3
phosphorylcholine (PC)
zwitterionic 
hydrophilic groups
phospholipid
amino acids
  2 
hydration in water,15-18 and nonfouling properties.6-9  Additionally, several examples are 
biomimetic and biocompatible.3-5  As depicted in Figure 1.1A, zwitterions are pervasive 
throughout Nature: free amino acids exist as zwitterions at physiological pH, and many of 
the polar head groups of phospholipids which comprise cellular membranes are 
zwitterionic moieties.19  Drawing inspiration from these natural examples, organic and 
polymer chemists have generated a diverse library of synthetic zwitterionic functionality, 
preparing analogues composed of varying cationic (e.g., alkylammonium, pyridinium, 
sulfonium, etc.)20,21 and anionic (e.g., phosphate, sulfonate, or carboxylate)9 chemical 
groups.  This thesis focuses on three classes of zwitterions—phosphorylcholine (PC), 
sulfobetaine (SB), and choline phosphate (CP) zwitterions—typically prepared by 
alkyamine-mediated ring-opening of phosphorous- and sulfur-containing heterocycles 
(Figure 1.1B). 
 PC- and SB-functionalized polymers prepared from 2-methacryloyloxyethyl 
phosphorylcholine (MPC)22,23 and sulfobetaine methacrylate (SBMA), respectively, 
represent two of the most extensively utilized and studied zwitterionic polymeric 
variants.24,25  As shown in Figure 1.2A, polyMPC and polySBMA are readily prepared 
using conventional free radical polymerization chemistries, as well as using controlled 
polymerization techniques (e.g., atom transfer radical polymerization or reversible 
addition-fragmentation chain transfer)26-29 which give access to PC- and SB-polymers with 
narrow molecular weight distributions, functional end groups, and complex architectures.  
In general, polyMPC-based materials are biocompatible,3,8,30 resist protein and bacterial 
adsorption,6,7,31 and demonstrate excellent aqueous solubility which is unaffected by 
temperature or salt.18  PolySBMA, on the other hand, exhibits upper critical solution 
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temperature miscibility in water and salt-responsive solublity due to intra- and 
interpolymer Coulombic interactions of pendent SB zwitterions (Figure 1.2B), which are 
broken upon addition of salt or by increasing solution temperature.25,32  As a result of this 
unique aqueous solubility, polySBMA is widely investigated for the synthesis of materials 
which exhibit responsive assembly in water and at interfaces.33-35  Methacrylate polymers 
bearing CP moieties, ‘reverse’ PC-zwitterions containing reactive chemical handles 
embedded directly within the zwitterionic functionality (Figure 1.2A), have emerged as 
functional zwitterionic materials readily synthesized using controlled polymerization 
techniques and amenable to post-polymerization modification via facile and reproducible 
‘click’ chemistries.36,37  As polyMCP variants have been shown to exhibit biocompatiblity 
comparable to polyMPC in human cells,36 these reverse zwitterionic materials hold great 
promise for drug delivery applications as implantable hydrogels or injectable polymer-drug 
conjugates. 
 Owing to the excellent dispersibility of zwitterions in aqueous solutions, 
zwitterionic functionality is useful as the hydrophilic component of polymer amphiphiles.  
 
Figure 1.2: (A) Chemical structures of PC-, SB-, and CP-methacrylate monomers and 
their respective polymers synthesized using various free radical polymerization 
chemistries; (B) depiction of the salt- and temperature-responsive solubility of 
polySBMA in water. 
(A)
CFRP
ATRP, RAFT
Zwitterion:
polyMPC polySBMA
polyMCP
(B)
salt or ∆
polySBMA
R:
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Of particular interest is the preparation of well-defined zwitterionic amphiphilic polymers 
using controlled polymerization methodologies, as these techniques give access to 
materials with tunable amphiphilicity (i.e., hydrophilic-lipophilic balance), molecular 
weight, and architecture (i.e., random vs. block copolymers).  Notable examples which 
demonstrate the versatility of zwitterionic polymer amphiphiles include work by the Armes 
and Ishihara groups describing the preparation of novel SB- and PC-functionalized block 
copolymer surfactants for interfacial stabilization, aqueous self-assembly, and surface 
modification.38-41  Armes and workers reported the reversible addition-fragmentation chain 
transfer (RAFT) polymerization-induced self-assembly of polySBMA-poly(2-
hydroxypropyl methacrylate) block copolymer amphiphiles in water.40  By varying the 
molecular weight of hydrophobic poly(2-hydroxypropyl methacrylate) polymerized from 
a hydrophilic polySBMA macro-chain transfer agent (macro-CTA), water-dispersible self-
assembled nanoparticles with micellar, worm-like, or vesicular morphologies were readily 
accessed.  Ishihara et al. reported the synthesis of polyMPC-poly(dimethylsiloxane)-
polyMPC triblock copolymers by macro-initiated atom transfer radical polymerization 
(ATRP) for the modification of hydrophobic poly(dimethylsiloxane) substrates and 
preparation of antifouling coatings.41 
 Chapters 2 and 3 of this thesis aim to contribute to the field of zwitterionic polymer 
amphiphiles through the synthesis and investigation of novel, versatile, and functional 
surfactants bearing pendent PC, SB, and CP zwitterions.  Critical to the preparation of 
zwitterionic polymer amphiphiles with tunable compositions are chemistries which allow 
for the modification and controlled polymerization of zwitterionic methacrylate monomers.  
As such, this thesis takes advantage of facile coupling reactions between thiol nucleophiles 
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and unsaturated chemical functionality (i.e., thiol-Michael addition, thiol-ene addition, and 
thiol-yne addition), as well as a controlled free radical polymerization methodology (i.e., 
ATRP).  Thiol-Michael and thiol-ene/yne addition chemistries, depicted in Scheme 1.1, 
allow for the efficient modification of small molecules and polymers via the reaction of 
thiol groups with α,β-unsaturated carbonyl (thiol-Michael addition) or alkene/alkyne 
(thiol-ene/yne) moieties.42-44   
 ATRP is a living free radical polymerization methodology discovered 
simultaneously by Mitsuo Sawamoto45 and Krzysztof Matyjaszewski46 which allows for 
the controlled polymerization of functional vinyl monomers (i.e., (meth)acrylates, 
(meth)acrylamides, and styrenes) and the preparation of polymeric materials with tunable 
molecular weight, narrow molecular weight distributions, well-defined polymer end 
groups, and diverse architectures.47,48  As shown by the mechanism in Figure 1.3, ATRP is 
initiated by the reversible homolytic cleavage of an organic halide in the presence of a 
transition metal catalyst.  Suitable organic halide initiating species include alkyl chloride, 
aryl chloride, alkyl bromide, and aryl bromide species, with cuprous halide salts most 
commonly employed as catalysts.  Upon electron transfer and formation of a carbon-
centered radical, the initiating R species adds across the unsaturated functionality of a 
Scheme 1.1: Modification of unsaturated chemical functionality using thiol-Michael 
addition and thiol-ene/yne ‘click’ chemistries. 
 
thiol-Michael addition thiol-ene/yne addition
radical initiation 
(heat or light)
+
base or nucleophile
catalysis
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suitable vinyl monomer, with further monomer propagation ensuing.  Terminating and 
chain transfer reactions, which increase the breadth of the molecular weight distribution of 
the resulting polymer product, are sufficiently suppressed by a redox equilibrium, 
established between propagating polymer chains and the oxidized cuprous catalyst, which 
predominantly favors the dormant species.  ATRP of zwitterionic PC-, SB-, and CP-
methacrylate monomers has previously been reported in protic solvents (i.e., water, 
methanol, and 2,2,2-trifluoroethanol),26,28,36,37 yielding well-defined zwitterionic 
homopolymers, random copolymers, and block copolymers.  Importantly, ATRP allows 
for the polymerization of vinyl monomers from the backbones or chain ends of halide-
functionalized materials (i.e., macro-initiated ATRP), allowing for the synthesis of block 
copolymer amphiphiles using commercial pre-polymers.38,41,49,50 
 Chapters 4 and 5 of this thesis seek to develop the polymer zwitterion concept 
further, transitioning from the synthesis and investigation of fundamental materials to the 
preparation and evaluation of zwitterionic polymers as injectable scaffolds for improving 
 
Figure 1.3: Mechanism for the polymerization of vinyl monomers (M) by atom transfer 
radical polymerization (ATRP). 
Initiation:
+ Cu(I)Br + Cu(II)Br2
+ M
Propagation:
+ M
M
+ Cu(II)Br2 + Cu(I)Br
termination/chain transfer
suppressed
active species dormant species
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the chemotherapeutic treatment of solid tumors.  While small molecule chemotherapeutics 
are essential for treating tumors, their efficacy is often hampered by rapid clearance upon 
administration and non-specific tissue accumulation.  The former behavior necessitates 
recurring dosing regimens to maintain efficacious drug concentrations, while the latter 
often results in undesired side effects that can impede treatment and reduce patient 
compliance.  Additionally, the hydrophobicity of many chemotherapeutics renders them 
poorly soluble in physiological solutions, reducing bioavailability and often requiring the 
use of potentially dangerous excipients.51-53  Polymer-drug conjugation, which affords 
soluble prodrugs that exhibit extended in vivo circulation, reduced toxicity, and enhanced 
selectively for tumoral tissue,54-57 offers a facile solution for augmenting chemotherapy.  
Poly(ethylene glycol) (PEG) is a hydrophilic polymer often investigated for preparing 
polymer-drug conjugates,58-60 and currently utilized in numerous FDA-approved injectable 
polymer therapeutics.61-64  Although modification of hydrophobic drugs with PEG (i.e., 
PEGylation) affords conjugates with enhanced hydrodynamic diameter and improved 
water-solubility, drug loading is inherently limited, with conjugation only feasible at the 
chain-end hydroxyl groups.  Moreover, recent clinical evaluations suggest PEGylated 
therapeutics can illicit undesired immunogenicity, leading to a reduction in the efficacy of 
PEG-based polymer therapeutics.65-68  As such, safe, non-immunogenic alternatives are 
desired for developing new polymer-based chemotherapeutics.  PolyMPC has emerged as 
a hydrophilic and biocompatible polymer scaffold well-suited for the preparation of 
polymer-chemotherapeutic conjugates.10-12,14,69,70  In addition to its extreme hydrophilicity, 
which allows for the solubilization of drugs with very poor aqueous solubility at high drug 
loadings, polyMPC is readily prepared with narrow molecular weight distributions and 
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tunable functionality using controlled free radical polymerization techniques.10,26,27,69,70  
The tolerance of these polymerization methodologies to various chemical functionalities 
allows for the preparation of zwitterionic polymer prodrugs by post-polymerization 
conjugation, or through direct RAFT copolymerization of chemotherapeutic-
functionalized monomers. 
 RAFT is a metal-free living polymerization technique which allows for the  
polymerization of vinyl-based monomers under free radical conditions.71,72  Additionally, 
this methodology is well-suited for generating polymer zwitterions with narrow molecular 
weight distributions and diverse chemical functionality through copolymerization.27,29,35-
37,70  The mechanism of a typical RAFT polymerization, initiated using a range of 
commercial free radical initiators under thermal or photolytic conditions, is depicted in 
Figure 1.4.  Critical to the synthesis of polymers with narrow molecular weight 
distributions is the inclusion of a thiocarbonylthio chain transfer agent (CTA) which 
establishes an equilibrium between dormant and active polymer chains through reversible 
chain transfer.  The new carbon-centered radical formed through chain transfer initiates a 
 
Figure 1.4: Mechanism for the polymerization of vinyl monomers (M) by RAFT 
methodology. 
Initiation:
Propagation:
∆ or hν
2
M
M
+ +
re-initiation
active 
species
dormant 
species
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new polymer chain, and the chain transfer equilibrium suppresses undesired termination 
events.  As RAFT methodology is amenable to polymerizing monomers with a diverse set 
of chemical functional groups and is conducted without the use of metal catalysts which 
can be toxic and difficult to remove, RAFT is well-suited for the preparation of polymeric 
materials intended for in vivo applications. 
 
1.2 Thesis Outline 
 This thesis describes the synthesis, characterization, and application of zwitterionic 
polymers as novel and functional amphiphiles for aqueous assembly, interfacial 
stabilization, and nanomaterials synthesis, as well as the development of a zwitterionic 
polymer prodrug platform for treating ovarian and brain tumors.  A particular focus of 
this work is the design and implementation of facile and modular synthetic strategies which 
allow zwitterions to be incorporated into diverse polymer compositions and architectures. 
 Chapter 2 describes the preparation of a series of water-soluble siloxane polymers 
with pendent PC and SB zwitterions using thiol-ene ‘click’ chemistry (Journal of Polymer 
Science Part A: Polymer Chemistry, 2016).74  Specifically, well-defined vinyl-substituted 
siloxane homopolymers and block copolymers were functionalized with small molecule 
zwitterionic thiols at room temperature.  Rapid and quantitative substitution of the pendent 
vinyl groups was achieved, and zwitterionic polysiloxanes of narrow molecular weight 
distribution were obtained.  The PC- and SB-substituted polymers were found to be readily 
soluble in pure, salt-free water.  Critical micelle concentrations (CMCs) of these polymers 
in water were measured using a pyrene fluorescence probe, with CMC values estimated to 
be < 0.01 g/L.  Polymer aggregates were studied by dynamic light scattering, and micelles 
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generated from the PC block copolymers were visualized, after drying, by transmission 
electron microscopy.  Aqueous solutions of these zwitterionic polysiloxanes significantly 
reduced the oil-water interfacial surface tension, functioning as novel polymer amphiphiles 
that lend stability to oil-in-water emulsions. 
 Chapter 3 describes novel zwitterionic polymer amphiphiles with chemical 
structures mimicking Pluronic® block copolymers prepared by ATRP of PC- or CP-
methacrylate monomers using a difunctional poly(propylene oxide) (PPO) macroinitiator.  
Well-defined, water-dispersible zwitterionic triblock copolymers, or ‘zwitteronics’, were 
prepared with PC content ranging from 5 to 47 mole percent and composition-independent 
surfactant properties in water which deviate from the properties of conventional Pluronic 
amphiphiles.  These PC-zwitteronics assembled into nanoparticles in water, with tunable 
sizes and critical aggregation concentrations based on their hydrophilic-lipophilic balance.  
Owing to the lower critical solution temperature miscibility of the hydrophobic PPO block 
in water, PC-zwitteronics exhibited thermoreversible aqueous solubility tuned by block 
copolymer composition.  The versatility of this approach was demonstrated by embedding 
chemical functionality, in the form of alkyne groups, directly into the zwitterionic moieties.  
These alkynes proved ideal for crosslinking the zwitteronic nanoparticles and generating 
nanoparticle-crosslinked hydrogels with tunable elastic properties using UV-initiated thiol-
yne ‘click’ chemistry. 
 Chapter 4 describes the evaluation of a polymer prodrug composed of doxorubicin 
(Dox) conjugated covalently to polyMPC for the treatment of human ovarian tumors in 
animals (Molecular Pharmaceutics, 2016).12  This work builds upon previous studies which 
describe the synthesis of polyMPC-Dox prodrugs and their utility for treating solid 
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tumors.10-12  PolyMPC-Dox prodrugs were prepared using facile conjugation chemistry to 
yield conjugates soluble in water and injectable saline, with a Dox weight percent loading 
of ~19%.  Toxicity evaluation showed that polyMPC was well-tolerated in mice at doses 
up to 800 mg/kg, confirming the biocompatibility of the polymer carrier at high 
concentration.  Additionally, the polyMPC-Dox prodrug was well-tolerated in animals at a 
Dox equivalent dose of 10 mg/kg, greater than twice the maximum tolerated dose of free 
Dox (~4 mg/kg) in the same mouse strain.  In a human ovarian tumor model (SKOV-3), 
polyMPC-Dox accumulated in tumors at twice the level of free Dox, with no additional 
off-target organ uptake, a result of improved pharmacokinetics afforded by the prodrug and 
passive targeting attributed to an enhanced permeability and retention effect.  When 
administered to human ovarian tumor-bearing mice using a recurring dosing regimen 
comparable to that used clinically, polyMPC-Dox significantly retarded tumor growth 
relative to treatment with free Dox.  Moreover, animals treated with multiple doses of 
polyMPC-Dox (eight total doses) exhibited enhanced survival, with a notably reduced 
incidence of toxicity or adverse events relative to mice treated with free Dox.  These in 
vivo results demonstrate advantages of treating human ovarian tumors with polyMPC-Dox, 
including reduced systemic toxicity, improved drug accumulation in tumors, and enhanced 
therapeutic efficacy. 
 Finally, Chapter 5 expands the polyMPC prodrug platform through the 
development of zwitterionic polymer prodrugs for treating glioblastoma, a highly 
aggressive malignant brain tumor.  A new and versatile synthesis was developed to produce 
polymer prodrugs composed of polyMPC conjugated covalently to the glioblastoma drug 
temozolomide (TMZ) (ACS Macro Letters, 2017).75  Through the development of a novel 
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TMZ-substituted methacrylate, and its subsequent RAFT copolymerization with MPC or 
chain-extension from a polyMPC macro-CTA, water-dispersible polyMPC-TMZ 
conjugates with random and block copolymer architectures were realized with TMZ 
loadings of approximately 16-50 and 14-35 mole percent, respectively.  After 
polymerization, the structural fidelity of conjugated TMZ, a drug acutely susceptible to 
undesired hydrolytic decomposition, was confirmed using NMR and UV-Vis 
spectroscopy, while molecular weight estimation by gel permeation chromatography 
confirmed the preparation of polymer-TMZ conjugates with narrow molecular weight 
distributions.  The fundamental solution properties of the polyMPC-TMZ copolymers, 
including their critical aggregation concentrations and hydrodynamic diameters in 
phosphate-buffered saline, were measured using dynamic light scattering, and 
nanoparticles formed from the block copolymer prodrugs were visualized using cyrogenic 
transmission electron microscopy.  Using UV-Vis spectroscopy, improvement in the 
aqueous stability of TMZ afforded through polymer conjugation was investigated, 
specifically examining effects of drug loading and polymer architecture.  The antitumor 
activity of these novel polyMPC-TMZ prodrugs was assessed in chemosensitive (U87MG) 
and chemoresistant (T98G) glioblastoma cell lines, and the impact of augmenting 
polyMPC-TMZ efficacy through co-delivery of a glioblastoma-sensitizing adjuvant was 
examined.  These studies demonstrate that prodrugs with a block copolymer architecture 
afford the most significant improvements in TMZ stability and anti-glioblastoma efficacy.  
This synthetic design opens new possibilities for formulating numerous types of polymeric 
TMZ-based structures, and demonstrates the viability of systemically treating glioblastoma 
tumors using injectable polyMPC-TMZ prodrugs.    
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CHAPTER 2 
 
WATER-SOLUBLE ZWITTERIONIC POLYSILOXANES 
2.1 Introduction 
 Polysiloxanes exhibit distinct properties from carbon-based polymers, most notably 
their flexibility and low temperature fluidity owing to the long Si—O and Si—C bonds in 
the structure.1  Siloxane polymers have excellent thermal stability, high gas permeability, 
and biocompatibility,2 and are important in applications ranging from microfluidic device 
fabrication3,4 to coatings, sealants, medical devices,5 and contact lenses.6 
 In siloxane-containing polymers, the “R” groups of the –R2Si–O– repeat unit are 
typically small, hydrophobic moieties such as methyl or phenyl groups.  The 
hydrophobicity and aqueous insolubility inherent to conventional siloxane polymers 
precludes their use in aqueous assembly and deposition processes.  Recent work seeking 
to improve the surface hydrophilicity and physiological properties of crosslinked silicones 
include methods to prepare water-soluble polysiloxanes as polymer surfactants, drug 
delivery vehicles, and polymer nanoreactors.7-14  For example, low molecular weight 
oligosiloxane surfactants with pendent zwitterions were prepared by successive 
hydrosilylation and SB formation,15 affording water-dispersible oligomers.  Cationic 
water-soluble polysiloxanes with pendent ammonium and imidazolium groups were 
prepared and studied as antimicrobial materials.16,17  Random copolymers of 
poly(dimethylsiloxane) (PDMS) and poly(azidopropylmethylsiloxane) gave access to 
PEGylated polysiloxanes by azide-alkyne cycloaddition.18  Additional examples include 
amphiphilic block copolymers with mixed siloxane-hydrocarbon backbones, such as block 
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copolymers of PDMS with poly(ethylene glycol),19,20 poly(2-alkyloxazolines),21,22 and 
polyMPC.23 
 The work described herein focuses on the preparation of water-soluble zwitterionic 
polysiloxanes with relatively high molecular weight and no hydrocarbon-containing block.  
This requires integrating useful functionality into the siloxane backbone, achieved, for 
example, by polymerization of 1,3,5-trivinyl-1,3,5-trimethylcyclotrisiloxane (D3v) or 
1,3,5,7-tetravinyl-1,3,5,7-tetramethylcyclotetrasiloxane (D4v).  For example, 
hexamethylcyclotrisiloxane (D3) polymerization initiated by n-butyllithium is followed by 
addition of D3v or D4v to generate PDMS-b-poly(vinylmethylsiloxane (PDMS-b-PVMS) 
block copolymers.  The pendent vinyl groups are then available for modification by 
platinum-catalyzed hydrosilylation with alkyl-, epoxy-, and alkoxy-silanes, or by thiol-ene 
chemistry using any of a variety of thiols.24,25  Common to both strategies is the similar 
organic solubility of the polymer and the groups selected for grafting, making 
functionalization straightforward relative to efforts to integrate strictly hydrophilic groups 
into the structure. 
 Successful syntheses of low polydispersity polysiloxanes functionalized with 
pendent zwitterions would provide new opportunities for siloxane polymers in aqueous 
assembly and interfacial science.  As such, polysiloxanes incorporating PC and SB 
zwitterions were targeted for their hydrophilicity,26,27 biocompatibility,28-30 and nonfouling 
properties.9,31-33  PVMS homopolymers and PDMS-b-PVMS block copolymers were 
prepared as functional precursors, and through facile thiol-ene addition,34 PC- and SB-
thiols were attached to the siloxane backbone.  Optimizing reaction conditions overcame 
solubility differences between the vinyl polysiloxanes and zwitterionic thiols.  
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Homopolymers having the pendent PC or SB groups on each monomer unit and block 
copolymers with zwitterion incorporations of 10-50 mole percent were synthesized.  
Percent vinyl conversion and polymer purity were confirmed by NMR spectroscopy, while 
molecular weight distribution was characterized by gel permeation chromatography 
(GPC).  The zwitterionic polysiloxanes displayed considerable surfactant properties, as 
determined by pendant drop interfacial tensiometry (IFT), while aqueous assembly 
characteristics of these novel polymers were examined by determining their critical micelle 
concentration (CMC) and measuring the size of structures formed in water by dynamic 
light scattering (DLS) and subsequently by transmission electron microscopy (TEM). 
 
2.2 Synthesis of PC- and SB-Polysiloxanes 
 Siloxane polymers with pendent vinyl groups were prepared by n-butyllithium-
initiated anionic ring-opening polymerization (ROP) using a procedure similar to that 
described by Frey and coworkers.24  Vinyl-bearing PVMS homopolymer P1 was 
synthesized by the room temperature polymerization of D3v in THF, as shown in Figure 
2.1A.  Kinetics of the D3v polymerization were monitored by analyzing aliquots of the 
reaction solution at various times using GPC eluting in THF and calibrated against 
polystyrene standards.  As shown in Figure 2.1B, the D3v monomer was consumed rapidly 
and the number-average molecular weight (Mn) of P1 approached a constant value within 
approximately 8 minutes of initiating polymerization.  Importantly, the polydispersity 
index (PDI) of P1 remained low throughout the polymerization.  P1 was purified by 
dialysis to remove unreacted monomer, and was isolated as a clear, colorless oil in 75% 
yield.  Polymer P1 was prepared with an Mn of 7,500 g/mol, as estimated using 
1H-NMR 
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spectroscopy, and a PDI of 1.07, as estimated using GPC eluting in THF relative to 
polystyrene standards. 
 PDMS-PVMS block copolymers were synthesized by anionic ring-opening 
polymerization using the sequential monomer addition strategy shown in Figure 2.2A.  D3 
polymerization was initiated with n-butyllithium, and the polymerization kinetics were 
monitored using GPC eluting in THF.  As shown in Figure 2.2B, the polymerization of D3 
was significantly slower than vinyl-functionalized D3v, with estimated Mn values for the 
PDMS homopolymer approaching a constant value after approximately 2 hours.  Following 
D3 consumption, D3v was added to initiate the second block from the chain-end silanoate, 
affording PDMS-b-PVMS copolymers with vinylsiloxane incorporation of 50 (polymer 
 
 
Figure 2.1: (A) Synthesis of PVMS homopolymer P1 by anionic ROP; (B) changes in 
the estimated Mn and PDI values for the room temperature, n-butyllithium-initiated 
anionic ROP of D3v in THF as a function of time. 
(A)
D3v P1
(B)
1) n-butyllithium, THF
2) TMS-Cl
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P2), 32 (polymer P3), and 10 (polymer P4) mole percent as clear, viscous oils in 70-80% 
yield.  The order of monomer addition was crucial for obtaining copolymers with excellent 
block purity, due to the faster rate of propagation of D3v relative to D3.35  In the 29Si-NMR 
spectra of block copolymers P2-P4, singlets were observed at -21.81 and -34.64 ppm 
(Figure 2.2C), representing Si resonances from the D3 and D3v block, respectively.   
 Values of the number-average degree of polymerization (Xn) of vinyl-substituted 
polysiloxanes P1-P4, summarized in Table 2.1, were determined by 1H-NMR spectroscopy 
by comparing the relative signal intensities of the dimethylsiloxane (δ = -0.06-0.10 ppm) 
and vinylmethylsiloxane (δ = 5.73-6.06 ppm) groups against that of the n-butyl (δ = 0.89 
ppm) chain end.  Molecular weight distributions (i.e., PDI values) of polymers P1-P4 were 
characterized by GPC eluting in THF and calibrated against polystyrene standards.24,25   
 
Figure 2.2: (A) One-pot synthesis of PDMS-b-PVMS copolymers P2-P4 by sequential 
monomer addition; (B) changes in the estimated Mn and PDI values for the room 
temperature, n-butyllithium-initiated anionic ROP of D3 in THF as a function of time; 
(C) representative 29Si-NMR spectrum of PDMS-b-PVMS.  Single resonances were 
observed for the PDMS and PVMS segments, confirming block purity. 
n-butyllithium
THF
1) D3v
2) TMS-Cl
D3 P2-P4
(A)
(C)
a b
a
b
(B)
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Reasonable agreement was seen between the molecular weights given by NMR and GPC, 
and the isolated polysiloxanes had low PDI values (<1.1) with vinyl incorporation (100, 
50, 32, and 10 mole percent) in excellent agreement with targeted amounts.  Although the 
measured degrees of polymerization and molecular weights were somewhat lower than 
targeted, the functional polysiloxanes were isolated with narrow molecular weight 
distributions in high yield and purity, suitable for post-polymerization modification with 
zwitterionic moieties.  
 As shown in Figure 2.3, polysiloxanes P1-P4 were modified by thiol-ene addition 
of zwitterionic thiols to the pendent vinyl groups on the polymer.  PC-thiol PC-SH, a 
known small molecule zwitterion from the work of Iwasaki and Miyahara,36 and newly 
synthesized SB-thiol SB-SH, were prepared by the Michael addition of 1,3-propanedithiol 
to the commercially available PC- and SB-methacrylates, respectively.  The zwitterionic 
methacrylates were reacted with excess dithiol to promote formation of monothiol 
Table 2.1: Molecular weight data for vinyl-substituted polysiloxanes P1-P4. 
 
 
Polymer 
 
XnTheor 
PDMSa 
 
XnNMR 
PDMSb 
XnTheor 
PVMSc 
XnNMR 
PVMSd 
MnTheor 
(g/mol) 
MnNMR 
(g/mol)e 
MnGPC 
(g/mol)f 
 
PDIf 
P1 N/A N/A 117 87 10,000 7,500 8,400 1.07 
P2 63 42 63 42 10,000 6,700 7,300 1.09 
P3 90 69 45 33 10,000 8,000 5,200 1.08 
P4 180 84 15 9 15,000 7,000 9,900 1.05 
a,cTheoretical number-average degree of polymerization (Xn) determined from the 
molar feed ratio of monomer to initiator. 
b,dXn measured using 
1H-NMR spectroscopy. 
eNumber-average molecular weight (Mn) measured using 
1H-NMR spectroscopy. 
fMn and PDI estimated by GPC eluting in THF relative to polystyrene standards. 
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substituted structures as the major product, and the zwitterionic thiols were isolated as 
hygroscopic solids by precipitation then purified by trituration in THF and/or diethyl ether 
to remove unreacted dithiol.  NMR characterization of PC-SH and SB-SH, shown in 
Figure 2.4, as well as electrospray ionization high-resolution mass spectrometry (ESI-
HRMS) analysis confirmed the expected structure of PC-SH ([M+H]+: 404.131 g/mol) and 
SB-SH ([M+H]+: 388.131 g/mol).  The zwitterionic thiols were soluble only in water, 
methanol (MeOH), and 2,2,2-trifluoroethanol (TFE), typical of small molecule zwitterions.  
 
Figure 2.3: (A) Synthesis of zwitterionic thiols PC-SH and SB-SH by the thiol-Michael 
addition of 1,3-propanedithiol to PC- and SB-methacrylate, respectively; (B) preparation 
of PC- (P7-P10) and SB- (P11-P14) polysiloxanes.  Zwitterionic thiols PC-SH and SB-
SH were introduced to PVMS-based precursors by thiol-ene addition to the pendent vinyl 
groups, affording homopolymers (m = 0) and block copolymers with zwitterion 
incorporation of 10, 32, or 50 mole percent. 
Zwitterion:
or
1.5 equiv.
cat.
or
PC-SH
SB-SH
(A)
(B)
DMPA, hν
THF : MeOH
PC-SH
DMPA, hν
THF : TFE
SB-SH
P1-P4
P7-P10
P11-P14
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In the mass spectra of PC-SH and SB-SH, signals were identified corresponding to 
disulfide dimers and bis-zwitterion sulfides of PC-SH and SB-SH.  Formation of such side 
products is expected, and was previously noted in the preparation of PC-SH.36  Comparing 
integral values in the 1H-NMR spectra of PC-SH and SB-SH corresponding to the 
trimethylammonium (peak k, δ = 3.16 ppm) and dimethylammonium (peak i, δ = 3.08-3.20 
ppm) protons, respectively, with the integral value for the methylene protons from the 
propane thiol chain (peak b, δPC-SH = 1.78 ppm, δSB-SH = 1.80 ppm), the formation of the 
mono-zwitterion as the major product (72% for PC-SH and 54% for SB-SH) was 
confirmed for each zwitterionic thiol.  Importantly, these additional products are 
nonproblematic with respect to polymer functionalization, and are removed from the 
polymer product by dialysis.  
 UV-assisted thiol-ene reactions of the vinyl-substituted polymers and zwitterionic 
thiols were conducted at room temperature using 2,2-dimethoxy-2-phenylacetophenone 
(DMPA) photoinitiation.37  The marked solubility differences between the zwitterionic 
thiols and vinyl-substituted polysiloxanes (the polymers are insoluble in water, MeOH, and 
TFE) led to an initial examination of biphasic thiol-ene reaction conditions38 in immiscible 
solvents such as MeOH/TFE.  However, no significant zwitterionic functionalization was 
 
 
Figure 2.4: 1H-NMR (500 MHz) spectra of PC-SH (A) and SB-SH (B) in MeOD-d4. 
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achieved under these conditions.  Homogenous solvent mixtures proved more successful: 
for example, adding a solution of PC-SH in MeOH to a THF solution of polymer resulted 
in full conversion of the vinyl groups to the corresponding sulfide product.  A similar 
strategy was used for the SB substitution, using TFE to solubilize SB-SH.  Room 
temperature thiol-ene addition of PC-SH and SB-SH to vinyl-substituted polymers was 
initiated by homolytic decomposition of DMPA at 365 nm, affording rapid and quantitative 
substitution in one hour.  Figure 2.5 shows 1H-NMR spectra of vinyl-substituted 
polysiloxane block copolymer P2 (50 mole percent vinylsiloxane), and the corresponding 
PC (P8) and SB (P12) copolymers. 
 
Figure 2.5: 1H-NMR (500 MHz) spectra of P2 in CDCl3 (top), P8 in 1:1 CDCl3:MeOD-
d4 (middle), and P12 in 1:2 CDCl3:TFE-d3 (bottom). 
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 In the 1H-NMR spectra of the zwitterion-substituted polymers, vinyl proton signals 
(region f, δ = 5.73-6.06 ppm) of the siloxane polymer starting material are notably absent, 
and characteristic signals of the PC and SB groups are introduced.  A new resonance is 
seen at δ = 0.59 ppm for the PC-polysiloxanes, and at δ = 0.92 ppm for the SB-
polysiloxanes, corresponding to the alpha methylene protons of each structure (donoted as 
g).  In the 29Si-NMR spectra, following thiol-ene substitution, a shift was observed in the 
Si resonance from the original vinyl-substituted polymers (δ = -34.97 ppm for P1, δ = -
34.64 ppm for P2-P4) (Figure 2.6A) to -19.94 and -23.93 ppm for PC- (Figure 2.6B) and 
SB-substitution (Figure 2.6C), respectively.  These spectra confirm an excellent conversion 
of the pendent alkenyl moieties to the desired sulfide-tethered zwitterions. 
 Molecular weight distributions for the zwitterion-substituted polysiloxanes were 
characterized by GPC in TFE, with calibration against poly(methyl methacrylate) (PMMA) 
standards.  GPC chromatograms of polymers P7-P10 and P11-P14 are shown in Figures 
2.7A and 2.7B, respectively.  As summarized in Figure 2.7C, the polymers were isolated 
with low PDI values and estimated Mn values in reasonable agreement with theoretical 
values.  Notably, for polymers P10 and P14, having the lowest percent zwitterion 
substitution of the samples prepared, a signal at low retention volume was observed in the 
 
Figure 2.6: Representative 29Si-NMR (99 MHz) spectra of vinyl-substituted 
polysiloxanes (A), PC-containing polysiloxanes (B), and SB-containing polysiloxanes 
(C). 
(A) (B) (C)a b
b
a
a b
a
b
b
a
a b
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chromatograms attributed to aggregate formation in this solvent environment.  Aggregation 
of polymers P10 and P14 in TFE was confirmed by DLS, which showed the formation of 
monomodal aggregates with hydrodynamic diameters of approximately 24 nm.  Single 
unimodal peaks were observed in the chromatograms of the other six PC- and SB-
substituted polysiloxanes having 32, 50, and 100 mole percent zwitterion.  Moreover, for 
all of the zwitterionic polysiloxanes, no low molecular weight species were observed in the 
chromatograms, confirming polymer purity and successful removal of unreacted small 
molecule zwitterions.  
 
Figure 2.7: GPC chromatograms of PC-substituted polysiloxanes P7-P10 (A) and SB-
substituted polysiloxanes P11-P14 (B) eluting in TFE; (C) molecular weights of 
zwitterionic polysiloxanes estimated by GPC eluting in TFE. 
(A) (B)
(C)
Polymer
Zwitterion Content
(mol %)
Mn
Theor
(g/mol)
Mn
GPC
(g/mol)a
PDIa
P7 100 (PC) 42,600 31,400 1.07
P8 50 (PC) 23,700 20,900 1.11
P9 32 (PC) 21,300 19,800 1.10
P10 10 (PC) 10,600 11,900 1.16
P11 100 (SB) 41,200 26,300 1.11
P12 50 (SB) 23,000 17,100 1.12
P13 32 (SB) 20,800 16,300 1.11
P14 10 (SB) 10,500 11,300 1.15
aMn and PDI values estimated by GPC against PMMA standards.
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  These zwitterionic polysiloxanes are amphiphilic and are expected to exhibit 
aqueous assembly and surfactant properties in water and at fluid-fluid interfaces.  The PC-
containing polysiloxanes are highly water-soluble, with P7-P10 dissolving in water at ≥ 5 
mg/mL.  In contrast, the only SB-containing polysiloxane having water solubility at 
comparable concentrations was homopolymer P11.  The pure water solubility of the SB-
substituted polysiloxane homopolymer contrasts that of other SB-substituted 
homopolymers in which inter-zwitterion interactions lead to insolubility in pure (salt-free) 
water.39  It is reasonable to hypothesize that the solubility of P11 benefits from weaker SB-
SB interactions due to the greater conformational and rotational flexibility of the siloxane 
backbone relative to hydrocarbon-based polymer zwitterions.40 
 CMC measurements of the zwitterionic polysilxoanes were performed using a 
pyrene fluorescence assay.  5 µL of a dilute pyrene solution in acetone was added to serial 
dilutions of the polymers in pure water.  The solutions were incubated at room temperature 
for approximately 18 hours, then analyzed by fluorescence spectroscopy.  As pyrene 
transitions from a hydrophilic to hydrophobic environment at the CMC, a distinct shift in 
fluorescence intensity from 334 to 339 nm is typically observed.  CMC is then estimated 
by plotting fluorescence intensity ratios (I339/I334) as a function of the log of the polymer 
concentration.  CMC for polymers P7-P11 were similar, with all estimated values < 0.01 
g/L.  DLS was employed to measure the size of these amphiphiles after dissolution in water 
at concentrations above the CMC ([polymer] = 1 g/L).  In water, the block copolymers may 
be expected to form micelles having a PDMS core and zwitterionic polysiloxane corona.  
These polymers have similar degrees of polymerization, such that as zwitterion content 
increases, the molecular weight of the PDMS segment decreases.  As shown in Figure 2.8, 
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this relationship is reflected in DLS: hydrodynamic diameters of the aggregates decreased 
with increasing zwitterion content, from 33 nm for P10 (10 mole percent PC) to 12 nm for 
P8 (50 mole percent PC).  The zwitterionic homopolymers P7 and P11 formed structures 
in water with small hydrodynamic diameters (< 7 nm) and readily encapsulated the pyrene 
fluorescence probe.  The homopolymers are likely solubilized polymer chains that collapse 
in water due to the hydrophobicity of the siloxane backbone.  For polymers exhibiting 
bimodal size distributions (P7, P8, and P11), number-based DLS plots confirmed the 
smaller aggregates as the predominant species.  
 Self-assembled structures formed by PC-containing polysiloxane block copolymers 
were visualized by TEM in collaboration with Ryan Selhorst.  Aqueous solutions of 
polymers P9 and P10 were prepared at concentrations above the CMC, dropcast onto grids 
and allowed to dry under ambient conditions.  Representative micrographs of assemblies 
formed from solutions of PC-substituted polysiloxanes are shown in Figure 2.9.  High 
 
Figure 2.8: Normalized DLS curves for aqueous solutions of P7-P11 at a concentration 
of 1 mg/mL. 
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densities of spherical objects with relatively low size distributions (30-45 nm diameter) 
and distinct boundaries were formed from P10 (Figure 2.9A).  For aqueous solutions of 
P9, two size populations were observed, consisting of smaller (12-18 nm diameter) and 
larger objects (35-55 nm) diameter (Figure 2.9B).  Since light scattering analysis of 
aqueous solutions of P9 shows a single size population (Figure 2.8), the appearance of two 
size populations by electron microscopy may be the result of drying and solvent 
evaporation. 
 The surfactant properties of these novel polysiloxane amphiphiles were evaluated 
by pendant drop interfacial surface tension (IFT) at room temperature.  IFT values (γ) of 
 
Figure 2.9: Representative TEM images of structures formed from aqueous solutions 
of P10 (A) and P9 (B) after casting on carbon-coated TEM grids. 
(A)
(B)
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P7-P11 in water were measured over a 30 minute period by immersing a 1,2,4-
trichlorobenzene (TCB) droplet in 1 mg/mL aqueous solutions of the zwitterionic 
polysiloxanes.  Equilibrium surface tension values (γeq), summarized in Table 2.2, were 
determined by averaging the values of γ observed at the conclusion of each measurement, 
and compared to the γeq of TCB at room temperature in pure water (γeq,TCB = 42.2 ± 0.3  
mN/m).  The equilibrium interfacial tension of TCB in aqueous solutions of PC-substituted 
polysiloxanes was reduced at least two-fold (γeq = 13.1-20.6 mN/m), relative to TCB-H2O.  
The most dramatic change was observed for the solution of P11, in which the interfacial 
tension for TCB was reduced to γeq,P11 = 10.7 mN/m.  In collaboration with Dr. Rachel 
Letteri, the room temperature γeq values of TCB in aqueous solutiosn of P7-P11 were 
compared to γeq values for aqueous solutions of methacrylate-based polyMPC or 
polySBMA homopolymers ([polymer] = 1 mg/mL).  In contrast to the amphiphilic 
zwitterionic polysiloxanes, the PC- and SB-polymethacrylate analogues produced little 
change in the interfacial tension (γeq = 39-40 mN/m).41  The excellent surfactant properties 
of water-soluble zwitterionic polysiloxanes—qualities not exhibited by conventional 
Table 2.2: Mean interfacial surface tension (γeq) values for aqueous solutions of 
polymers P7-P11 and TCB measured using pendant drop tensiometry. 
Polymer 
γeq 
(mN/m) 
P7 17.3 ± 0.1 
P8 20.2 ± 0.1 
P9 16.2 ± 0.1 
P10 13.1 ± 0.1 
P11 10.7 ± 0.1 
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methacrylate-based polymer zwitterions—may prove useful for a wide variety of surfactant 
emulsion applications. 
 
2.3.  Synthesis of Functional Zwitterionic Polysiloxanes 
 The versatility of the zwitterionic polysiloxane platform was further augmented by 
synthesizing functional copolymers bearing residual pendent vinyl moieties.  Such latent 
chemical functionality affords materials suitable for the post-polymerization modification 
of water-soluble polysiloxanes, as well as the production of robust self-assembled 
nanomaterials (i.e., crosslinked micelles) and networks (i.e., films, hydrogels, and 
elastomers).  Furthermore, the thiol-ene addition chemistry allows for the preparation of 
functional zwitterionic polysiloxanes with tunable zwitterion content and copolymer 
architecture (i.e., random and block copolymers).   
 Initial investigations explored the synthesis of functional PC-polysiloxane 
copolymers using the UV-mediated thiol-ene strategy depicted in Scheme 2.1.  Thiol-ene 
modification of vinyl-containing polysiloxanes was performed in THF:MeOH mixtures 
using the conditions summarized in Table 2.3.  Following thiol-ene reactions, vinyl content 
remaining in the isolated copolymers was estimated using 1H-NMR spectroscopy by 
comparing the integral values of signals corresponding to newly formed alpha methylene 
Scheme 2.1: Synthesis of functional PC-polysiloxane copolymers by thiol-ene 
modification. 
 
DMPA, hν
THF:MeOH
PC-SH
Functional 
PC-polysiloxanes
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protons of PC-modified segments (δ = 0.40-0.69 ppm) and residual vinyl protons (δ = 5.37-
5.84 ppm).  Additionally, PDI values for the PC-substituted copolymers were estimated 
using GPC eluting in TFE relative to PMMA standards.  Thiol-ene reactions performed at 
high vinylsiloxane concentrations (reactions 1 and 2) led to undesired polymer 
crosslinking, which was attributed to radical coupling of pendent vinyl moieties following 
PC-SH consumption.  Reactions performed at lower vinylsiloxane concentrations 
(conditions 3-8), on the other hand, yielded soluble PC-polysiloxanes with residual vinyl 
groups, narrow molecular weight distributions, and low PDI values.  As shown by the 
results obtained for the thiol-ene conditions of reactions 3-5, the PDI values for the vinyl-
containing PC-polysiloxanes were found to decrease with decreasing intial vinylsiloxane 
concentration.  Notably, reducing the starting vinyl concentration had a negligible effect 
Table 2.3: Thiol-ene conditions investigated for the preparation of functional PC-
polysiloxanes. 
 
Reaction 
Conditions 
[vinyl]a 
(M) 
[PS-SH]:[vinyl] 
Irradiation 
Timeb 
(min) 
Residual 
Vinyl 
Contentc 
(mol %) 
 
PDId 
1 2.9 0.3 60 70e crosslinked 
2 1.9 0.7 60 54e crosslinked 
3 0.4 0.9 30 50 1.44 
4 0.2 0.9 30 49 1.21 
5 0.08 0.9 30 52 1.16 
6 0.1 1.5 10 23 1.13 
7 0.1 1.5 20 17 1.12 
8 0.1 1.5 30 13 1.12 
aInitial concentration of vinylsiloxane moieties. 
bIrradiation at λ = 365 nm. 
cResidual vinyl content estimated by 1H-NMR spectroscopy in 1:1 CDCl3:MeOD-d4. 
dPDI values estimated using GPC eluting in TFE relative to PMMA standards. 
eEstimated for the soluble fraction. 
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on the content of pendent vinyl groups remaining following thiol-ene functionalization.  
Varying the UV irradiation time (λ = 365 nm) for the thiol-ene modification of the vinyl-
functionalized polysiloxane precursors at a similar vinyl concentration (reactions 6-8) 
afforded copolymers with similarly low PDI values and tunable latent vinyl content.  These 
results provide a proof-of-principle for synthesizing water-soluble, functional zwitterionic 
polysiloxanes. 
 
2.4. Conclusions 
 In summary, the work presented in this chapter described the preparation of novel 
polysiloxane homopolymers and block copolymers containing pendent PC and SB 
zwitterions, enabled by facile thiol-ene addition chemistry.  These zwitterionic 
polysiloxanes exhibit aqueous solubility, mediation of fluid-fluid interfaces, and micelle 
formation, all useful properties for advancing the chemistry and applications of 
polysiloxanes in aqueous media.  Adjusting thiol-ene modification conditions, 
polysiloxanes bearing pendent zwitterions and residual reactive functionality were readily 
prepared.  Future studies will utilize functional zwitterionic polysiloxane compositions for 
the preparation of novel biomaterials, with suitable applications ranging from crosslinked 
micelles for sustained drug delivery to hydrogel networks for ocular therapeutic 
applications.  Additionally, latent vinyl functionality allows for covalent incorporation of 
these zwitterionic polysiloxane structures into silicone elastomers through conventional 
hydrosilylation chemistry.  Such zwitterion-containing elastomers hold potential as novel 
antifouling coatings and hydrophilic substrates for microfluidic device fabrication.  
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CHAPTER 3 
 
ZWITTERIONIC PLURONIC MIMICS 
3.1 Introduction 
 Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-
PEO) triblock copolymers comprise a family of versatile surfactants utilized commercially 
as emulsifiers, antifoaming agents, detergents, dispersants, coatings, and pharmaceutical 
excipients.1-7  Known commonly under the trade name Pluronic®, these water-dispersible 
block copolymer amphiphiles are prepared by the sequential ring-opening polymerization 
of propylene oxide and ethylene oxide,1 affording copolymers with narrow molecular 
weight distributions and varying hydrophilic-lipophilic balance (HLB).  In aqueous 
solution, Pluronics exhibit complex assembly behavior, including micelle formation above 
a critical concentration with aggregation and morphological properties dependent on 
copolymer HLB, concentration, solution conditions, and processing.3,7-15  For most 
Pluronic compositions, aqueous micelle formation is thermoreversible, a behavior which 
arises from the lower critical solution temperature (LCST) miscibility of PPO in water.  
Additionally, several Pluronic copolymers undergo thermally induced physical gelation at 
high polymer concentrations,16 a characteristic mediated by micellar aggregation.  Owing 
to their aqueous assembly properties, Pluronics are used as templates for mesoporous and 
nanomaterials synthesis and are investigated extensively for drug delivery.6,7,16-19 
 Synthetic modifications of Pluronics alter their solution properties in water,20,21 
produce bioconjugates,22 and enhance their stability via covalent crosslinking.23-25  Due to 
the inert nature of the polyether backbone, functionalization is restricted to the chain-end 
hydroxyl groups.  Strategies currently employed in Pluronic functionalization are generally 
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tedious and inefficient, requiring long reaction times to approach complete chain-end 
modification.  Alternative approaches that produce chemical compositions mimicking 
conventional PEO-PPO-PEO copolymers will allow access to amphiphiles with tunable 
chemical functionality, while retaining the desirable surfactant qualities of Pluronics.  
Notable examples include biodegradable compositions which incorporate hydrolytically 
labile ester, phosphoester, or acetal moieties,26-28 as well as analogs that exhibit aqueous 
assembly behavior and present pendent moieties amenable to post-polymerization 
modification.29-32 
 Zwitterionic polymers, containing polar moieties composed of covalently tethered 
anion-cation pairs, are of interest as the hydrophilic components of polymer amphiphiles.33-
38  Typical examples incorporate the zwitterions as pendent or chain-end groups and serve 
as novel materials for controlled release, aqueous assembly, antifouling coatings, and 
interfacial stabilization.  Though numerous amphiphiles have been reported, only two 
examples of zwitterionic materials which mimic conventional Pluronics have been 
reported.37,38  Li, et al. described poly(carboxybetaine methacrylate)-PPO-
poly(carboxybetaine methacrylate) triblock copolymers as functional antifouling coatings 
for hydrophobic surfaces.37  While these zwitterionic triblock copolymers produced 
nonfouling surfaces amenable to protein conjugation through the pendent carboxybetaines, 
the chemical characterization of these block copolymer amphiphiles was not reported, and 
their aqueous solution properties were not investigated.  Jeong and coworkers reported the 
chain-end modification of PPO with PC groups, affording PC-PPO-PC amphiphiles which 
exhibited aqueous assembly and thermal gelation.38  Although this PPO derivative is well-
suited as a thermoreversible matrix, accessing water-dispersible polymer amphiphiles with 
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tunable critical aggregation concentrations (CACs), aggregate size, and LCST values is 
precluded using this strategy.  As such, this work set out to prepare and investigate poly(2-
methacryloyloxyethyl phosphorylcholine)-b-PPO-b-poly(2-methacryloyloxyethyl 
phosphorylcholine) (polyMPC-b-PPO-b-PPO) as Pluronic analogs with a modular and 
functional amphiphilic design. 
 This section focuses on a new class of Pluronic mimics incorporating PC groups as 
naturally occurring zwitterions to impart antifouling properties, biocompatibility,39-41 and 
excellent aqueous dispersibility.36  These novel ‘zwitteronics’ were prepared by atom 
transfer radical polymerization (ATRP) of zwitterionic methacrylates initiated from the 
chain-ends of homotelechelic PPO macroinitiators.  Upon discovering optimal 
polymerization conditions, a series of triblock copolymers was prepared by the 
macroinitiated polymerization of MPC.  These polyMPC-PPO-polyMPC triblock 
copolymers were synthesized with narrow molecular weight distributions (PDI = 1.14-
1.32), as characterized by gel permeation chromatography (GPC), and with MPC 
incorporation ranging from 5-47 mole percent.  Owing to the exceptional hydrophilicity of 
the pendent zwitterions, the PC-zwitteronic amphiphiles were readily dispersed in water 
and exhibited surfactant behavior, which by surface tensiometry proved distinct from 
Pluronics.  These triblock copolymers self-assembled in water into soft nanoparticles, and 
several compositions exhibited thermoreversible aggregation.  Their aqueous assembly 
properties, including critical aggregation concentration (CAC), nanoparticle size, and 
LCST miscibility, were assessed using a pyrene fluorescence assay, dynamic light 
scattering (DLS), and UV-Vis spectroscopy, respectively.  Importantly, the block 
copolymer assembly parameters were tuned readily by varying zwitterion content and 
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block copolymer HLB.  Seeking to demonstrate the versatility of this novel materials 
platform, functional zwitteronics were prepared by copolymerizing MPC with an alkyne-
substituted choline phosphate methacrylate (MCP), a ‘reverse’ zwitterionic monomer that 
embeds alkynes directly within the choline phosphate moieties.42  Functional zwitteronics 
with 15-17 mole percent alkyne incorporation were prepared, and their amenability to post-
polymerization thiol-yne modification was utilized for nanoparticle crosslinking and the 
formation of robust, covalently crosslinked nanoparticle networks. 
 
3.2 Synthesis of Zwitterionic Pluronic Mimics 
 A homotelechelic PPO macroinitiator bearing chain-end alkyl halides suitable for 
initiating ATRP of methacrylate monomers was synthesized following a modified 
procedure.30  As shown in Scheme 3.1, macroinitiator P15 was prepared by esterification 
of commercial PPO with 2-bromoisobutyrylbromide in dry tetrahydrofuran (THF).  
Macroinitiator purification—critical for preparing block copolymer samples devoid of 
homopolymer contaminants—was performed by washing with aqueous sodium hydroxide 
(NaOH) and stirring over decolorizing carbon.  This procedure afforded P15 as a viscous 
orange oil in excellent purity and good yield (~70-75%). 
Scheme 3.1: Synthesis of PPO macroinitiator P15. 
 
TEA, THF
0  C  r. temp.
P15
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 Macroinitiator P15 was characterized by NMR spectroscopy to confirm 
esterification at each chain end.  In the 1H-NMR spectrum of P15, a singlet at 1.92 ppm 
corresponded to the methyl protons of the bromoisobutyrates; this signal was notably 
absent in the spectrum of the PPO starting material (Figure 3.1A).  Additionally, 13C-NMR 
resonances of P15 (Figure 3.1B) at 172.26/172.25 and 57.36/57.33 ppm were attributed to 
the carbonyl and quaternary alkyl bromide moieties, respectively, of each esterified chain-
end.  Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry provided additional confirmation of the macroinitiator chain-end identity, 
with spectra of the PPO starting material and polymer P15 shown in Figure 3.2.  In each 
spectrum, major and minor signals are attributed to sodiated and potassiated analytes, 
respectively; the most intense signals corresponding to analytes with number-average 
degree of polymerization (Xn) of 79-82 are magnified.  Differences in mass-to-charge ratio 
(m/z) values for structures of similar Xn ranged from 297.3 to 298.9, with a mean difference 
of 298.3, in excellent agreement with the change expected following the addition of two 
 
Figure 3.1: (A) 1H-NMR (500 MHz) spectra of the PPO starting material (top) and 
macroinitiator P15 (bottom) in MeOD-d4; (B) 
13C-NMR (125 MHz) of the PPO starting 
material (top) and macroinitiator P15 (bottom) in MeOD-d4. 
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α,ω-bromoisobutyrate groups (∆ m/z = 298.0).  MALDI-TOF measured the absolute 
molecular weight of PPO macroinitiator P15 as 5,060 g/mol with a PDI value of 1.01, with 
a lower molecular weight fraction attributed to oligomeric species (this was also observed 
in the spectrum of the commercial PPO starting material).  Characterization of both 
polymer samples using gel permeation chromatography (GPC), eluting in 2,2,2-
trifluoroethanol (TFE), showed similar evidence of oligomeric impurities, suggesting that 
these structures did not arise from ionization-induced fragmentation during MALDI-TOF 
analysis.  Importantly, this minor oligomeric component did not interfere with the block 
copolymer syntheses. 
 
Figure 3.2: MALDI-TOF mass spectra of the commercial PPO starting material (top) 
and macroinitiator P15 (bottom).  Signals attributed to analytes with Xn values of 79-
82 for each polymer are inset with corresponding m/z values. 
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 PC-zwitteronics, termed P16-P20, were prepared by ATRP of MPC from the chain 
ends of macroinitiator P15, as shown in Scheme 3.2.  Polymerizations were conducted at 
room temperature at a monomer concentration of 0.5 M in TFE, mediated with a copper(I) 
bromide (CuBr)/2,2’-bipyridyl (Bipy) catalyst system.  When targeting MPC 
incorporations of 7-46 mole percent, monomer conversions of 83-97% were achieved, as 
estimated by 1H-NMR spectroscopy.  Polymerizations were quenched by exposure to air 
and residual copper was removed by elution through a short plug of silica gel.  The 
polymers were purified further by dialysis in water, followed by lyophilization to afford 
P16-P20 in 42-78% yield.  P16, containing the shortest polyMPC blocks, was isolated as 
a semi-solid, while P17-P20 were obtained as white powders. 
 Successful incorporation of polyMPC into block copolymers P16-P20 was 
confirmed and quantified by NMR spectroscopy.  As shown in the representative 1H-NMR 
spectrum of P20 in Figure 3.3A, characteristic resonances for both the polyMPC and PPO 
blocks were observed, including signals attributed to the trimethylammonium group (peak 
k, δ = 3.32 ppm) and PPO methylene protons (peaks a and b, δ = 3.41-3.67 ppm).  A single 
resonance corresponding to the phosphate moieties of the PC groups was observed in the 
31P-NMR spectrum of P20 at -0.51 ppm (Figure 3.3B), confirming successful 
polymerization of MPC from the macroinitiator.  As summarized in Figure 3.3C, 
polymerization stoichiometries targeted MPC incorporations of 7, 16, 28, 38, and 46 mole 
Scheme 3.2: Synthesis of PC-zwitterions P16-P20 by macroinitiated-ATRP. 
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percent for P16-P20, respectively.  MPC incorporations in the block copolymers were 
estimated by integration of 1H-NMR signal intensities of PC methylene (peaks g-i, δ = 
4.01-4.41 ppm) vs. PPO methylene resonances (peaks a and b, δ = 3.41-3.67 ppm).  In 
general, these NMR-estimated values were in excellent agreement with targeted 
incorporations.  Using the Xn value for polymer 1 obtained by MALDI-TOF analysis (Xn = 
82), the compositions of the PC-zwitteronic block copolymers were estimated.  As shown 
in Figure 3.3C, PC-zwitteronics were prepared with varying solution properties due to the 
polyMPC Xn values, ranging from 2 to 36. 
 
Figure 3.3: (A) Representative 1H-NMR spectrum (500 MHz) of PC-zwitteronic P20 
in MeOD-d4; (B) representative 
31P-NMR spectrum (202 MHz) of P20 in MeOD-d4; 
(C) targeted and estimated copolymer compositions of block copolymers P16-P20. 
Polymer
Targeted MPC 
incorporation
(mol %)
Measured MPC 
incorporation 
(mol %)a
Copolymer
composition
P16 7 5 polyMPC2-PPO82-polyMPC2
P17 16 15 polyMPC7-PPO82-polyMPC7
P18 23 20 polyMPC11-PPO82-polyMPC11
P19 38 35 polyMPC22-PPO82-polyMPC22
P20 46 47 polyMPC36-PPO82-polyMPC36
(A)
(C)
aMeasured using 1H-NMR spectroscopy (500 MHz, MeOD-d4)
(B)
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 Selecting a suitable polymerization solvent proved crucial for preparing PC-
zwitteronic block copolymers with narrow molecular weight distributions.  Polymerization 
in methanol (MeOH) gave block copolymer products with bimodal molecular weight 
distributions, as characterized by GPC (Figure 3.4A).  This lack of control over 
polymerization kinetics was attributed to phase separation that occurred upon mixing 
homogenous solutions of MPC and P15.  In contrast, polymerizations performed in TFE, 
a good solvent for polymer zwitterions,36,43 led to well-defined triblock copolymers.  
Molecular weight distributions of polymers P15-P20, shown in Figure 3.4B, were 
characterized by GPC eluting in TFE, with Mn and PDI values estimated relative to PMMA 
 
Figure 3.4: (A) GPC chromatograms of PC-zwitteronics eluting in TFE prepared using 
MeOH as the polymerization solvent with polyMPC segments having Xn values of 5 or 
18; (B) GPC chromatograms of polymers P15-P20 eluting in TFE; (C) values of Mn 
and PDI for P15-P20 estimated by GPC eluting in TFE relative to PMMA standards. 
Polymer
Mn
(g/mol)a PDIa
P15 19,850 1.01
P16 20,850 1.14
P17 25,180 1.18
P18 26,530 1.17
P19 29,200 1.16
P20 34,670 1.32
aMn and PDI values estimated by GPC eluting in TFE
relative to PMMA standards.
(A) (B)
(C)
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calibration standards (Figure 3.4C).  As anticipated, Mn values for P16-P20 increased with 
polyMPC Xn, and all block copolymers were isolated with reasonably low PDI values.  
High and low molecular weight shoulders were noted in the chromatograms of P16 and 
P19, respectively.  Although these features suggest varying rates of MPC initiation from 
the PPO macroinitiator chain ends, they were at low intensity relative to the main polymer 
peaks.  Moreover, the macroinitiated ATRP of MPC in TFE affords polyMPC-PPO-
polyMPC triblock copolymers with precisely tunable compositions and narrow molecular 
weight distributions. 
 Owing to the orthogonal solubility of the PPO and zwitterionic blocks, the PC-
zwitteronics readily aggregated into nanoparticles in water with hydrodynamic diameters 
ranging from 16 to 164 nm.  CAC values of block copolymers P16-P20 were estimated in 
pure water using a pyrene fluorescence assay in which photoluminescence (PL) emission 
of the hydrophobic fluorophore is sensitive to its local chemical environment.44  In aqueous 
surfactant-containing solutions, the ratio of the PL peak intensities corresponding to the 
first (I1, λem ~ 374 nm) and third (I3, λem ~ 385 nm) vibronic bands decreases sharply as 
pyrene is encapsulated in the nanoparticle core.  To estimate CAC values for the PC-
zwitteronic block copolymers, pyrene was added at ~0.6 µM in serial aqueous dilutions of 
polymers P16-P20.  After incubating at room temperature for 16-18 hours, PL emission 
spectra were collected at an excitation wavelength of 336 nm.  Figure 3.5A shows a 
representative plot of I1/I3 values for P19 at different polymer concentrations.  Above a 
critical concentration, the I1/I3 value decreased rapidly, indicating pyrene solubilization 
into the nanoparticle core.  Similar behavior was noted for the other PC-zwitteronics, and 
the CAC of each block copolymer was estimated from the onset of the I1/I3 reduction.  The 
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estimated CACs, summarized in Figure 3.5C, decreased with polyMPC block length.  
Relative to comparable Pluronic compositions (i.e., Pluronic L121, P123, and F127), PC-
zwitteronics exhibited higher CACs, evident by comparing values determined for P17 and 
P19 with those of commercial Pluronics having hydrophilic segments with similar Xn 
values (L121 and P123, respectively).45  Furthermore, P19 and P20 exhibited higher CAC 
values than F127, a Pluronic having Xn for each PEO segment of 100.  These higher CAC 
 
Figure 3.5: (A) A representative plot of the relative fluorescence intensity of the first 
(I1) and third (I3) vibronic bands for pyrene in aqueous solutions at varying P19 
concentrations; (b) DLS plots for P16-P20 in water above CAC at 25 °C; (c) CAC 
values for P16-P20 and Pluronics L121, P123, and F127 estimated using a pyrene 
fluorescence assay, as well as corresponding aggregate hydrodynamic diameters 
measured using DLS. 
(C)
Polymer
CACa
(mg/mL)
Pluronic
Equivalent CAC45
(mg/mL)
Hydrodynamic
Diametere
(nm)
P16 0.0017 - 164
P17 0.0055 0.0044b 122
P18 0.011 - 106
P19 0.058 0.025c 38, 122
P20 0.062 0.035d 16, 79
aAqueous CAC values estimated using a pyrene fluorescence assay fluorescence 
assay.  bPluronic L121 (PEO5-PPO68-PEO5).  
cPluronic P123 (PEO20-PPO69-PEO20).  
dPluronic F127 (PEO100-PPO65-PEO100).  eHydrodynamic diameters of PC-
zwitteronics measured by DLS analysis of 1 mg/mL aqueous suspensions.
(B)(A)
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values suggest a greater hydrophilicity of the zwitterionic blocks relative to PEO, findings 
consistent with investigations demonstrating greater hydration and hydrophilicity of 
zwitterionic vs. EO-based surfactants, hydrogels, and films.46-49  
 The hydrodynamic diameters of these zwitteronic nanoparticles, comprising 
hydrophobic PPO cores and hydrophilic polyMPC coronae, were assessed by DLS at 
concentrations well above the CAC of each polymer (1 mg/mL).  DLS plots and 
hydrodynamic diameters for P16-P20, after filtration through 0.45 µm membranes, are 
shown in Figure 3.5B.  Block copolymers P16-P18 formed monomodal particles with 
mean diameters ranging from 106-164 nm which decreased with zwitterion content.  In 
contrast, the more hydrophilic block copolymers P19 and P20 formed bimodal 
nanoparticles consisting predominantly of the smaller (38 and 16 nm, respectively) 
aggregates, as confirmed by number-based DLS analysis. 
 In addition to exhibiting concentration-dependent assembly properties, PC-
zwitteronics exhibited thermoresponsive aqueous miscibility and clouding behavior 
analogous to conventional Pluronics.  Aqueous solubility was assessed by measuring 
visible light transmission (λ = 550 nm) through 10 mg/mL suspensions of PC-zwitteronics 
in water as a function of temperature.  As shown in Figure 3.6, block copolymers P16-P18 
exhibited sharp LCST transitions ranging from -2.6 to 0.5 °C, increasing with PC content.  
On the other hand, the more hydrophilic P19 showed a weak cloud point transition at 9.9 
°C, while the triblock copolymer with the longest polyMPC block, P20, demonstrated no 
LCST behavior.  Surprisingly, the PC-zwitteronic block copolymers did not undergo the 
thermally induced physical gelation characteristic of conventional Pluronics, even at 
polymer concentrations approaching 200 mg/mL (17 weight percent) in water and at 
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temperatures up to 95 °C.  In comparison, Pluronic F127 gelled at 200 mg/mL and 36 °C.  
As physical crosslinking of Pluronics solutions is induced by hydrophobic interactions and 
micellar aggregation,16 the absence of thermal gelation behavior exhibited by the 
zwitteronic block copolymers suggests that the pendent zwitterions are sufficiently 
hydrated so as to prevent aggregation, even at high concentrations.  
 Surface tension measurements of aqueous suspensions of P16-P20, above their 
CAC values, were performed using a Langmuir instrument equipped with cylindrical glass 
troughs (0.2 cm depth, 1.5 cm diameter) and a metal probe (0.51 mm diameter).  
Measurements were conducted by inserting the tip of the probe into the polymer 
suspensions (~350 µL), allowing the block copolymer amphiphiles to spread from the air-
water interface to the probe surface.  The probe was equilibrated in each polymer solution 
for at least 10 minutes, and equilibrium surface tension values (γeq) were obtained by 
averaging the observed γ values at the end of each measurement.  Values of γeq for P16-
P20 are shown in Figure 3.7A, along with γeq obtained for the PPO starting material, a 
 
Figure 3.6: Cloud point curves for P16-P20 suspensions (10 mg/mL in water). 
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polyMPC homopolymer sample prepared by reversible addition-fragmentation chain-
transfer (RAFT) polymerization (P21, Mn = 38,500 g/mol, PDI = 1.08), and a commercial 
sample of PEO (Mn ~ 1,500 g/mol).  While the PEO homopolymer showed a slight 
reduction in aqueous surface tension (γeq = 68.8-65.6), water-soluble polyMPC P21 
 
Figure 3.7: (A) Room temperature γeq values for aqueous suspensions of PC-
zwitterionics P16-P20, polyMPC P21, PEO, and PPO at varying polymer 
concentrations.  The blue line shows γeq for pure water (72.8 mN/m); (B) room 
temperature γeq values measured for Pluronics L121, P123, and F127 at varying 
polymer concentrations in pure water. 
(A)
(B)
water (γ = 72.8 mN/m)
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exhibited γeq values comparable to pure water (72.1-73.0 mN/m), demonstrating its 
hydrophilic, non-surface-active nature.  The PC-zwitteronics, on the other hand, markedly 
altered the aqueous surface tension, reducing γeq to 37.8-42.4 and 36.0-37.4 mN/m at 
concentrations of 0.1 and 10 mg/mL, respectively.  Values of γeq for P16-P20 were nearly 
equivalent to that of the PPO starting material at all concentrations.  Pluronics L121 and 
P123 showed similar surface activity in water, reducing γeq to values of 36.2 and 36.6 
mN/m respectively, at a concentration of 0.1 mg/mL, and 34.2 and 34.1 mN/m at 10 mg/mL 
(Figure 3.7B).  In comparison, the more hydrophilic Pluronic F127 was less surface active, 
reducing γeq to values of 44.7 and 39.5 mN/m at concentrations of 0.1 and 10 mg/mL, 
respectively.  This diminished surface activity is characteristic of Pluronics, for which 
aqueous surface tension values of compositions with similar PPO molecular weight 
generally increase with increasing PEO molecular weight.3,50  In contrast, PC-zwitteronics 
P16-P20 exhibited a non-monotonic change in γeq with increasing polyMPC Xn and 
demonstrated composition-independent surfactant properties. 
 
3.3 Synthesis of Functional Zwitterionic Pluronic Mimics 
 Seeking to expand the scope of the zwitteronics platform by introducing reactive 
functionality, zwitteronic block copolymers bearing pendent alkyne moieties distributed 
randomly throughout the hydrophilic blocks were synthesized by macroinitiated-ATRP.  
Alkyne groups, amenable to modification using azide-alkyne cycloaddition or thiol-yne 
chemistries, were incorporated into the hydrophilic segments by copolymerization of 
trimethylsilyl (TMS) alkyne-substituted choline phosphate methacrylate 1 with MPC.42  As 
shown in Figure 3.8A, alkyne-substituted P22 and P23 were synthesized by 
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Figure 3.8: (A) Synthesis of functional zwitteronic block copolymers P22 and P23 
bearing pendent alkyne moieties by the macroinitiated-ATRP of MPC and monomer 1, 
with subsequent TMS-deprotection performed using KF in MeOH; representative 1H-
NMR spectra of TMS-protected (B) and deprotected (C) functional PC-zwitteronic P23 
obtained in MeOD-d4. 
(A)
1)  CuBr, Bipy
TFE, r. temp.
2) KF, MeOH, 35  C
P22, P23
1
P15
(B)
(C)
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copolymerization of MPC and monomer 1 in TFE using macroinitiator P15 and a 
CuBr/bipyridine catalyst system.  Syntheses targeted TMS-alkyne incorporations of 20 
mole percent and zwitterionic blocks with Xn values of 12 and 24.  Monomer conversions 
reaching >90% were achieved and the TMS-protected polymers were purified in similar 
fashion as P16-P20.  Silyl deprotection was achieved by stirring the functional block  
copolymers at 35 °C in a methanolic solution of potassium fluoride (KF), and the 
deprotected polymers were purified by dialysis against water then isolated by 
lyophilization to afford functional zwitteronics P22 and P23 as white powders. 
 Figure 3.8 shows representative 1H-NMR spectra of P23 before (Figure 3.8B) and 
after (Figure 3.8C) TMS deprotection.  In both spectra, characteristic resonances of pendent 
PC and alkyne-CP moieties were observed, including signals corresponding to 
trimethylammonium (peak k, δ = 3.22-3.34 ppm) and dimethylammonium (peak n, δ = 
3.34-3.43 ppm) protons of the PC and CP zwitterions, respectively.  In the spectrum of the 
protected block copolymers, a sharp singlet for protons of the TMS protecting groups was 
seen at 0.14 ppm.  Comparing integral values for signals corresponding to the TMS and 
PC methylene protons (peak j, δ = 3.67-3.79 ppm) before (Figure 3.8B) and after treatment 
with KF (Figure 3.8C), deprotection afforded polymers P22 and P23 with ~95 of the TMS 
protecting groups removed.  Copolymer compositions for the functional zwitteronics, 
summarized in Table 3.1, were estimated prior to TMS removal using 1H-NMR 
spectroscopy by comparing relative intensities of the CP, PC, and PPO resonances.  The 
estimated compositions of P22 and P23 were in excellent agreement with targeted values.  
Functional block copolymers P22 and P23 were prepared with monomodal molecular 
  59 
weight distributions and reasonably low PDI values (Table 3.1), as estimated using GPC 
eluting in TFE. 
  Possessing hydrophilic segments with reactive alkynes embedded directly within 
the zwitterion, block copolymers P22 and P23 are functional amphiphiles well-suited for 
nanomaterials synthesis using facile click reactions.  To demonstrate the versatility of these 
functional Pluronic mimics, thiol-yne chemistry was employed to covalently crosslink 
nanoparticles and hydrogels.  Such crosslinked structures are of particular interest as robust 
or even injectable materials and for encapsulation and release of hydrophobic moieties (i.e., 
therapeutics, dyes, etc.)51,52; notably, nanoparticle-crosslinked hydrogels have been 
examined as mechano-responsive networks and biocompatible matrices for tunable drug 
delivery.53-56  
 As shown in Scheme 3.3, UV-mediated crosslinking of aqueous P22 or P23 
nanoparticle suspensions afforded shell-crosslinked nanoparticles or nanoparticle-
crosslinked hydrogels depending on the composition of the thiol crosslinker.  Thiol-yne 
crosslinking of nanoparticle coronae to give stable zwitteronic nanoparticles was carried 
out by irradiation of aqueous polymer suspensions using 365 nm light in the presence of 
dithiothreitol (DTT) as a difunctional crosslinker and Irgacure 2959 as the photoinitiator.  
Table 3.1: Composition and molecular weight data for functional zwitteronics P22 and 
P23. 
Polymer 
Targeted 
Xn 
(MPC, MCP) 
Measured Xna 
(MPC, MCP) 
Mnb 
(g/mol) 
PDIc 
P22 10, 2 11, 2 23,450 1.16 
P23 19, 5 19, 4 31,310 1.31 
 
aEstimated by 1H-NMR spectroscopy (500 MHz) in MeOD-d4. 
bEstimated using GPC eluting in TFE and calibrated against PMMA standards. 
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The thiol-yne reactions were performed at 1:2 alkyne:thiol ratio and polymer concentration 
of either 50 or 100 mg/mL.  DLS curves of P22 and P23 in MeOH at 1 mg/mL are shown 
in Figure 3.9A.  Prior to UV exposure, the pristine P22 and P23 formed well-dispersed 
unimers with mean hydrodynamic diameters of ~14 and 21 nm in MeOH, respectively, a 
good solvent for both the PPO and zwitterionic segments.  Following irradiation in the 
presence of DTT, the P22 nanoparticles remained intact in MeOH and exhibited a 
significantly larger average hydrodynamic diameter (ca. 44 nm) than did the MeOH-
soluble P22 prior to the reaction.  Similar results confirming DTT nanoparticle crosslinking 
were also observed for P23.  Aqueous suspensions of the DTT-crosslinked P22 and P23 
nanoparticles, diluted to a concentration of 1 mg/mL, were cast on carbon-coated grids, 
allowed to dry at room temperature under ambient conditions, and visualized by 
transmission electron microscopy (TEM).  As shown in the representative TEM 
micrographs in Figure 3.9B, spherical P22 (left) and P23 (right) nanoparticles were 
observed, with estimated diameters of 80 ± 30 nm and 51 ± 22 nm, respectively.  Though 
the nanoparticles exhibited relatively broad size distributions, they were observed as well-
dispersed structures with discrete and intact coronae, suggesting a minimal degree of inter-
particle coupling.  
Scheme 3.3: Synthesis of shell-crosslinked nanoparticles by aqueous thiol-yne 
crosslinking of functional zwitteronics. 
 
 
Irgacure 2959
H2O, hν
crosslinked
nanoparticles
P22 or P23
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 Substituting DTT with a tetra-functional PEO thiol (alkyne:thiol molar ratio of 1:1) 
and using a similar UV-initiated thiol-yne strategy afforded hydrogels crosslinked through 
alkyne-bearing zwitteronic nanoparticles.  Figure 3.10 shows images of 10, 25, 50, and 100 
mg/mL P23 aqueous suspensions before and after irradiation at 365 nm.  Following 
irradiation, the 25, 50, and 100 mg/mL suspensions no longer flowed upon vial inversion, 
demonstrating network formation.  Reactions performed at zwitteronic concentrations of 
10 mg/mL failed to yield macroscopic hydrogels, suggesting a critical concentration of 
alkyne functionality is necessary to afford robust covalent hydrogels from the functional 
zwitteronics. 
 In collaboration with Yalin Liu, hydrogels prepared from functional zwitteronics 
P22 and P23 at concentrations of 50 and 100 mg/mL were allowed to swell in water at 
room temperature for 18-24 hours and were characterized by rheology at 37 °C.  A 
 
Figure 3.9: (A) DLS curves of P22 (left) and P23 (right) in MeOH (1 mg/mL) before 
and after UV exposure, confirming thiol-yne crosslinking; (B) TEM images of P22 
(left) and P23 (right) DTT-crosslinked nanoparticles cast on carbon-coated TEM grids. 
crosslinked P22 nanoparticles crosslinked P23 nanoparticles
pre-UV
(unimer)
post-UV
(crosslinked nanoparticle)
P22 in MeOH
(A)
(B)
P23 in MeOH
pre-UV
(unimer) post-UV
(crosslinked nanoparticle)
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representative plot of the elastic modulus (G’), viscous modulus (G”), and tan(delta) for 
the 100 mg/mL P23 hydrogel are shown in Figure 3.11A.  Values of G’ and tan(delta) 
remained relatively constant at varying frequencies, confirming crosslinking of the 
nanoparticle network; similar behavior was noted for the P22 hydrogels and the P23 
network prepared at a zwitteronic concentration of 50 mg/mL.  Values of G’ measured at 
nearly all frequencies for the P22 and P23 gels were more than an order of magnitude 
greater than corresponding G” values, demonstrating that the thiol-yne crosslinked 
hydrogels exhibit predominantly elastic behavior.  Elastic moduli of the nanoparticle-
crosslinked hydrogels were estimated from G’ values obtained at the lowest frequency 
tested (1 rad/s).  As shown in the table in Figure 3.11B, hydrogels prepared from polymers 
P22 and P23 exhibited elastic moduli of 1.03-3,950 Pa and 1,110-14,800 Pa, respectively.  
 
Figure 3.10: (A) Preparation of nanoparticle-crosslinked hydrogels by thiol-yne 
crosslinking of P22 or P23 in water using tetrafunctional PEO thiol; (B) images of P23 
suspensions before and after UV-mediated thiol-yne crosslinking at polymer 
concentrations of 10, 25, 50, and 100 mg/mL. 
P23 Pre-UV
25 mg/mL 50 mg/mL 100 mg/mL10 mg/mL
P23 Post-UV
25 mg/mL 50 mg/mL 100 mg/mL10 mg/mL
Irgacure 2959
H2O, hν
P22 or P23
nanoparticle-crosslinked
hydrogels
(A)
(B)
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For both P22 and P23 hydrogels, the gel stiffness increased with functional zwitteronic 
concentration.  Additionally, hydrogels prepared from P23 exhibited higher elastic moduli 
than comparable P22 gels, suggesting that the stiffness of these nanoparticle-crosslinked 
hydrogels can readily be tuned over four orders of magnitude through changes in polymer 
concentration and functional group incorporation.  Notably, the elastic modulus estimated 
for the 100 mg/mL P23 gel was comparable to that of a Pluronic F127 thermogel prepared 
at concentration of 200 mg/mL.  As Pluronic F127 thermogels have been examined for 
controlled drug delivery,57-62 the results of this rheological characterization suggest that 
matrices prepared from functional zwitteronic block copolymers possess elastic properties 
potentially suitable for therapeutic applications. 
 
3.4 Conclusions 
 To summarize, a novel and versatile platform of zwitterionic Pluronic mimics, or 
zwitteronics, was prepared by ATRP methodology starting from a difunctional PPO 
macroinitiator.  Optimized polymerization conditions afforded polyMPC-b-PPO-b-
polyMPC copolymers with narrow molecular weight distributions and compositions in 
 
Figure 3.11: (A) representative plots of the elastic modulus (G’), viscous modulus (G”), 
and tan(delta) measured for the 100 mg/mL P23 hydrogel; (B) elastic moduli of P22, 
P23, and Pluronic F127 hydrogels measured by rheology. 
G’
G”
tan(delta)
Polymer
Concentration
(mg/mL)
Elastic 
modulusa
(Pa)
P22 50 1.03
P22 100 3,950
P23 50 1,110
P23 100 14,800
Pluronic F127 200 10,200
aElastic modulus values estimated from G’ values
measured at a frequency of 1 rad/s.
(A) (B)
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which Xn of the polymer zwitterion block ranged from 2 to 36.  Upon dispersion in water, 
PC-zwitteronics formed nanoparticles with CAC values and hydrodynamic diameters 
readily tuned via zwitterion content.  PC-zwitteronics are surfactants which reduce aqueous 
surface tension values similar to those of conventional Pluronics, while also exhibiting 
unique composition-independent surface activity.  Furthermore, PC-zwitteronics 
demonstrated similar LCST miscibility as Pluronics while requiring significantly lower 
hydrophilic block content to form homogenous, non-clouding suspensions.  Interestingly, 
the zwitteronic block copolymers did not form physical gels at high concentrations; this 
behavior was attributed to the extreme hydrophilicity of the pendent zwitterions which 
precludes intermicellar aggregation.  By copolymerizing MPC with an alkyne-substituted 
choline phosphate methacrylate, functional zwitteronic block copolymers amenable to 
post-polymerization modification were prepared with functional group incorporations of 
20 mole percent.  As an initial demonstration, the functional Pluronic mimics were used to 
generate robust, crosslinked nanoparticles and hydrogels via thiol-yne coupling.   
 The modular synthetic strategy presented in this work gives access to amphiphiles 
with tunable composition and properties.  As such, future syntheses aim to incorporate 
diverse chemical functionality (e.g., alkyl or alkene moieties) through pendent choline 
phosphate groups, as well as temperature and salt-responsive sulfobetaine (SB) zwitterions.  
Additionally, future studies will examine zwitteronic amphiphiles as dispersants, and 
investigate crosslinked zwitteronic nanoparticles and networks for sustained release 
applications. 
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CHAPTER 4 
 
POLYMER PRODRUGS FOR TREATING OVARIAN TUMORS 
4.1 Introduction 
 Ovarian cancer is the most lethal gynecological malignancy among women in the 
United States, and remains a leading cause of death with approximately 22,000 diagnoses 
and 14,000 deaths annually.1  Early tumor detection is challenging, and patients often 
present advanced, metastatic, or disseminated disease at diagnosis.  Conventional treatment 
involves surgical de-bulking of solid tumor accompanied by chemotherapy.  Doxorubicin 
(Dox), an anthracycline chemotherapeutic, remains a prominent treatment option for 
various hematologic cancers and solid tumors, including malignant ovarian neoplasms.2,3  
While Dox is a powerful antitumor agent, its efficacy is limited by rapid clearance kinetics 
and non-specific accumulation in healthy tissue.  This poor specificity leads to off-target 
toxicity resulting in myelosuppression, gastrointestinal irritation, and cardiotoxicity, thus 
limiting Dox dosing even when otherwise effective for tumor reduction.2,4   
 To improve the therapeutic efficacy of Dox, specifically its pharmacokinetics, 
toxicity, and tumor accumulation, conjugation to polymers offers a convenient and 
attractive strategy.  Polymer-drug conjugation affords prodrugs of larger hydrodynamic 
size than the drug alone.  This lengthens renal clearance half-life and prolongs in vivo 
circulation.5  Coupling this improved pharmacokinetic profile with the enhanced 
permeability and retention (EPR) effect, whereby polymer-drug conjugates penetrate into 
the leaky vasculature of tumors and become entrapped due to poor tumoral lymphatic 
drainage, drug uptake in solid tumors is enhanced and off-target organ accumulation 
reduced.6-8  For ease of delivery, hydrophilic polymers solvate otherwise water insoluble 
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drugs at high loadings,9-15 and are potential replacements for excipients (i.e., ethanol or 
Cremophor® EL) which prove problematic in some patient populations for causing severe 
or even fatal anaphylactic reactions.16,17 
 Emrick and coworkers previously reported the synthesis and in vivo evaluation of 
a polymer-Dox prodrug prepared from poly(2-methacryloyloxyethyl phosphorylcholine) 
(polyMPC),18,19 a hydrophilic polymer noted for its exceptional water solubility and 
biocompatibility.20-22  Using a polyMPC copolymer containing pendant acyl hydrazines, 
Dox conjugation was achieved by formation of hydrazone bonds, which are acid-sensitive 
and thus cleavable in vivo in the acidic microenvironment of solid tumors,23,24 or 
intracellularly in acidic endosomes and lysosomes.25  PolyMPC-Dox prodrugs exhibited 
an in vivo circulation half-life of greater than 2 hours, and in an aggressive mouse breast 
tumor model (4T1 cell line) administration of polyMPC-Dox reduced the mean tumor size 
and afforded a two-fold increase in survival time over Dox-treated mice.  Dox in the 
prodrug animal group accumulated in tumors at twice the level of free Dox, with a 
corresponding reduction in off-target organ uptake. 
 To gauge the therapeutic breadth and clinical relevance of polyMPC-based 
chemotherapeutics (i.e., polyMPC-Dox), work presented in this section sought to test the 
effectiveness of polyMPC-Dox in a human tumor line, specifically the SKOV-3 ovarian 
tumor model.  SKOV-3 tumors are Dox-resistant at dosing levels tolerated by animals,3 
and thus this model allows evaluation of polymer-Dox conjugates in a challenging human 
tumor model.  Experiments were performed with polyMPC and polyMPC-Dox to evaluate 
in vivo biocompatibility and establish a maximum tolerated dose (MTD) of the prodrug.  
Mice with subcutaneously established SKOV-3 xenografts were treated with Dox or 
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polyMPC-Dox using a recurring dosing schedule resembling that employed for human 
patients.26  Animals were monitored for symptoms of treatment-associated toxicity, change 
in tumor size, and survival.  The overall accumulation of Dox and polyMPC-Dox in solid 
ovarian tumors was compared, as was the specificity for uptake in tumor tissue versus off-
target organs.  In vivo experiments discussed in this section were performed in 
collaboration with researchers at the Pioneer Valley Life Sciences Institute (Springfield, 
MA). 
 
4.2 Evaluation of PolyMPC-Dox Prodrugs in Human Ovarian Tumors 
 PolyMPC P24 was prepared for in vivo biocompatibility evaluation by the room 
temperature atom transfer radical polymerization (ATRP) of MPC in methanol (MeOH) 
using copper(I) bromide (CuBr) and 2,2’-bipyridyl (Bipy) as the catalyst and ligand, 
respectively (Figure 4.1A).18  Following the polymerization, residual reagents were 
removed by passing the product mixture through a plug of silica gel, then dialyzing against 
pure water.  Polymer P24 was isolated by lyophilization as a granular, white solid in up to 
75% yield, and its purity was confirmed by NMR spectroscopy (Figure 4.1B).  Number-
average molecular weights (Mn) of polymer P24 were estimated by gel permeation 
chromatography (GPC) in 2,2,2-trifluoroethanol (TFE) to be 41,900-43,500 g/mole, 
 
Figure 4.1: (A) Synthesis of polyMPC P24 by ATRP of MPC in MeOH; (B) 1H-NMR 
(500 MHz) spectra of polymer P24 in MeOD-d4. 
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relative to poly(methyl methacrylate) (PMMA) calibration standards, with polydispersity 
index (PDI) values of 1.17-1.25.  Given its similarity in chemical structure, PMMA, for 
which TFE is a good solvent, is a useful GPC standard for P24.  These Mn estimates for 
P24 were in general agreement with targeted values (~35,000 g/mole).  It should be noted 
that the zwitterionic structure of the polymer precludes molecular weight evaluation by 
mass spectrometry such as matrix-assisted laser desorption time-of-flight (MALDI-TOF) 
techniques. 
 Three batches of polyMPC-Dox P26 were synthesized to gauge its in vivo toxicity, 
biodistribution, and tumor efficacy.  Functional polyMPC-hydrazine P25, with randomly 
incorporated pendent acyl hydrazine moieties, was prepared by ATRP and post-
polymerization modification using a strategy described by Emrick and coworkers (Figure 
4.2A).18,19  A 22 mole percent hydrazine content in polymer P25 was estimated by 1H-
NMR spectroscopy (Figure 4.2B).  As shown in Figure 4.2A, polymer prodrug P26 was 
prepared by reacting P25 with Dox•HCl in acidified methanol (MeOH), affording covalent 
conjugation by acyl hydrazone formation.  Residual Dox•HCl was removed by passing the 
prodrug solution through size exclusion media eluting with MeOH and then pure water.  
Following lyophilization, polymer prodrug P26 was isolated as a dark red powder in yields 
greater than 84%.  The purity of P26 was assessed by GPC in TFE, with detection by UV 
absorbance.  In chromatograms of polymer P26 (Figure 4.2C), a single unimodal peak was 
observed, with a notable absence of low molecular weight components, demonstrating the 
successful removal of residual Dox•HCl from the prodrug.  UV-Vis analysis of aqueous 
solutions of different batches of P26 (Figure 4.2D) confirmed Dox conjugation and gave 
calculated Dox weight percent loadings of 16.7-20.6%, comparable loading to the prodrug 
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assessed by Emrick and coworkers in the 4TI mouse breast cancer model.19  PolyMPC-
Dox P26 was found to have an average hydrodynamic size in phosphate-buffered saline 
(PBS) of 13.9 ± 0.2 nm, as determined by dynamic light scattering (DLS).  The formation 
of a very minor population of self-associated aggregates was noted, behavior which was 
similarly observed for solutions of polymer P24 in PBS.  In both cases, unimers were the 
predominant population, suggesting that polymers P24 and P26 are well-dispersed in 
injectable saline. 
 
Figure 4.2: (A) Synthesis of polyMPC-Dox prodrug P26 by conjugation of polyMPC-
hydrazine P25 and Dox•HCl; (B) 1H-NMR spectrum of polymer P25 in MeOD-d4; 
(C) TFE GPC chromatograms of Dox and polyMPC-Dox P26.  For prodrug P26, a 
single polymer fraction was observed (24.8 minutes), with a notable absence of any 
residual Dox (33.6 minutes); (D) UV-Vis absorbance spectra of Dox (0.05 mg/mL, 
λmax = 494 nm) and P26 (0.25 mg/mL, λmax = 487 nm) in pure water. 
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 The in vivo biocompatibility of P24 was assessed using a dosing study to establish 
an MTD of polyMPC, or the lowest dose at which systemic toxicity is observed.  Non-
obese diabetic severe combined immunodeficient (NOD SCID) mice, commonly used for 
xenograft tumor models,27,28 received solutions of P24 in Hank’s balanced salt solution 
(HBSS) at doses of 50, 100, 200, 400, or 800 mg/kg.  Two intravenous injections of these 
doses were administered, at Day 0 and 17, and the weight, physical appearance and 
behavior of the animals were monitored daily and compared to a control group 
administered HBSS.  Polymer P24 was well-tolerated with no noted physical or behavioral 
indication of toxicity.  As shown in Figure 4.3A, mice given polymer P24 at all doses 
exhibited weight gains similar to those of control mice, indicating excellent 
biocompatibility of injected polyMPC.  Histological evaluation of the heart, kidneys, 
spleen, and lungs resected from mice treated with polymer P24 showed no differences from 
the organs of the control animals.  The livers of mice administered polymer P24 exhibited 
a minor increase in lymphocyte concentration at higher polymer doses with no 
corresponding effect on the health of the hepatocytes, as shown in Figure 4.3B.  While this 
work initially sought to establish a definitive MTD for polymer P24, solutions of the 
polymer at doses greater than 800 mg/kg were exceedingly viscous and unsuitable for 
intravenous administration.  Nonetheless, these experiments suggest polyMPC to be non-
toxic even at high doses and indicate a general suitability of polyMPC as an injectable drug 
carrier. 
 The toxicity of polymer prodrug P26 was evaluated in NOD SCID mice to 
determine appropriate doses for subsequent biodistribution and tumor efficacy studies.  
While prodrug P26 was tolerated in athymic nude mice at Dox equivalent doses greater 
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than three-fold the reported MTD of 8 mg/kg for free Dox,18,29 NOD SCID mice are 
uniquely sensitive to Dox,30 with systemic toxicity to Dox observed at doses as low as 4 
mg/kg, necessitating a re-establishment of the prodrug MTD.  NOD SCID mice were 
administered a single tail vein injection of P26 in injectable saline at Dox equivalent doses 
of 10, 20, 30, 40 or 50 mg/kg, with control animals given a single injection of HBSS.  As 
shown in Figure 4.3C, mice given the prodrug at doses of 20-50 mg/kg experienced weight 
loss and required removal from the study by euthanasia.  However, mice administered P26 
 
Figure 4.3: (A) Percent change in the weight of mice administered two injections of 
HBSS (control) or polymer P24 at doses of 50-800 mg/kg.  Black arrows indicate days 
of administration (Day 0 and 17).  Error bars represent ± the standard error the mean 
(SEM); (B) representative hematoxylin and eosin (H&E) staining of liver sections of 
mice administered HBSS (left) and 800 mg/kg polyMPC P24 (right).  Generalized 
increased inflammation, indicated by green arrows, was observed in the livers of mice 
administered polyMPC P24 at a dose of 800 mg/kg.  Images were taken at 20X 
magnification with 40X magnification inlay images.  Scale bars represent 50 µm; (C) 
percent change in the weight of mice administered a single injection of HBSS (control) 
or polyMPC-Dox P26 at Dox equivalent doses of 10-50 mg/kg.  The black arrow 
indicates the day of administration (Day 0).  Error bars represent ± the SEM.  (D) 
representative H&E staining of liver sections of mice administered HBSS (left) and 
polyMPC-Dox P26 (right) at a Dox equivalent dose of 10 mg/kg.  Green arrows indicate 
evidence of increased lymphocytes and enlarged hepatocytes in the livers of mice 
administered P26.  Images were taken at 20X magnification with 40X magnification 
inlay images.  Scale bars represent 50 µm.  
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at a Dox equivalent dose of 10 mg/kg maintained healthy weights, and aside from minor 
injection site irritation in one animal, exhibited no overt signs of systemic toxicity.  
Histopathologic analysis of liver sections of mice administered prodrug P26 demonstrated 
evidence of lymphocytic infiltration and hepatocyte enlargement, as indicated in Figure 
4.3D.   However, as Dox treatment is commonly accompanied by hepatotoxicity, these 
changes are attributed to Dox itself.31,32  From these results, the Dox equivalent MTD of 
polymer prodrug P26 in NOD SCID mice was estimated to be 10 mg/kg, although the 
actual value might be higher, since dosing between 10 and 20 mg/kg was not performed.   
Similar to our previous findings, the MTD of the polyMPC-Dox prodrug was significantly 
higher than that of the drug alone, confirming the capacity of polyMPC to mask dose-
limiting Dox toxicity, and enable dosing at higher levels. 
 The in vivo biodistribution of both polymer-drug conjugate P26 and free Dox was 
assessed in mice bearing human ovarian tumors, comparing drug accumulation in tumor 
 
Figure 4.4: Biodistribution results following a single injection of free Dox (6 mg/kg) 
or polyMPC-Dox P26 (6 mg/kg, Dox equivalent weight) in SKOV-3 tumor-bearing 
mice.  Accumulation, expressed as ng Dox/g of tissue, was measured in tumors and 
major organs using HPLC.  Error bars represent ± the SEM (*p ≤ 0.1). 
*
Dox
P26
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tissue and off-target organs (i.e., liver, kidney, spleen, lung, and heart).  Subcutaneous 
SKOV-3 tumors were established in the right flanks of NOD SCID mice, and single doses 
of free Dox, at 6 mg/kg, or prodrug P26 at a Dox equivalent dose of 6 mg/kg, were 
administered by tail vein injection (n=3 mice per group).  These selected doses were 
consistent with the previous biodistribution analysis of prodrug P26 in a breast tumor 
model.19  As a control, three tumor-bearing mice were given a single injection of HBSS.  
Three days post-injection, the mice were euthanized, and the tumors and organs removed, 
weighed, and homogenized in acidified isopropanol.  The extracts were analyzed by high-
performance liquid chromatography (HPLC), and using the fluorescence and UV-Vis 
absorbance of Dox the concentration of accumulated drug was measured in each tissue, 
with data shown in Figure 4.4.19  Three days after introduction of the drug, mean tumor 
tissue accumulation of Dox from prodrug P26, and from free Dox, was 1120 ng/g and 567 
ng/g, respectively.   The accumulation of Dox from prodrug P26 in the solid tumors was 
nearly two-fold that of free Dox after a single injection, a significant difference at α = 0.10 
(p = 0.064).  However, no significant differences were observed for prodrug and Dox 
accumulation in off-target organs.  The greater Dox accumulation found in tumors resulting 
from the prodrug delivery system mirrors biodistribution analysis of polyMPC-Dox in a 
mouse breast cancer model.19 
 The efficacy of polymer prodrug P26 for treating human ovarian cancer was 
assessed using a SKOV-3 tumor model.  NOD SCID mice, with subcutaneously established 
SKOV-3 tumors, were divided into groups of eight and treated with HBSS saline (control), 
free Dox at 2 mg/kg (~ ½ MTD),30 or prodrug P26 at a Dox equivalent dose of 5 mg/kg (~ 
½ MTD).  Following tumor establishment, one mouse from the polyMPC-Dox group was 
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excluded due to formation of an intramuscular tumor (precluding accurate tumor volume 
measurements).  Dosing at approximately one-half of the MTD was selected in an attempt 
to minimize dose-limiting toxicity during the weekly dosing schedule designed to mimic 
current clinical dosing practice.26  Throughout the study, mice were monitored every 24-
48 hours, as were tumor volumes, weights, and overall health of the animals.  Animals 
were removed from the study when tumor volume exceeded 1,500 mm3, weight decreased 
by more than 20%, or signs of distress in appearance or behavior were evident.  Mice 
administered HBSS alone and prodrug P26 received a total of eight doses, while mice given 
free Dox received six or seven treatments (the seventh injection was withheld from several 
animals due to ulcer formation at the injection site).  By Day 50, seven of eight control 
animals were euthanized due to excessive tumor growth.  As a result of losing the control 
animals, final treatments were administered to all groups at Day 53.  An attempt to treat a 
set of animals with 5 mg/kg of Doxil, the liposomal formulation of Dox, failed due to a 
rapid systemic toxicity observed in these NOD SCID animals at that dosing level. 
 A summary of the efficacy study, shown in Figure 4.5, plots survival curves (Figure 
4.5A) and the percent change in mean tumor volumes (Figure 4.5B) following treatment 
with HBSS (control), free Dox, and polyMPC-Dox P26.  As shown in Figure 4.5A, mice 
treated with prodrug P26 exhibited mean survival time of 79 days, almost twice that of the 
control mice (~47 days) and 15 days longer than mice treated with free Dox (~64 days).  
Moreover, by Day 60, when all control mice had been euthanized, 86% of the animals 
treated with prodrug P26 were alive, while only 50% of the mice from the free Dox group 
had survived.  Overall survival for mice treated with prodrug P26 was 121 days, greater 
than two-fold the overall survival of the control mice, and 35 days longer than the free Dox 
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group.  It should be noted that survival curves were found to be significantly different (p = 
0.006) using log-rank analysis.  Additionally, the survival of mice treated with prodrug 
P26 was significant compared to control animals (p = 0.0016), and approached significance 
relative to the survival of mice treated with free Dox (p = 0.107).     
 In addition to improved survival, treatment with prodrug P26 reduced tumor growth 
compared to the free Dox and control groups, as shown in Figure 4.5B.  At Day 30, prior 
to euthanizing any animals, the average tumor volumes for HBSS, free Dox, and prodrug 
mice were 888 mm3, 660 mm3, and 588 mm3, respectively.  Tumors in mice administered 
HBSS or free Dox grew slowly for 40 days, after which the tumor growth rate in both 
groups rapidly increased.  At Day 79, the mean tumor volume for the free Dox group 
dropped sharply, a result of seven of eight mice requiring euthanasia due to tumor volumes 
exceeding the established maximum values.  Mean tumor growth in the prodrug P26 group, 
on the other hand, remained comparatively stagnant for approximately 80 days.  Moreover, 
the therapeutic effects of prodrug P26 lasted well beyond the end of the treatment schedule 
 
Figure 4.5: Survival curves (A) and percent change in mean tumor volumes (B) for 
SKOV-3 tumor-bearing mice treated with HBSS (control), free Dox (2 mg/kg), or 
polyMPC-Dox (5 mg/kg Dox equivalent dose).  The last treatment day for all groups 
was Day 53.  Error bars represent ± SEM. 
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(Day 53), as the change in mean tumor volume was suppressed continuously for nearly 4 
weeks following the final dose. 
 The systemic effects of free Dox and polyMPC-Dox treatments were gauged by 
measuring animal weight throughout the study, and monitoring their general appearance 
and behavior.  As shown in Figure 4.6, the mean weight of mice treated with prodrug P26 
and free Dox increased similarly to the control group, suggesting that treatments were well-
tolerated.  This is an impressive result, as mice were administered high cumulative doses 
of either free Dox (12-14 mg/kg) or prodrug P26 (40 mg/kg) without experiencing systemic 
toxicity.  Evidence of tail necrosis (manifested as ulcers at injection sites) was observed in 
several mice treated with free Dox, as well as in one mouse treated with prodrug P26, 
necessitating euthanasia.  While wounds observed in mice treated with free Dox eventually 
resolved, several ulcers were severe enough to prevent additional injections. 
 To assess the physiological effects of the recurring treatment regimen, animal 
organs were harvested, weighed, and evaluated (Figure 4.7A).  For the heart, lungs, and 
 
Figure 4.6: Percent change in mean weights of SKOV-3 tumor-bearing mice treated 
with HBSS (control), free Dox (2 mg/kg), or polyMPC-Dox (5 mg/kg Dox equivalent 
dose). 
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spleen, no significant differences in mean proportional weights were observed among 
treatment groups.  Histological analysis of heart sections for mice treated with free Dox 
 
Figure 4.7: (A) Proportional organ weights at time of euthanasia for NOD SCID mice, 
bearing subcutaneous SKOV-3 human ovarian tumors, treated with multiple 
administrations of HBSS (control), Dox (2 mg/kg), or polyMPC-Dox P26 (5 mg/kg 
Dox equivalent dose).  * and ** represent statistically significant differences at α = 
0.05 and α = 0.01, respectively.  Error bars represent ± SEM; (B) representative H&E 
staining of heart (left) and liver (right) sections of mice administered HBSS, Dox (2 
mg/kg), and polyMPC-Dox P26 (5 mg/kg Dox equivalent dose) in a SKOV-3 human 
ovarian tumor efficacy study.  Green arrows indicate eosinophilic fibers observed in 
the hearts of mice treated with free Dox and polyMPC-Dox P26.  Livers of mice 
treated with free Dox and polyMPC-Dox P26 exhibited generalized increased 
inflammation and hepatocyte enlargement relative to the livers of mice administered 
HBSS, as indicated by green arrows.  Images were obtained at 20X magnification 
with 40X inlay images.  Scale bars represent 50 µm. 
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and prodrug 26 showed evidence of minor myocyte eosinophilic fibers indicative of 
ischemic changes in the cardiac tissue, as depicted in Figure 4.7B.  However, these findings 
were variable and no consistent quantitative measure or trend was identified among 
treatment groups.  Differences were noted between the proportional weights of the liver 
and kidneys of control mice and mice treated with prodrug 26.  As shown in Figure 4.7B, 
histology of liver sections from mice treated with free Dox and the prodrug revealed 
evidence of enlarged hepatocytes, increased mitotic activity, and lymphocytic infiltration 
indicative of hepatotoxic injury.   These findings were even more striking within the liver 
sections of mice treated with free Dox, which is consistent with the known hepatotoxic 
nature of Dox.31,32  The changes observed in liver tissue, therefore, are attributable to Dox 
itself, and not the prodrug or polymer carrier.  Moreover, given the serial administration of 
drug used in this efficacy study, accumulation of Dox in organs involved in drug clearance 
would be expected.  Further research is thus warranted to examine polyMPC-Dox 
clearance, especially under treatment conditions that resemble current clinical regimens. 
 
4.3 Conclusions 
 This work described the first evaluation of a polyMPC cancer prodrug in a human 
tumor model.  The polyMPC-Dox conjugates employed are water-soluble polymer 
prodrugs, with an average Dox weight percent loading of ~19%.  The performance of the 
prodrug was compared to that of free Dox in a human ovarian tumor model (SKOV-3) to 
assess its toxicity, tumor accumulation properties, and therapeutic efficacy.  Toxicity and 
efficacy studies demonstrated that polyMPC-Dox could be administered to mice at greater 
than twice the dose of free Dox without causing systemic toxicity.  Moreover, polyMPC 
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itself was well-tolerated in these animals, even at very high doses (i.e., 800 mg/kg), 
demonstrating its utility in injectable polymer therapeutics.  From a single injection 
biodistribution study, Dox accumulation from the prodrug group in tumor tissue was nearly 
two-fold that of free Dox, without observation of enhanced uptake in off-target organs.  In 
an efficacy study, ovarian tumor-bearing mice receiving weekly prodrug dosing exhibited 
improved survival time and reduced tumor growth relative to free Dox treatment.  These 
results demonstrate the advantages of treating human ovarian tumors using the polyMPC-
Dox prodrug, including enhanced tumor uptake with reduced off-target toxicity, higher 
dosing capabilities, and improved therapeutic efficacy.  In vivo evaluation in human 
ovarian tumors suggests that the polyMPC-Dox prodrug is safer and more effective in the 
treatment of solid tumors compared to Dox.  Moreover, treatment with polyMPC-Dox did 
not elicit evidence of severe cardiotoxicity, even with recurring doses.  This study thus 
demonstrates the viability of polyMPC-Dox cancer therapy, and that a simple water-
soluble polymer-drug conjugate is useful for improving drug delivery to tumors, even 
without the presence of targeting groups or biorecognition sequences in the delivery 
vehicle. 
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CHAPTER 5 
 
POLYMER PRODRUGS FOR TREATING GLIOBLASTOMA 
5.1 Introduction 
 Glioblastoma is a solid neoplasm which originates from non-neuronal glial cells of 
the brain and represents the most commonly diagnosed central nervous system tumor in 
the United States.1  Due to its highly aggressive and infiltrative nature, the current 
prognosis for glioblastoma patients is poor: with combined neurosurgery, radiation 
therapy, and chemotherapy, median survival is 12-15 months.2-5  For complete eradication 
of infiltrative cells in surrounding healthy tissue, chemotherapy is critical to treatment.  
However, selection of appropriate drugs—typically alkylating agents such as 
temozolomide, carmustine, lomustine, and procarbazine (Figure 5.1)—is challenging, as 
the blood-brain barrier (BBB) generally only allows passage of lipophilic small molecules 
and essential nutrients from the bloodstream to the brain.6,7  This, combined with issues 
typical of most small molecule chemotherapeutics (i.e., off-target toxicity, rapid clearance 
following administration, and poor tumor selectivity), drives the development of new 
strategies for efficacious treatment of glioblastoma.   
 Local treatment immediately following surgical resection has been pursued as a 
potential alternative to systemic tumor treatment as a means of bypassing the BBB and 
 
Figure 5.1: Chemical structures of small molecule chemotherapeutics commonly 
utilized in treating glioblastoma. 
Temozolomide Carmustine ProcarbazineLomustine
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delivering chemotherapeutics to invasive cells in a sustained and targeted fashion.  To date, 
Gliadel®, a biodegradable carmustine-loaded polymeric wafer, remains the only approved 
local glioblastoma treatment.  While effective for carmustine delivery, the clinical use of 
Gliadel® is limited by severe side effects, including seizures, cerebral edemas, and 
intracranial bleeding, as well as wafer migration and incomplete degradation.8  Though 
‘softer’ matrices, such as drug-loaded hydrogels,9 may prove to be safe alternatives to 
Gliadel®, noninvasive systemic treatments which can cross the BBB have the potential to 
improve glioblastoma chemotherapy without the side effects of implantable materials. 
 Temozolomide (TMZ), a bis(imidazotetrazine) heterocycle, is the first-line drug 
used for treating glioblastoma, and, as such, current research efforts predominantly focus 
on enhancing its delivery and efficacy.  Administered orally, TMZ is a prodrug which 
releases a DNA alkylating methyldiazonium cation upon decomposition at physiological 
pH, as shown in Figure 5.2.10,11  Alkylation occurs primarily at O6 positions on guanine 
residues, generating apoptotic DNA mismatch errors.11  Owing to the slightly alkaline 
microenvironment of brain tumors,12 this pH- induced mechanism confers selective 
cytoxicity for malignant vs. healthy brain tissue, resulting in limited off-target toxicity.2  
 
Figure 5.2: Temozolomide (TMZ) decomposition at physiological pH affords 5-(3-
methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), and subsequent acid-catalyzed 
degradation yields 5-aminoimidazole-4-carboxamide (AIC) and the methyldiazonium 
cation which alkylates DNA (shown at the O6 position of guanine). 
 
H2O, pH 7.4
-CO2
[H+]
DNA alkylation
of guanine residues
alkylating 
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Temozolomide (TMZ)
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While TMZ effectively crosses the BBB, its efficacy is impeded by hydrolytic instability: 
TMZ rapidly degrades in vivo and exhibits a plasma half-life < 2 hours.10  As such, frequent 
dosing is required to maintain suitable antitumor activity.10,11,13  This hydrolytic instability 
also complicates clinical TMZ administration, as TMZ degrades over time if not stored 
under dry conditions.14-16  In addition to poor stability and a short in vivo half-life, TMZ 
efficacy is hampered by chemoresistance induced by O6-methylguanine-DNA methyl 
transferase (MGMT), a native enzyme that repairs damaged DNA following 
methylation.10,11  MGMT activity in glioblastoma tumors can be depleted by sustained 
TMZ exposure,17,18 and recurrent glioblastoma treated with dose-dense TMZ regimens 
improves tumor response.18-22  As these dose-dense treatments can increase occurrence of 
dose-limiting hematoxicity, new synthetic designs are needed which extend TMZ 
circulation and allow for delivery of high concentrations of drug, while simultaneously 
masking undesired off-target toxicity. 
 Previously investigated strategies to improve TMZ delivery include its co-
crystallization with organic acids,16 encapsulation in injectable nanomaterials,23,24 and 
conjugation to biocompatible polymer backbones.25,26  Covalent polymeric conjugation 
offers significant advantages, including extending TMZ lifetime in vivo, improving drug 
pharamacokinetics, allowing for high drug loading while retaining aqueous solubility, and 
masking drug-related toxicity.27-29  This section extends the poly(2-methacryloyloxyethyl 
phosphorylcholine) (polyMPC) prodrug platform30,31 discussed in Chapter 4 to TMZ, and 
presents the development of water-soluble polyMPC-TMZ conjugates for treating 
glioblastoma.  Through a novel TMZ-methacrylate derivative,32 TMZ was incorporated as 
pendent moieties in polyMPC-based random and block copolymers using reversible 
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addition-fragmentation chain-transfer (RAFT) polymerization.  The polymerization 
experiments afforded polyMPC-TMZ conjugates with tunable drug incorporation and 
narrow molecular weight distribution.  Polymerization conditions were optimized to ensure 
fidelity of the TMZ structure such that the conjugates would retain the efficacy of TMZ.  
Solutions properties of the polyMPC-TMZ copolymers were examined, and the effect of 
polymer architecture on the stability of pendent drug moieties was probed.  The antitumor 
activity of the prodrugs was tested in chemosensitive and chemoresistant glioblastoma cell 
lines, and their uptake by glioblastoma cells was assessed using confocal microscopy and 
flow cytometry.  Finally, this polymer prodrug platform was expanded through co-delivery 
of TMZ and O6-benzylguanine (O6-BG), an alkylating agent which shows promise for 
sensitizing TMZ-resistant glioblastoma tumors.33-36 
 
5.2 Synthesis of TMZ-Methacrylate 
 TMZ-methacrylate (TMZ-MA), the key monomer in this work, was prepared as 
shown in Scheme 5.1.  TMZ-carboxylic acid (TMZ-COOH) was synthesized by 
diazotization and hydrolysis of pristine TMZ in nitrous acid, generated in situ from sodium 
nitrite (NaNO2) and sulfuric acid (H2SO4), using a procedure similar to that described by 
Stevens and co-workers.37  Precipitation over ice afforded TMZ-COOH as a fine white 
solid in yields of up to 75%.  The absence of TMZ amide resonances in the 1H-NMR 
spectrum of TMZ-COOH (Figure 5.3) indicated complete carbamoyl hydrolysis and 
Scheme 5.1: Synthesis of TMZ-methacrylate (TMZ-MA). 
 
NaNO2, H2SO4, H2O
0  C  r. temp.
TMZ-COOH
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TMZ-MATMZ
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electron ionization high-resolution mass spectrometry  (HRMS-EI) confirmed the expected 
structure of TMZ-COOH ([M]+ calculated for C6H5N5O3: 195.0392 g/mol, found: 
195.0395 g/mol). 
 Esterification of TMZ-COOH with 2-hydroxyethyl methacrylate (HEMA) was 
initially attempted via the corresponding acid chloride by reaction of TMZ-COOH with 
thionyl chloride,38 resulting in imidazotetrazine degradation.  The comparatively mild 
carbodiimide-mediated esterification proved more effective.  As shown in Scheme 5.1, 
TMZ-MA was synthesized from TMZ-COOH and HEMA in the presence of 1-(3-
(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC) and catalytic 4-
(dimethylamino)pyridine (DMAP).  TMZ-MA was purified simply by aqueous extraction 
and isolated in 71% yield as a flaky white solid, with the expected molar mass confirmed 
by fast-atom bombardment HRMS (HRMS-FAB) ([M+H]+ calculated for C12H14N5O5: 
308.0995, found: 308.0989).  Spectroscopic characterization of TMZ-MA confirmed 
 
Figure 5.3: 1H-NMR (500 MHz) spectra of TMZ (A), TMZ-COOH (B), and TMZ-
MA (C) obtained in DMSO-d6; (D) UV-Vis absorption spectra of TMZ and TMZ-MA 
in 2,2,2-trifluoroethanol (TFE) at a concentration of 0.01 mg/mL. 
(A) (B)
(C) (D)
TMZ
TMZ-MA
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retention of the intact TMZ-moiety.  In the 1H-NMR spectrum of TMZ-MA (Figure 5.3C), 
resonances corresponding to the imidazole (δ = 8.85 ppm) and methyltriazene (δ = 3.88 
ppm) protons were observed; the UV-Vis absorption spectra of TMZ (λmax = 325 nm) and 
TMZ-MA (λmax = 323 nm) were nearly identical (Figure 5.3D). 
 
5.3 PolyMPC-TMZ Prodrugs: Synthesis, Solution Properties, and In Vitro Evaluation 
 The RAFT-mediated copolymerization of MPC and TMZ-MA was attempted 
initially in a methanol (MeOH)/dimethyl sulfoxide (DMSO) solvent mixture to ensure 
homogeneity.  Although monomer conversion was high (87%), UV-Vis characterization 
of the isolated copolymer showed a signfiicant absorption at λmax = 287 nm, indicative of 
TMZ decomposition to the AIC byproduct.38  This observation prompted an investigation 
of the stability of TMZ in organic solvents, findings not reported previously.  Solutions of 
TMZ in 1:1 MeOH/DMSO, DMSO, acetonitrile, and 2,2,2-trifluoroethanol (TFE) were 
incubated at room temperature, 50 °C, and 70 °C.  UV-Vis spectroscopy showed the 
absorption spectrum of TMZ to remain unchanged after 24 hour incubation in DMSO and 
acetonitrile at all temperature, as shown in Figure 5.4.  In contrast, TMZ heated to 50 or 70 
°C in 1:1 MeOH/DMSO degraded completely in 1 hour; significant degradation was 
observed even at room temperature.  Importantly, TMZ proved stable in TFE, a generally 
good solvent for polymer zwitterions, at temperature up to 70 °C for >24 hours.  The 
marked difference in TMZ stability in MeOH versus TFE is attributed to the weaker 
nucleophilicity of the latter, which slows or precludes imidazotetrazine solvolysis.39 
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 Given the insight derived from this TMZ stability analysis, polyMPC-TMZ 
prodrugs with random and block copolymer architectures were prepared by RAFT  
polymerization methodology in TFE.  As shown in Figure 5.5, random copolymers P27-
 
Figure 5.4: UV-Vis absorption spectra of TMZ solutions incubated at room temperature 
(left), 50 °C (middle), and 70 °C (right) in 1:1 MeOH/DMSO (A), DMSO (B), 
acetonitrile (C), and TFE (D). 
Room Temperature 50  C 70  C
(A)
(B)
(C)
(D)
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P30 were prepared by the copolymerization of MPC and TMZ-MA at 70 °C, utilizing 4-
cyano-4-phenyl(carbonothioylthio)pentanoic acid and 4,4’-azobis(4-cyanovaleric acid) 
(ACVA) as chain transfer agent (CTA) and initiator, respectively.  Reagent stoichiometries 
were adjusted to target copolymers with approximate number-average molecular weight 
(Mn) values of 30,000 g/mol, and monomer feed ratios were intended to afford 20, 25, 35, 
and 50 mol percent incorporation of TMZ-MA into polymers P27-P30, respectively.  
Monomer conversions >85% were achieved in polymerization times of 6-9 hours.  
Polymerizations were terminated by exposure to air, and the polymer products were 
purified by repeated precipitation into tetrahydrofuran (THF), followed by centrifugal 
dialysis against aqueous 0.1 M HCl.  The conjugates were then lyophilized, giving P27-
P30 in yields of 70-80% as pink solids that readily dispersed in water at concentrations 
>20 mg/mL. 
 PolyMPC-TMZ prodrugs with a diblock architecture were synthesized starting 
from a polyMPC macro-CTA bearing a dithioester chain-end suitable for RAFT chain 
extension with TMZ-MA (Figure 5.5).  PolyMPC macro-CTA P31 was prepared by 
homopolymerization of MPC in TFE, targeting an approximate Mn of 15,000 g/mol and 
quenching the polymerization at < 80% conversion (estimated using 1H-NMR 
spectroscopy).  Following purification by precipitation into THF and dialysis in water, 
 
Figure 5.5: Synthesis of polyMPC-TMZ copolymers with random (P27-P30) and block 
(P32-P34) copolymer architectures by RAFT polymerization of TMZ-MA. 
TMZ-MA
ACVA, TFE, 70  C
ACVA, TFE, 70  C
P27-P30
P31
P32-P34
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polymer P31 was isolated by lyophilization in 80% yield.  1H-NMR spectroscopy of P31 
(Figure 5.6) showed resonances corresponding to chain-end phenyl protons at 7.45-7.90 
ppm (region h), confirming a high degree of retention of the dithioester chain end.  
Comparing the integrations of the phenyl end group vs. PC methylene (δ = 3.75 ppm, region 
f) resonances, the Mn of polymer P31, prepared in numerous batches, was estimated as 
20,900-21,900 g/mol.  Characterization of P31 by GPC eluting in TFE gave estimated 
polydispersity index (PDI) values of 1.05-1.13 (relative to poly(methyl methacrylate) 
(PMMA) standards).  As shown in Figure 5.5, TMZ-functionalized block copolymers, 
P32-P34, targeting drug loadings of 20, 26, and 36 mole percent, respectively, were 
prepared by polymerizing TMZ-MA in TFE at 70 °C using macro-CTA P31 and ACVA 
as a radical initiator.  Monomer conversions of >90% were achieved in approximately 4-8 
hour reaction times, and the block copolymers were purified in similar fashion to the 
random copolymers and isolated as pink solids in >50% yield. 
 
Figure 5.6: 1H-NMR (500 MHz) spectrum of polyMPC macro-CTA P31 obtained in 
MeOD-d4. 
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 NMR and UV-Vis spectroscopy confirmed the structural integrity of the pendent 
TMZ moieties in copolymers P27-P30 and P32-P34.  In representative 1H-NMR spectra 
of the polyMPC-TMZ prodrugs, resonances corresponding to TMZ imidazole protons were 
observed at 8.53 and 8.72 ppm for the random (Figure 5.7A, left) and block (Figure 5.7A, 
right) copolymers, respectively.  Additional resonances at 3.92 (random) and 3.88 (block) 
ppm are attributed to the TMZ methyltriazene protons.  Importantly, these signals for the 
polymer-bound TMZ are single resonances for both copolymer architectures, with no 
additional resonances indicative of undesired degradation to the AIC by-product.  13C-
NMR spectroscopy of the polyMPC-TMZ copolymers further confirmed retention of the 
TMZ structure, with characteristic resonances of the urea, imidazole, and methyltriazene 
groups observed at 140.81/140.01, 131.28/131.34, and 38.22/38.51 ppm for the 
 
Figure 5.7: (A) Representative 1H-NMR (500 MHz) spectra of P30 (left) and P34 
(right) obtained in TFE-d3; UV-Vis spectra of polyMPC-TMZ random copolymers 
P27-P30 (left) and block copolymers P32-P34 (right) in TFE at a concentration of 0.05 
mg/mL in TFE.  A representative spectrum of degraded TMZ is shown for each 
compilation; (C) representative GPC chromatograms of polyMPC-TMZ copolymers 
P30 and P34 eluting in TFE. 
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random/block architectures, respectively.  Figure 5.7B shows the UV-Vis absorption 
spectra of solutions of polymer P27-P30 (left) and P32-P34 (right) in TFE, as well as the 
spectrum of TMZ which was allowed to decompose fully.  Each copolymer possessed an 
absorption maximum at 323 nm characteristic of the urea of intact TMZ, as well as a 
notable absence of any spectral features to suggest TMZ degradation. 
 TMZ incorporations for polyMPC-TMZ copolymers P27-P30 and P32-P34 were 
estimated using 1H-NMR spectroscopy by comparing the integrations of TMZ imidazole 
and PC trimethylammonium (δrandom = 2.86-3.29 ppm, δblock = 2.78-3.22 ppm) protons.  For 
each copolymer, numerous samples were prepared for in vitro evaluation in glioblastoma 
cell lines.  Characterized drug loading in these samples, summarized in Table 5.1, were in 
excellent agreement with targeted values and exhibited minimal variation.  Additional 
syntheses targeted TMZ loadings of 65 and 50 mole percent for copolymers with random 
and block architecuters, respectively.  While copolymers with these very high drug loads 
were synthetically accessible, these materials were poorly soluble in water, even at 
Table 5.1: Incorporation of TMZ-MA and molecular weight characterization of 
polyMPC-TMZ copolymers P27-P30 and P32-P34. 
Polymer 
Targeted TMZ-MA 
incorporation 
(mol %) 
Measured TMZ -MA 
incorporationa 
(mol %) 
Mnb 
(g/mol) 
PDIb 
P27 17-20 16-17 38,600-42,800 1.20-1.22 
P28 25 23-26 39,400-42,100 1.21 
P29 35 32-33 36,200-40,500 1.14-1.20 
P30 50 47-50 40,600-46,400 1.15-1.28 
P32 20 14-16 23,600-24,800 1.14-1.15 
P33 26 24-25 22,600-24,100 1.09-1.15 
P34 36 31-35 24,900-31,500 1.09-1.21 
aMolar incorporation estimated by 1H-NMR spectroscopy in TFE-d3
. 
bValues of Mn and PDI estimated using GPC eluting in TFE relative to PMMA 
standards. 
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concentrations <1 mg/mL, making them unsuitable for further evaluation as polymer 
prodrugs. 
 The molecular weights of polyMPC-TMZ copolymers were estimated by GPC, 
eluting in TFE and calibrated against PMMA standards.  Representative chromatograms 
for random and block copolymers P30 and P34, shown in Figure 5.7C, were relatively 
narrow and monomodal.  As shown in Table 5.1, polyMPC-TMZ random and block 
copolymers were isolated with Mn values of 36,200-46,400 and 22,600-31,500 g/mol, 
respectively, and PDI values of 1.09-1.28.  Copolymers of the same architecture were 
found to possess similar estimated Mn across multiple samples, demonstrating the 
reproducibility of this synthetic approach.  Importantly, GPC chromatograms of polyMPC-
TMZ copolymers obtained with UV detection at λ = 323 nm showed a notable absence of 
residual TMZ-MA or other small molecule impurities.  This molecular weight 
characterization confirmed that RAFT methodology is amenable to preparing well-defined 
polymer-TMZ conjugates using the TMZ-MA monomer. 
 Possessing both hydrophilic PC zwitterions and hydrophobic TMZ moieties, 
polyMPC-TMZ copolymers were anticipated to form aqueous assemblies with larger 
hydrodynamic sizes relative to TMZ itself, which in turn would extend TMZ circulation 
half-life in vivo.  The critical aggregation concentration (CAC) of the polyMPC-TMZ 
copolymers was estimated in pH 7.4 phosphate-buffered saline (PBS) at 37 °C using 
dynamic light scattering (DLS);40 the absorption characteristics of TMZ preclude using 
fluorescent (e.g., pyrene)41 or absorption (e.g., 1,6-diphenyl-1,3,5-hexatriene)42 assays.  
Representative plots of DLS scattering intensty for solutions of P30 and P34 in PBS at 
polymer concentrations ranging from 0.005-5 mg/mL are shown in Figure 5.8A.  
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Copolymer P34 exhibited a sharp increase in scattering intensty at a critical concentration 
of approximately 0.48 mg/mL, indicating copolymer aggregation.  Similar behavior was 
observed for polymers P32 and P33 at concentrations of 0.70 and 0.45 mg/mL.  In contrast, 
the scattering intensity values for solutions of P30 remained relatively constant at each 
polymer concentration, suggesting an indiscernible CAC for polyMPC-TMZ random 
copolymers. 
 The hydrodynamic diameters (dh) of structures formed from P32-P34 in PBS at 37 
°C were estimated using DLS above the CAC of each polymer at a concentration of 1 
 
Figure 5.8: (A) Representative scattering intensities for suspensions of polymers P30 
and P34 with varying polymer concentrations in pH 7.4 PBS at 37 °C measured using 
DLS.  For block copolymers P32-P34, the CAC (represented by the dotted black line) 
was estimated as the onset of increasing scattering intensity; (B) DLS plots of polymers 
P32-P34 and P30 in pH 7.4 PBS (37 °C) at a concentration of 1 mg/mL; (C) 
representative cryo-TEM image of P34 nanoparticles in water at a concentration of 1 
mg/mL. 
unimer
unimer
(P27-P30)
nanoparticle
(P32-P34) 7 nm 24 nm
33 nm
38 nm
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mg/mL.  The DLS plots in Figure 5.8B show polyMPC-TMZ block copolymers to form 
monomodal nanoparticles (dh
 = 24-38 nm) with no evidence of particle aggregation.  
Importantly, these block copolymers readily assembled in water into well-defined and 
narrowly dispersed aggregates without using intricate procedures (e.g., solvent-directed 
assembly or thin film hydration).43-45  In contrast, a bimodal size distribution was observed 
for random copolymer P30, dominated by the smaller structures (dh ~ 7 nm).  As expected, 
the hydrodynamic diameters of P27-P29 were similarly small (dh ~ 6-9 nm).  Suspensions 
of block copolymer P34 in pure water were cast on carbon-coated copper grids, vitrified in 
liquid ethane, and visualized using cryogenic transmission electron microscopy (cryo-
TEM).  As shown in Figure 5.8C, P34 nanoparticles were obsersved in high density as 
spherical aggregates with discrete coronae.  The nanoparticles exhibited a narrow size 
distribution and a mean estimated diameter of 12.6 ± 2.8 nm.  The larger diameter estimated 
using DLS relative to cryo-TEM is attributed to hydration layer of the hydrophilic corona; 
similar overestimation by DLS has been observed for other polymeric nanoparticles.46 
 The hydrolytic instability of TMZ leads to rapid decomposition in physiological 
conditions, with reported half-lives in pH 7 PBS and blood plasma of approximately 1 and 
1.8 hours, respectively.47  Premature degradation to methyldiazonium cations (Figure 5.2) 
leads to off-target hematoxicity and reduces the concentration of TMZ available to 
glioblastoma cells.  As such, frequent dosing is required to maintain efficacious drug 
concentrations.  Developing TMZ formulations which stabilize the drug and extend its half-
life in solution is critical to augmenting efficacy.  The decomposition of TMZ is readily 
monitored using UV-Vis spectroscopy: as TMZ degrades, the absorption corresponding to 
the urea moiety of pristine TMZ (λ = 328-330 nm) decreases in intensity, as shown in 
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Figure 5.9A, and a new absorption attributed to the amide group of the AIC byproduct is 
observed at λ = 265-267 nm.16,38 
 In collaboration with Sarah Ward, the impact of polyMPC conjugation, drug 
loading, and copolymer architecture on the hydrolytic stability of TMZ was investigated 
by UV-Vis spectroscopy.  PolyMPC-TMZ random copolymers P27-P30 and block 
copolymers P32-P34 were incubated at 37 °C in pH 7.4 PBS and compared to TMZ itself.  
UV-Vis absorption spectra were recorded over time, and degradation profiles constructed 
from the absorption decrease at λ = 328-330 nm (Figure 5.9B).  Half-life (t1/2) values for 
TMZ and the polyMPC-TMZ copolymers, summarized in Figure 5.9C, were obtained from 
exponential decay curves generated by plotting the normalized absorbance (A/A0) as a 
function of incubation time.  As shown in Figure 5.9, TMZ degraded quickly in PBS, 
exhibiting a t1/2 of only 1.0 hours.  Conjugation to the random copolymers improved TMZ 
lifetime 2- to 3-fold, extending t1/2 to values of 2.7-3.2 hours.  Notably, this t1/2 increase 
 
Figure 5.9: (A) Representative UV-Vis cascade curves showing the degradation of 
TMZ (evidenced by a decrease in peak intensity at λ = 328-330 nm, corresponding to 
the intact TMZ urea) to the AIC byproduct (evidenced by an increase in peak intensity 
at λ = 265-267 nm, corresponding to the AIC amide); (B) degradation profiles for TMZ, 
P27-P30, and P32-P34 incubated in pH 7.4 PBS at 37 °C; (C) values of t1/2 estimated 
for TMZ, P27-P30, and P32-P34 estimated from exponential fitting of decay curves, 
as well as percentages of TMZ remaining at the conclusion of each incubation 
experiment. 
Sample
t1/2
(h)
Residual
TMZ 
(%)
TMZ 1.0 0.6
P27 3.1 3.3
P28 3.2 4.2
P29 2.7 1.3
P30 3.2 0
P32 12.8 18.6
P33 18.9 35.5
P34 19.1 37
intact TMZ
degradation 
byproduct
(A) (B) (C)
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was independent of mole percent TMZ incorporation for the random copolymers.  Polymer 
architecture also had a significant effect on TMZ solution stability, with block copolymers 
P32, P33, and P34 exhibiting t1/2 values of 12.8, 18.9, and 19.1 hours, respectively.  In 
contrast to the random copolymers, increasing TMZ incorporation from 16-17 to 23-26 
mole percent significantly increased the TMZ t1/2; however, additional TMZ incorporation 
beyond 26 mole percent did not further improve solution stability.  While TMZ conjugated 
to P27-P30 degraded almost entirely within 24 hours, significant amounts of TMZ (18-
37%) incorporated into the block copolymers remained intact, even after incubation at pH 
7.4 and 37 °C for 33 hours.  These results suggest that polymer architecture plays a more 
significant role than drug loading in improving TMZ solution stability.  The improvements 
in TMZ stability exhibited by the polyMPC-TMZ platform are comparable, if not superior, 
to other delivery systems,25,26 while also retaining synthetic practicality. 
 In addition to investigating TMZ stabilization by polymer conjugation, stabilization 
by uptake into block copolymer surfactants was explored.  Aqueous suspensions of block 
copolymer amphiphiles—polyMPC-TMZ block copolymer P33 and a polyMPC-b-
poly(butyl methacrylate) (polyMPC-BMA) (P35) copolymer with 28 mole percent 
BMA—were used to solubilize free TMZ in pH 7.4 PBS at polymer concentrations of 5 
mg/mL.  By eye, TMZ-contaning polymer P33 solubilized TMZ more rapidly than the 
common polyMPC-BMA surfactant.  Furthermore, the polyMPC-TMZ block copolymer 
suspended free TMZ completely at a drug concentration of 4 mg/mL, while the 
corresponding polyMPC-BMA suspension showed residual undissolved TMZ.  These 
TMZ-block copolymer suspensions were diluted approximately 400 times and incubated 
at 37 °C monitoring TMZ structural stability by UV-Vis spectroscopy.  Under these 
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conditions, the solution stability was not significantly extended in comparison to free 
TMZ—half-lives of 1.3 and 1.4 hours were measured for TMZ suspensions prepared using 
polyMPC-TMZ P33 and polyMPC-BMA P35, respectively.  TMZ stability was also 
examined at a P35 concentration of 1 mg/mL, well above the estimated CAC of P35 in 
water (CACP35 ~ 0.02 mg/mL, estimated using a pyrene fluorescence assay41).  Despite 
solublization and encapsulation of TMZ into the hydrophobic core of the block copolymer 
aggregates, the TMZ t1/2 was only extended to 1.8-2.7 hours; owing to the high absorbance 
of TMZ-containing block copolymers at a concentration of 1 mg/mL, a comparable 
experiment was not feasible for the polyMPC-TMZ prodrugs.  These results suggest that 
polymer-TMZ conjugation is superior to encapsulation for significantly enhancing TMZ 
solution stability. 
 To investigate the uptake of polyMPC-TMZ copolymers into glioblastoma cells, 
fluorescent random copolymers with 16 and 51 mole percent TMZ (P36 and P37, 
respectively) and block copolymers with 11 and 33 mole percent TMZ loadings (P39 and 
P40, respectively) were synthesized by RAFT integrating fluorescein O-methacrylate in 
low (<1 mole percent) incorporations (Figure 5.10).  Fluorescein O-methacrylate 
incorporations in polymers P36-P40 were estimated by fluorescence spectroscopy to be 
0.067 (P36), 0.068 (P37), 0.32 (P38), 0.032 (P39), and 0.021  (P40) weight percent.  In 
collaboration with Dr. Banishree Saha, cellular uptake was investigated by treating 
U87MG glioblastoma cells with solutions of fluorescent polyMPC-TMZ copolymers in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
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serum (FBS) at a TMZ-equivalent  concentration of 200 µM.  U87MG cells were also 
treated with a 0.35 mg/mL solution of fluorescein-labeled polyMPC P38.  Cells were 
incubated at 37 °C for 2 hours, washed with PBS, treated with solutions of Lysotracker® 
Red and 4’-6-diamidino-2-phenylindole (DAPI) to stain cellular lyosomes and nuclei, 
respectively, and fixed with paraformaldehyde.  The cells were then imaged by 
fluorescence confocal microscopy.  As shown in the fluorescent micrographs in Figure 
5.11, polymers P36-P40 were internalized in the glioblastoma cells and were observed as 
green puncate spots in the perinuclear region of the cytoplasm.  Signficant co-localization 
of the fluorescein and Lysotracker® Red signals was seen, suggesting polyMPC and 
polyMPC-TMZ copolymers are uptaken into glioblastoma cells through endocytosis.   
 
Figure 5.10: Synthesis of fluorescent polyMPC-TMZ random (A) and block (B) 
copolymers by RAFT polymerization methodology. 
TMZ-MA
(A)
ACVA, TFE, 70  C
P36 (16 mol% TMZ); P37 (51 mol% TMZ)
(B)
ACVA, TFE, 70  C ACVA, TFE, 70  C
TMZ-MA
P39 (11 mol% TMZ); P40 (33 mol% TMZ)P38
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Figure 5.11: Fluorescent confocal micrographs of U87MG glioblastoma cells incubated 
with fluorescein-labeled (green) polyMPC P38, polyMPC-TMZ random copolymers 
P36/P37, and polyMPC-TMZ block copolymers P39/P40.  Following a 2-hour 
incubation at 37 °C, the cells were treated with solutions of DAPI and Lysotracker® 
Red to stain the nuclei (blue) and lysozomes (red). 
 
 
Fluorescein signal
(green)
Lysotracker® signal
(red) Merged
P38
P36
P37
P39
P40
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 The internalization of polymers P36-P40 by U87MG glioblastoma cells was 
quantified using flow cytometry.  Cells were incubated at 37 °C with fluorescein-labeled 
polyMPC-TMZ copolymers P36, P37, P39, and P40 at a TMZ-equivalent concentration 
of 200 µM for 2 hours at 37 °C, and were then washed with PBS to residual non-   
internalized polymer.  Cells were also treated with a solution of fluorescent polyMPC P38 
([polymer] = 0.35 mg/mL).  Polymer uptake into the glioblastoma cells was measured by 
flow cytometry, detecting fluorescence from pendent fluorescein moieties.  As shown in 
Figure 5.12, the polyMPC-TMZ block copolymers exhibited greater uptake than random  
copolymers P36 and P37, with block copolymer P40 (33 mole percent TMZ) exhibiting 
the greatest degree of internalization.  While greater TMZ mole percent incorporation led 
to enhanced cellular internalization for the polyMPC-TMZ block copolymers, TMZ 
incorporation in polymer prodrugs with a random architecture did not affect cellular 
uptake.  Notably, minimal cellular internalization was observed for polyMPC P38, a result 
which is consistent with a previous report by Ishihara and coworkers demonstrating that 
polyMPC does not effectively cross cellular membranes.48  These cellular internalization 
assays demonstrate that polyMPC-TMZ conjugates are effectively uptaken by 
 
Figure 5.12: Mean fluorescence intensity measured by flow cytometry for U87MG 
glioblastoma cells treated with fluorescein-labeled polyMPC-TMZ random (P36, P37) 
copolymers, block (P39, P40) copolymers, and polyMPC (P38). 
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glioblastoma cells, and suggest that prodrugs prepared with a block copolymer architecture 
are advantageous for efficient uptake, which is enhanced by increasing TMZ incorporation. 
 In collaboration with Dr. Banishree Saha, the antitumor activity of polyMPC-TMZ 
copolymers was investigated in TMZ-senstive (i.e., U87MG) and TMZ-resistant (i.e., 
T98G) glioblastoma cells.  These cell lines have been utilized extensively for testing the 
cytotoxicity of TMZ,49-53 and its delivery systems.26,54,55  In dose-response assays in the 
literature, a broad range of reported IC50 values are reported for pristine TMZ:  
approximately 10-500 µM for U87MG cells and 250-1600 µM for T98G cells.53  This wide 
variation in IC50 values arises from differences in experimental protocols; such 
inconsistencies have also been noted for other small molecule chemotherapeutics (e.g., 
doxorubicin).56-59  Moreover, the poor aqueous solubility and hydrolytic instability of TMZ 
add a layer of complexity which increases variability in cell culture experiments, as 
aqueous TMZ solutions must be added to cells immediately after preparation.  As such, 
recognizing the challenges in handling TMZ and accurately measuring its cytotoxicity, 
great care was taken to limit aqueous exposure and degradation in the in vitro anti-
glioblastoma assays. 
 To evaluate cytotoxicity in glioblastoma cells, free TMZ and polyMPC-TMZ 
copolymers P27-P30 and P32-P34 were incubated at TMZ-equivalent concentrations with 
U87MG or T98G cells for 6 days, with polyMPC ([polymer] = 25.9 mg/mL) serving as a 
negative control.  Cell viability was measured using a CellTiter-Glo® assay to generate the 
dose-response curves shown in Figure 5.13.  As summarized in Table 5.2, free TMZ 
exhibited IC50 values of 192 ± 72 μM and 418 ± 116 μM in U87MG and T98G cells, 
respectively; these values are consistent with those previously reported.53  The IC50 values 
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for the polyMPC-TMZ copolymers were approximately 7- to 10-fold higher than the free 
TMZ values in both cell lines.  The reduced cytotoxicity of conjugated TMZ relative to 
free TMZ is typical of polymer prodrugs,60,61 and is behavior we have noted previously in 
evaluating polymer-doxorubicin and polymer-camptothecin conjugates.62-64  As expected, 
the IC50 values measured for the polyMPC-TMZ random and block copolymers were lower 
in the TMZ-sensitive U87MG cells than those measured in the TMZ-resistant T98G 
cells.  For both cell lines, IC50 values plateaued above a critical TMZ incorporation (>20 
mole percent): P27 and P32 had significantly higher IC50 values, as compared to P28-P30 
and P33-P34, respectively.  While polymer architecture did not significantly affect the 
cytotoxicity of polyMPC-TMZ copolymers in chemosensitive U87MG cells, block 
copolymers with sufficiently high TMZ loading (>20 mole percent) exhibited significantly 
lower IC50 values (approximately 54-82% lower) in the resistant T98G cells, relative to 
 
Figure 5.13: Cell viability of polyMPC-TMZ random and block copolymers in U87MG 
and T98G glioblastoma cells.  
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comparable random copolymer prodrugs.  The potentiated cytotoxicity observed for 
polyMPC-TMZ block copolymers in the TMZ-resistant T98G cells was attributed to the 
enhanced TMZ solution stability and cellular internalization afforded by the block 
copolymer architecture. 
 A critical challenge in treating glioblastoma tumors is resistance to alkylating 
agents mediated by O6-methylguanine-DNA methyltransferase (MGMT), an enzyme 
found within the cellular cytoplasm and nucleus which repairs cytotoxic methylated 
guanine lesions via methyl abstraction by a highly active cysteine residue (Cys145) (Figure 
5.14A).11  The Cys145 methylation is irreversible and leads to inactivation of the MGMT 
enzyme.  Reduced MGMT activity through promoter gene silencing,65-67 as well as 
depletion of MGMT concentration in tumors by hyperalkylation,17 has been associated 
with improved outcomes and more effective treatment of glioblastoma tumors with 
chemotherapeutics such as TMZ.  O6-benzylguanine (O6-BG), shown in Figure 5.14A, is 
an MGMT inhibitor which effectively alkylates MGMT enzymes, and has been examined 
as an adjuvant therapeutic for augmenting TMZ potency.68-70  Despite promising in vitro 
and in vivo results which show that O6-BG can reduce the IC50 value of TMZ in 
Table 5.2: IC50 values for U87MG and T98G glioblastoma cells treated with TMZ and 
polyMPC-TMZ copolymers (± indicates standard deviation). 
IC50 (µM) U87MG T98G 
TMZ 192 ± 72 418 ± 116 
P27 1282 ± 58 4987 ± 26 
P28 426 ± 48 2119 ± 77 
P29 495 ± 61 2719 ± 98 
P30 738 ± 84 2281 ± 132 
P32 1095 ± 81 5529 ± 79 
P33 396 ± 65 1748 ± 107 
P34 517 ± 55 1477 ± 113 
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glioblastoma cells by more than an order of magnitude, the poor aqueous solubility and 
severe off-target toxicity exhibited by O6-BG has limited its successful translation to 
clinical treatments.34  As polyMPC-based delivery systems impart aqueous solubility to 
hydrophobic therapeutics and have been shown to reduce undesired off-target toxicity,71-73 
the solubilization and co-delivery of TMZ and O6-BG to glioblastoma cells was 
investigated through its encapsulation into a polyMPC-TMZ block copolymer. 
 U87MG and T98G glioblastoma cells were treated with aqueous suspensions of 
polyMPC-TMZ block copolymer P33 containing O6-BG at a constant concentration of 100 
µM; this dose has previously been investigated for sensitizing U87MG and T98G cell lines 
to TMZ.74  As controls, cells were treated with free TMZ, a mixture of TMZ and 100 µM 
 
Figure 5.14: (A) Mechanism for the repair of methylated guanine nucleobases by the 
MGMT enzyme, and the chemical structure of the MGMT inhibitor O6-benzylguanine 
(O6-BG); (B) IC50 values of U87MG and T98G glioblastoma cells treated with TMZ or 
polyMPC-TMZ block copolymer P33 in conjunction with O6-BG (100 µM). 
(A)
(B)
IC50 (µM) U87MG T98G
TMZ 471 ± 65 707 ± 106
TMZ + O6-BG 88 ± 56 194 ± 87
P33 5084 ± 1004 10778 ± 1627
P33 + O6-BG 606 ± 330 2986 ± 1660
MGMT DNA repair O
6-benzylguanine 
(O6-BG)
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O6-BG, and polyMPC-TMZ P33 alone.  Dose-response curves were generated, giving IC50 
values for free TMZ alone in U87MG and T98G cells of 471 and 707 µM, respectively 
(Figure 5.14B).  As observed previously, the IC50 values measured for P33 were more than 
an order of magnitude higher in both cell lines than free TMZ.  Co-treatment with O6-BG 
significantly potentiated the cytotoxicity of the free and polymer-bound TMZ, reducing the 
P33 IC50 values to 606 and 2986 µM in the U87MG and T98G cells, respectively.  Notably, 
O6-BG alone at a concentration of 100 µM was well-tolerated in both cell lines, with 
U87MG and T98G cells exhibiting viabilities of 84% and 78%, respectively, relative to 
untreated cells.  These results suggest a synergistic benefit to treating glioblastoma tumor 
cells with a combination of a cytotoxic polymer-TMZ surfactant and an MGMT inhibitor. 
 
5.4 Conclusions 
 In summary, TMZ, a first-line glioblastoma chemotherapeutic, was incorporated 
successfully into a series of polyMPC conjugates by RAFT copolymerization of a novel 
TMZ-methacrylate monomer.  TMZ was integrated into copolymers with random and 
block copolymer architectures at tunable drug loadings, and the conjugates were obtained 
with narrow molecular weight distributions.  This method for preparing well-defined 
polymer-TMZ prodrugs uses simple and effective polymerizations that are metal-free, 
avoid the need for post-polymerization drug conjugation, and preserve the potent chemical 
structure of TMZ.  The results of this work suggest that polymer conjugation to the water-
soluble polyMPC backbone significantly improves the physiological stability of TMZ, 
with block copolymer prodrugs affording the most profound improvement.  Notably, 
conjugation was found to be much more effective for enhancing TMZ stability than 
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encapsulation in self-assembled aggregates.  Cellular uptake, investigated using confocal 
microscopy and flow cytometry, suggested that polyMPC-TMZ copolymers are readily 
internalized in glioblastoma cells by endocytosis, and that block copolymer prodrugs 
undergo more efficient endocytosis than comparable random copolymer conjugates.  
Through in vitro cell viability experiments, the antitumor activity of these novel polyMPC-
TMZ copolymers was demonstrated in chemosensitive and chemoresistant glioblastoma 
cell lines.  PolyMPC-TMZ prodrugs exhibited higher IC50 values than free TMZ, a feature 
characteristic of polymer-drug conjugates, and TMZ incorporation and copolymer 
architecture were found to impact the efficacy of polymer-TMZ prodrugs.  Specifically, 
drug loadings >20 mole percent were necessary to achieve suitable cytotoxicity, and the 
block copolymer prodrugs were more efficacious in killing TMZ-resistant glioblastoma 
cells than the comparable random copolymer prodrugs.  Finally, the in vitro antitumor 
activity of a polyMPC-TMZ block copolymer was shown to be significantly enhanced 
through the co-delivery of the MGMT inhibitor O6-BG. 
 Owing to the versatile reactivity of the TMZ-methacrylate derivative, opportunities 
for introducing TMZ into a variety of biocompatible polymer compositions and networks 
are now available, providing access to a polymer-TMZ therapeutic platform suitable for 
systemic and local chemotherapy.  Going forward, effective use of such polymers by 
systemic administration will require retention of the blood-brain barrier crossing properties 
inherent to TMZ itself, which may require biorecognition with small molecules (i.e., 
thiamine)75 or peptides (i.e., glutathione)76,77 to facilitate transcytosis.  Future studies aim 
to further augment this novel therapeutic platform by incorporating TMZ-sensitizing 
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molecules, such as O6-BG, as pendent moieties in the polyMPC-TMZ backbone for 
overcoming the TMZ-resistance exhibited by many glioblastoma tumors.     
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CHAPTER 6 
 
OUTLOOK 
6.1 Functional, Water-Dispersible Polysiloxanes 
 Chapter 2 presented the synthesis of water-dispersible, zwitterionic siloxane 
polymers through the thiol-ene modification of vinyl-functionalized precursors with 
phosphorylcholine (PC)- and sulfobetaine (SB)-thiols.  Preliminary syntheses investigated 
the preparation of functional zwitterionic polysiloxanes via non-stoichiometric conversion 
of pendent vinylsiloxane moieties.  Proof-of-principle demonstrations suggested these 
structures could be accessed with tunable vinyl incorporations while retaining the well-
defined characteristics of the polymer precursors (i.e., narrow molecular weight 
distributions).  These water-dispersible materials are amenable to further post-
polymerization modification, including crosslinking to afford robust self-assembled 
nanoparticles or zwitterionic silicone hydrogels.  Additionally, these vinyl-containing 
zwitterionic polysiloxanes could be bleneded commercial silicone formulations (i.e., 
Sylgard 184), affording hydrophilic silicone elastomers through metal-catalyzed 
hydrosilylation crosslinking chemistries.  Such elastomers are potentially of interest for 
microfluidic device fabrication, as well as antifouling coatings.  In contrast to conventional 
hydrocarbon-based polymers, polysiloxanes undergo depolymerization and rearrangement 
in the presence of silanol nucleophiles and metal oxides.1,2.  As PC- and SB-functionalized 
siloxane polymers readily assemble at interfaces, these materials hold utilty for 
synthesizing covalent antifouling coatings through water-borne deposition and subsequent 
depolymerization/rearrangement at a range of liquid/solid interfaces.  As such, the 
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zwitterionic polysiloxanes described in this dissertation hold promise as versatile and 
functional polymer amphiphiles. 
 
6.2 Zwitterionic Pluronic Mimics 
 In Chapter 3, the synthesis of novel PC-functionalized zwitterionic Pluronic 
mimics, termed ‘zwitteronics’, was described.  These triblock copolymers were prepared 
by the macroinitiated atom transfer radical polymerization (ATRP) of 2-
methacryloyloxyethyl phosphorylcholine (MPC), affording polymer amphiphiles with 
tunable hydrophilic-hydrophobic balance and relative narrow molecular weight 
distributions.  Aqueous suface tensiomery suggested that these water-dispersble polymer 
surfactants exhibited composition-independent surface activity, behavior which is unique 
to the surfactant properties of commercial Pluronics.  Future studies should probe this 
behavior further, specifically by preparing PC-zwitteronic block copolymers with higher 
polyMPC number-average degree of polymerization (Xn) values (i.e., > 36).  Such studies 
would provide a richer understanding of the fundamental properties of these novel 
zwitterionic surfactants, especially as they compare to commercial Pluronics. 
 Future syntheses of zwitterionic Pluronic mimics should seek to develop novel 
compositions, including analogs bearing pendent SB and choline phosphate (CP) 
zwitterions.  Owing to the temperature- and salt-responsive solubility of SB polymers in 
water, poly(sulfobetaine methacrylate)-b-poly(propylene oxide)-b-poly(sulfobetaine 
methacrylate) (polySBMA-PPO-polySBMA) are of interest as a Pluronic mimics for 
triggered aqueous nanomaterials assembly.  The CP-containing zwitteronic block 
copolymers afford functional polymer amphiphiles, which were shown to provide a facile 
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strategy for nanomaterials crosslinking.  Future investigations will look to utilize these self-
assembled materials for the encapsulation and relase of various hydrophobic and 
hydrophilic moleucles, as well as aim to incorporate additional chemical moetiies through 
pendent CP zwitterions, including diol functionality3 amenable to boronic ester 
crosslinking and the generation of biocompatible, self-healing networks.4,5 
 
6.3 Expanding the PolyMPC-Doxorubicin Prodrug Platform 
 Chapter 4 expanded upon previous investigations of the polyMPC-Doxorubicin 
(polyMPC-Dox) prodrug platform,6,7 presenting the first in vivo assessment of a polyMPC-
chemotherapeutic conjugate in a human tumor model.  This evaluation represents a 
significant step towards realizing the utilization of polyMPC as a biocompatible scaffold 
for injectable polymeric medicines, and as a potential replacement for poly(ethylene 
glycol) (PEG) in the synthesis of polymer-drug and polymer-protein conjugates.  Utilized 
in numerous approved treatments, PEG remains the gold standard for polymer-based 
therapies, serving as a biocompatible scaffold which can improve the pharmacokinetics, 
physiological stability, and aqueous solubility of hydrophobic drugs and therapeutically 
active proteins.8  Despite its demonstrated benefits, PEGylation has shortcomings, 
including inherently limited drug loading, as well as immunogenic effects which can 
reduce therapeutic efficacy following repeated administration.9-12  As MPC is readily 
copolymerized with a variety of functional monomers, the polyMPC platform allows for 
high drug loadings not achieved through conventional PEGylation.  Investigations probing 
the maximum tolerated dose (MTD) of polyMPC suggest this material is well-tolerated in 
animals at very high doses.  Future studies will continue to examine the safety of polyMPC 
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as an injectable scaffold, specifically assessing the immunogenicity of aqueous polyMPC 
solutions in vitro and in vivo.  These studies are critical for demonstrating the suitability of 
polyMPC as a PEG replacement.  Additional work will look to further expand the 
polyMPC-Dox platform through the preparation of multi-drug therapeutics which allow 
for the treatment of tumors using chemotherapeutic cocktails, potentially overcoming 
challenges related to chemoresistance and augmenting antitumor efficacy. 
 
6.4 New Polymer-Temozolomide Therapeutics 
 Chapter 5 described the preparation of polyMPC-temozolomide (polyMPC-TMZ) 
conjugates for the treatment of glioblastoma.  A critical discovery resulting from this work 
was the development of a TMZ-methacrylate monomer which allows, for the first time, 
TMZ to be directly incorporated into polymer backbones using free radical polymerization 
chemistries.  Optimized polymerization conditions gave polyMPC-TMZ therapeutics with 
narrow molecular weight distributions, tunable drug loadings, and varying architecture 
(i.e., random and block copolymers).  Moreover, polymerization conditions were 
developed which preserve the labile chemical structure of pendent TMZ moieties.  
Conjugation was found to significantly enhance the stability of TMZ at physiological 
conditions, and the polyMPC-TMZ therapeutics exhibited antitumor activity in 
chemosensitive and chemoresistant human glioblastoma tumor cells.  
 TMZ-methacrylate is a versatile monomer which gives access to a range of new 
polymer-TMZ therapeutics.  Future studies aiming to advance the polymer-TMZ 
therapeutic platform will focus on novel systemic and local modes of TMZ delivery.  For 
injectable medicines, the impact of polymer molecular weight and composition on 
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antitumor activity will be evaluated.  Additionally, syntheses will be developed for 
generating prodrugs with functionality which can overcome clinical challenges of treating 
glioblastoma, including blood-brain barrier crossing and chemoresistance.  In addition to 
water-soluble polymer prodrugs, the TMZ-methacrylate monomer allows for the 
preparation of TMZ-containing networks and wafers, including implantable hydrogels and 
thermoplastics for local drug delivery following surgical tumor resection. 
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CHAPTER 7 
 
EXPERIMENTAL SECTION 
7.1 Materials 
 2-Methacryloyloxyethyl phosphorylcholine (MPC), [2-
(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (SBMA), 1,3-
propanedithiol, diisopropylamine, 2,2-dimethoxy-2-phenylacetophenone (DMPA), 
chlorotrimethylsilane, 1,2,4-trichlorobenzene (TCB), pyrene, sodium trifluoroacetate, 
calcium hydride, sodium benzophenone, pentane, poly(propylene oxide) (PPO), 
poly(ethylene oxide) (PEO) (Mn ~ 1,500 g/mol), 2-bromoisobutyryl bromide, triethylamine 
(TEA), activated carbon, copper(I) bromide (CuBr), 2,2’-bipyridyl (Bipy), 2-
(dimethylamino)ethyl methacrylate, potassium fluoride (KF), Pluronic® F127, Pluronic® 
P123, Pluronic® L121, anhydrous acetonitrile, Irgacure 2959, 2-(4’-
hydroxybenzeneazo)benzoic acid (HABA), dithiothreitol (DTT), 4,4’-azobis(4-
cyanovaleric acid) (ACVA), and 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid, 
ethyl α-bromoisobutyrate (EBiB), trifluoroacetic acid, sodium nitrate, anhydrous methanol 
(MeOH), sodium nitrite, 2-hydroxyethyl methacrylate (HEMA), 4-
(dimethylamino)pyridine (DMAP), dimethylsulfoxide (DMSO), and fluorescein O-
methacrylate were purchased from Sigma-Aldrich.  2,2,2-Trifluoroethanol (TFE), n-
butyllithium (2.5M in hexanes), and ethylene chlorophosphate were purchased from Alfa 
Aesar.  Chloroform, MeOH, tetrahydrofuran (THF), dichloromethane (DCM), hexanes, 
anhydrous diethyl ether, sodium sulfate anhydrous, sodium chloride (NaCl), sodium 
hydroxide (NaOH), acetic acid, high performance liquid chromatography (HPLC) grade 
acetonitrile, magnesium sulfate, HPLC grade water, ethyl acetate, concentrated sulfuric 
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acid, dichloromethane (DCM), and hydrochloric acid (HCl) were purchased from Fisher 
Scientific.  4-Methoxyphenol was purchased from Acros Organic.  4-Trimethylsilyl-3-
butyn-2-ol was purchased from GFS Chemicals.  Deuterated solvents were purchased from 
Cambridge Isotope Laboratories, Inc.  Tetra-functional PEO thiol (Mn ~ 5,000 g/mol) was 
obtained from JenKem Technology USA.  Doxorubicin hydrochloride (Dox•HCl) was 
purchased from 21CEC.  Sodium azide was purchased from EMD Millipore.  Sephadex 
LH-20 and G-25 size exclusion media were purchased from GE Healthcare and were 
swollen in appropriate solvent overnight prior to use.  Temozolomide (TMZ) and 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) were purchased from 
TCI America.  O6-benzylguanine (O6-BG) was purchased from Santa Cruz Biotechnology.  
Deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc., and 
Sigma-Aldrich.  Amicon® Ultra-15 regenerated cellulose centrifugal filters with a nominal 
molecular weight cutoff of 10,000 Da were purchased from Merck Millipore Ltd.  Unless 
otherwise stated, all chemicals were used as received without further purification.  HEMA 
was purified by short-path vacuum distillation using a Kugelrohr apparatus.  Anhydrous 
THF and TEA were obtained by distillation over sodium/benzophenone and calcium 
hydride, respectively.  D3 and D3v were obtained from Gelest and purified by vacuum 
distillation over calcium hydride.  Prior to polymerization, inhibitor was removed from 
MPC following a previously described procedure.1  Human epithelial ovarian (SKOV-3) 
adenocarcinoma cells and human glioblastoma (U87MG and T98G) cells were purchased 
from the American Type Culture Collection (ATCC).  Hank’s balanced salt solution 
(HBSS), RPMI-1640 medium, Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine 
serum (FBS), pH 7.4 phosphate-buffered saline (PBS), penicillin, streptomycin, and 
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antiobiotic-antimycotic solution were purchased from Life Technologies (Gibco).  FBS 
used for culturing glioblastoma cells was purchased from GE Healthcare Life Sciences.  
NOD SCID mice were purchased from Charles River Laboratories and handled according 
to the guidelines of the Institutional Animal Care Use Committee.  The CellTiter-Glo® 
luminescent cell viability assay was purchased from Promega.  The Lysotracker® Red and 
4’,6-diamidino-2-phenylindole (DAPI) stains were purchased from ThermoFisher 
Scientific, respectively.  The 35 mm glass dishes used in confocal microscopy experiments 
were obtained from MatTek Corporation. 
 
7.2 Instrumentation 
 1H-NMR (500 MHz), 13C-NMR (125 MHz), 29Si-NMR (99 MHz), and 31P-NMR 
(202 MHz) spectra were obtained using a Bruker Ascend™ 500 spectrometer equipped 
with a Prodigy cryoprobe.  High-resolution mass spectral (HRMS) data were obtained on 
a Bruker MicrOTOF-II spectrometer.  Matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectra were obtained using a Bruker MicroFlex working in 
linear mode and a HABA matrix.  Gel permeation chromatography (GPC) eluting in THF 
was performed against polystyrene standard, operating at 1.0 mL/min and 40 °C with an 
Agilent 1260 isocratic pump, an autosampler, a PLgel guard column (50 x 7.8 mm2), two 
PLgel Mixed C columns (300 mm x 7.8 mm x 5 µm), one PLgel mixed D column (300 
mm x 7.8 mm x 5 µm), and an Agilent 1260 refractive index detector.  GPC eluting in TFE 
containing 0.02 M trifluoroacetate was performed against poly(methyl methacrylate) 
standards, operating at 40 °C with a flow rate of 1.0 mL/min using an Agilent 1200 system 
equipped with an isocratic pump, a degasser, an autosampler, one 50 x 8 mm2 Polymer 
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Standards Service (PSS) PFG guard column, three 300 x 7.5 mm2 PSS PFG analytical 
linear M columns with 7 µm particle size, and Agilent 1200 refractive index and UV 
detectors.  Molecular weight and polydispersity of polymer 25 were estimated by GPC in 
aqueous buffer (0.1 M sodium nitrate, 0.02 weight percent sodium azide) against 
poly(ethylene oxide) (PEO) standards, operated at 1.0 ml/min and 40 °C with an Agilent 
1260 isocratic pump, a Waters Ultrahydrogel Linear guard column (40 x 6 mm), three 
Waters Ultrahydrogel Linear columns (300 x 7.8 mm), and an Agilent 1260 refractive 
index detector.  HPLC was performed using a Waters Alliance system eluting with 40/60 
acetonitrile/water containing 1% trifluoroacetic acid, operated at 1.0 ml/min and 25 °C, 
with a Microsorb C18 column (250 x 4.6 mm), and Waters photodiode array (λ=480 nm) 
and fluorescence (λexcitation=480 nm, λemission=580 nm) detectors.  Fluorescence spectra were 
recorded on a Perkin-Elmer LS55 fluorescence spectrometer.  UV-Vis absorption spectra 
were collected using PerkinElmer Lambda 25 and Shimadzu UV-2600 spectrometers.  
Dynamic light scattering (DLS) was performed using a Malvern Zetasizer NanoZS.  
Pendant drop interfacial tension (IFT) measurements were performed on a Marlin F131B 
IRF camera (Allied Vision Technologies) interfaced with MATLAB.  Transmission 
electron microscopy (TEM) was performed on a JEOL JEM-2000FX microscope using 
samples prepared on PELCO® carbon-coated 300 mesh copper grids (Ted Pella, Inc.) or 
400 square mesh carbon-coated copper grids (Electron Microscopy Sciences).  Cryogenc-
TEM (cryo-TEM) was performed on an FEI-Tecnai-T12 microscope equipped with a cryo-
transfer holder using samples prepared on carbon-coated 400 mesh copper grids and 
vitrified in liquid ethane.  Vitrification of cryo-TEM samples was performed using an FEI 
Vitrobot™.  Lower critical solution temperature (LCST) measurements were performed 
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using a Hitachi U-3010 spectrophotometer operating at λ = 550 nm and equipped with a t2 
temperature-controlled cuvette holder and a TC-1 temperature controller (Quantum 
Northwest).  TMZ solution stability experiments were performed using a Shimadzu UV-
2600 spectrometer equipped with a Quantum Northwest dual temperature-controlled 
cuvette holder and a TC-1 temperature controller.  Surface tensiometry was performed 
using a Kibron MicrotroughX Langmuir instruments equipped with a Kibron DyneProbe 
(diameter = 0.51 mm) and custom cylindrical glass troughs (diameter = 1.5 cm, depth = 
0.2 cm).  Thiol-ene and thiol-yne reactions were performed in a UV box (model CL-1000L, 
UVP).  Rheology was performed using a Malvern Kinexus Pro stress-controlled rheometer 
with a gap resolution of 0.1 µm, an environmental control range and resolution of -40-200 
°C and 0.01 °C, respectively, a torque range in oscillatory mode of 0.05-200 µN∙m with 
0.1 nN∙m resolution, and a frequency range of 6.28-942 rad/s.  Fluorescence confocal 
micrographs were obtained using a Nikon A1 Resonant Scanning Confocal with Structured 
Illumination microscope equipped with a 60x objective lens.  Flow cytometry experiments 
were performed using a BD DUAL LSRFortessa flow cytometer, and data was analyzed 
using FlowJo software (Flowjo, LLC).  Viability measurements of glioblastoma cells 
treated with polyMPC-TMZ copolymers were performed using a FLUOstar OPTIMA plate 
reader (BMG LABTECH), and IC50 values were calculated using GraphPad Prism 7 
software (GraphPad Software, Inc.). 
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7.3 Methods 
• Synthesis of poly(vinylmethylsiloxane) (PVMS) (P1) 
 
D3v (5.00 mL, 18.7 mmol) was dissolved in anhydrous THF (19 mL) in a flame-dried 
Schlenk flask charged with a stir bar.  Polymerization was initiated by addition of 2.5 M 
n-butyllithium in hexanes (0.19 mL, 0.48 mmol), and the mixture was stirred under 
nitrogen at room temperature for 30 minutes.  The polymerization was quenched with 
chlorotrimethylsilane (0.18 mL, 1.4 mmol).  After stirring for an additional 10 minutes, the 
solution was transferred to a 1:1 mixture of pentane and water.  The organic layer was 
isolated, and the aqueous layer was washed with an additional portion of pentane.  The 
organic portions were combined, washed twice with water, and dried over sodium sulfate.  
Pentane was removed by rotary evaporation, and the residue was dialyzed against THF (or 
DMC) to remove monomer.  The dialyzed polymer solution was passed through a 0.45 µm 
PTFE membrane, and solvent removed by rotary evaporation.  The product was dried under 
high vacuum, and polymer 1 was isolated as a clear, viscous oil.  Number-average degree 
of polymerization (Xn) and molecular weight (Mn) were determined by comparing the 
relative 1H-NMR signal intensities of the pendent vinyl protons (5.73-6.06 ppm) and the 
terminal methyl protons (0.89 ppm).  Yield: 75%.  1H-NMR (500 MHz, CDCl3, δ, ppm): -
0.03-0.30 (m), 0.62 (t, 2H), 0.89 (t, 3H), 1.25-1.37 (m, 4H), 5.63-6.15 (m).  29Si-NMR (99 
MHz, CDCl3, δ, ppm): -34.97 (s).  Mn, NMR = 7,500 g/mol, Mn, GPC = 8,400 g/mol, PDI = 
1.07. 
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• General Procedure for the synthesis of poly(dimethylsiloxane)-b-PVMS (PDMS-
b-PVMS) copolymers (P2-P4) 
 
 
Block copolymers P2-P4 were synthesized by a modified literature procedure.2  D3 (2.33 
g, 10.5 mmol) was distilled over calcium hydride under vacuum into an oven dried Schlenk 
flask charged with a stir bar, then dissolved in anhydrous THF (9.5 mL) under inert 
nitrogen.  The polymerization was initiated by addition of a solution of 2.5 M n-
butyllithium in hexanes (0.20 mL, 0.5 mmol) and the mixture was stirred at room 
temperature for 2 hour under nitrogen.  D3v (2.80 mL, 10.5 mmol) was then added to the 
flask through a dry syringe and needle, and the reaction mixture was stirred under nitrogen 
at room temperature for 2 hours.  The polymerization was quenched by the addition of 
chlorotrimethylsilane (0.19 mL, 1.5 mmol), and polymers P2-P4 were isolated as clear, 
viscous oils in similar fashion to polymer P1.  Xn of each block was determined by 
comparing the 1H-NMR signal intensities at -0.06-0.10 ppm (Si—(CH3)2) (PDMS block) 
and 5.73-6.06 ppm (Si—CH=CH2) (PVMS block) to that of the terminal methyl protons 
(0.89 ppm).  Typical isolated yields were 70-80%.  1H-NMR (500 MHz, CDCl3, δ, ppm): 
-0.06-0.10 (m), 0.0-0.28 (m), 0.54 (t, 2H), 0.89 (t, 3H), 1.25-1.37 (m, 4H), 5.73-6.06 (m).  
29Si-NMR (99 MHz, CDCl3, δ, ppm): -21.81 (s), -34.64 (s). 
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• Synthesis of PC-thiol (PC-SH)  
 
Compound PC-SH was synthesized following a modified literature procedure.3  
Chloroform (60 mL) was degassed with nitrogen in a flame-dried RB flask charged with a 
stir bar.  MPC (10.0 g, 33.9 mmol) and 1,3-propanedithiol (5.10 mL, 50.9 mmol) were 
added to the chloroform to give a cloudy suspension.  Diisopropylamine (0.20 mL, 1.4 
mmol) was added, and the mixture was stirred under nitrogen for 24 hours at room 
temperature, noting that the solution gradually became clear and colorless.  Solvent was 
removed by rotary evaporation, and PC-SH was isolated by precipitation into THF.  The 
precipitate was triturated extensively against THF to removed unreacted dithiol, and PC-
SH was isolated by centrifugation and dried under high vacuum to afford a white, tacky 
solid in 84% yield.  1H-NMR (500 MHz, MeOD-d4, δ, ppm): 1.24 (dd, J = 7.1, 1.1 Hz, 
3H), 1.85 (m, 2H), 2.56-2.87 (m, 6H), 3.24 (s, 9H), 3.65 (q, J = 4-5 Hz, 2H), 4.08 (m, 2H), 
4.29 (m, 4H).  13C-NMR (125 MHz, MeOD-d4, δ, ppm): 17.38, 23.87, 30.53, 31.70, 32.12, 
34.76, 36.28, 41.74, 54.89, 60.57, 64.82, 65.44, 67.62, 176.86.  31P-NMR (202 MHz, 
MeOD-d4, δ, ppm): -0.42.  HRMS-ESI (m/z): [M+H]+ calculated for C14H30NO6PS2: 
404.133, found: 404.131. 
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• Synthesis of SB-thiol (SB-SH)  
 
To a flame-dried RB flask charged with a stir bar was added SBMA (20.0 g, 71.6 mmol), 
1,3-propanedithiol (14.40 mL, 143.2 mmol), and degassed MeOH (100 mL).  To this clear 
solution catalytic diisopropylamine (0.40 mL, 2.9 mmol) was added, and the solution was 
stirred under nitrogen at room temperature for 24 hours.  The mixture was concentrated by 
rotary evaporation, and the product precipitated into THF.  The precipitate was triturated 
with THF, isolated by vacuum filtration, and washed with diethyl ether.  The solid was 
dried under high vacuum, and SB-SH was isolated as a fine white powder in 67% yield.  
1H-NMR (500 MHz, MeOD-d4, δ, ppm): 1.27 (d, J = 6.5 Hz, 3H), 1.85 (m, 2H), 2.24 (m, 
2H), 2.58-2.72 (m, 4H), 2.78-2.91 (m, 4H), 3.18 (s, 6H), 3.61 (m, 4H), 3.75 (m, 2H), 4.58 
(br, 2H).  13C-NMR (125 MHz, MeOD-d4, δ, ppm): 17.19, 20.16, 23.87, 31.74, 34.74, 
36.20, 41.54, 52.14, 52.50, 56.96, 59.11, 64.14, 65.35, 66.74, 175.93.  HRMS-ESI (m/z): 
[M+H]+ calculated for C14H29NO5S3: 388.128, found: 388.131. 
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• General procedure for the synthesis of zwitterionic polysiloxanes (P7-P14) 
 
Polysiloxanes P1-P4 were dissolved in THF in a glass scintillation vial charged with a stir 
bar.  Thiols PC-SH and SB-SH (3 molar equivalents relative vinylsiloxane groups) were 
dissolved in MeOH and TFE, respectively.  The desired thiol solution was added to the 
scintillation vial to afford a clear, colorless mixture.  DMPA (0.3 molar equivalents relative 
to vinylsiloxane) was added to the vial as a solid.  The mixture was degassed nitrogen for 
15 minutes, then stirred and subjected to 365 nm light (~3.5 mW/cm2) in a UV box for 1 
hour at room temperature.  The PC-substituted polysiloxanes (P7-P10) were purified by 
dialysis against MeOH and water, and isolated by lyophilization as fluffy, white solids.  
Typical yields were 85-90%.  P7: 1H-NMR (500 MHz, MeOD-d4, δ, ppm): 0.24 (br, 3H), 
0.97 (br, 2H), 1.27 (br, 3H), 1.88 (br, 2H), 2.48-2.90 (m, 9H), 3.26 (s, 9H), 3.68 (br, 2H), 
4.08 (br, 2H), 4.17-4.38 (br, 4H).  31P-NMR (202 MHz, MeOD-d4, δ, ppm): -0.46.  SB-
containing polysiloxanes (P11-P14) were isolated by precipitation: THF was removed 
from the crude reaction mixture by rotary evaporation, and the polymer solution was 
precipitated into MeOH (repeated three times).  The polymers were isolated by 
centrifugation and dried under high vacuum to afford off-white solids in 35-45% yield.  
P11: 1H-NMR (500 MHz, TFE-d3, δ, ppm): 0.06 (br, 3H), 0.82 (br, 2H), 1.14 (br, 3H), 1.73 
(br, 2H), 2.11 (br, 2H), 2.32-2.89 (m, 11H), 3.00 (s, 6H), 3.40 (br, 2H), 3.51 (br, 2H), 4.41 
(br, 2H). 
P7-P10 P11-P14
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• Synthesis of the PPO macroinitiator (P15) 
 
PPO macrointiator P15 was synthesized using a modified literature procedure.4  In a flame-
dried round-bottom flask charged with a stir bar, PPO (24.12 g, 6.0 mmol) and anhydrous 
TEA (3.3 mL, 24.0 mmol) were dissolved in anhydrous THF (50 mL).  The solution was 
cooled at 0 °C, and 2-bromoisobutyryl bromide (3.0 mL, 24.0 mmol) was added slowly 
using a syringe, resulting in the formation of a white precipitate.  The suspension was 
allowed to warm to room temperature and stir under nitrogen for 48 hours, after which time 
the mixture was vacuum filtered.  The precipitate was washed with diethyl ether (3 x 25 
mL), and the filtrate was concentrated by rotary evaporation.  The crude product mixture 
was dissolved in ethyl acetate (1500 mL) and washed with aqueous 1 M NaOH (5 x 100 
mL) and saturated brine (2 x 100 mL).  The organic layer was stirred over decolorizing 
carbon, filtered, concentrated by rotary evaporation, and dried under high vacuum to afford 
P15 as an orange viscous oil in 73% yield.  1H-NMR (500 MHz, MeOD-d4, δ, ppm): 1.04-
1.21 (br), 1.25 (t), 1.92 (s), 3.33-3.70 (m).  13C-NMR (125 MHz, MeOD-d4, δ, ppm): 17.75, 
31.19, 31.22, 57.33, 57.36, 73.99, 74.01, 74.07, 74.09, 74.34, 74.38, 76.46, 76.60, 76.62, 
76.73, 172.25, 172.26. 
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• General procedure for the synthesis of PC-zwitteronics (P16-P20) 
 
In a two-neck round-bottom flask charged with a stir bar, P15 and MPC were dissolved in 
TFE ([monomer] = 0.5 M).  The solution was cooled at 0 °C and degassed with bubbling 
nitrogen for 15 minutes, after which CuBr and Bipy were added under positive nitrogen 
pressure at [P15]0:[CuBr]0:[Bipy]0 = 1:2:4.  The resulting mixture was degassed with 
nitrogen for 10 minutes and then was stirred at room temperature.  Polymerization progress 
was monitored using 1H-NMR spectroscopy.  The polymerization was quenched by 
exposure to ambient atmosphere, and copper was removed by passing the crude polymer 
product through a silica gel plug eluting with MeOH.  The polymer effluent was 
concentrated by rotary evaporation, centrifuged (10,000 rpm, 5 minutes), passed through a 
0.45 µm PTFE membrane, and dialyzed against water.  Lyophilization gave PC-
zwitteronics P16-P20 in yields of 42-78%.  1H-NMR (500 MHz, MeOD-d4, δ, ppm): 0.72-
1.04 (br), 1.04-1.26 (s), 1.71-2.16 (m), 3.32 (s), 3.41-3.50 (br), 3.50-3.56 (br), 3.56-3.67 
(br), 3.68-3.83 (br), 4.01-4.15 (br), 4.15-4.30 (br), 4.30-4.41 (br).  31P-NMR (202 MHz, 
MeOD-d4, δ, ppm): -0.51 ppm. 
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• Synthesis of alkyne-substituted choline phosphate methacrylate (MCP) (1)  
 
Alkyne-substituted MCP 1 was prepared following a previously described procedure.5 
 
• Synthesis polyMPC by reversible addition-fragmentation chain-transfer 
polymerization (RAFT) (P21) 
 
In a 20 mL glass vial charged with a stir bar, MPC (1.2034 g, 4.1 mmol), 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid (8.7 mg, 0.031 mmol), and ACVA (2.1 mg, 
0.0075 mmol) were dissolved in MeOH (3 mL).  The resulting solution was degassed with 
bubbling nitrogen for 15 minutes and was heated at 70 °C.  At a monomer conversion of 
87%, estimated using 1H-NMR spectroscopy, the polymerization was quenched by 
exposure to air, and the solution was precipitated in THF (35 mL).  The crude polymer 
product was isolated by centrifugation (4000 rpm, 5 min) and was purified by dialysis 
against water.  Lyophilization afforded polyMPC as a pink solid in a yield of 74%.  1H-
NMR (500 MHz, MeOD-d4, δ, ppm): 0.66-1.34 (m, 3H), 1.65-2.20 (m, 2H), 3.26-3.36 (s, 
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9H), 3.64-3.78 (br, 2H), 3.96-4.12 (br, 2H), 4.12-4.26 (br, 2H), 4.26-4.38 (br, 2H).  Mn, GPC 
= 38,500 g/mol, PDI = 1.08. 
 
• Synthesis of functional zwitteronics (P22, P23)  
 
TMS-protected functional block copolymers P22 and P23 were prepared by 
macroinitiated-ATRP of MPC and monomer 1 using a similar procedure as polymers P16-
P20.  TMS-protected P22 and P23 were isolated in yields of 57%.  TMS-protected P23:  
1H-NMR (500 MHz, MeOD-d4, δ, ppm): 0.14 (s), 0.88-1.04 (br), 1.04-1.25 (br), 1.80-2.14 
(br), 1.92 (s), 2.55-2.68 (br), 3.31 (s), 3.34-3.43 (br), 3.43-3.50 (br), 3.50-3.57 (br), 3.57-
3.66 (br), 3.67-3.79 (br), 3.81-3.90 (br), 3.90-4.03 (br), 4.03-4.15 (br), 4.15-4.29 (br), 4.29-
4.41 (br), 4.42-4.62 (br).  13C-NMR (125 MHz, MeOD-d4, δ, ppm): 0.23, 17.69, 22.96, 
31.17, 46.09, 53.17, 54.80, 60.63, 64.32, 65.02, 67.42, 74.40, 76.66, 76.68, 76.79, 86.58, 
104.42, 178.21, 179.10.  31P-NMR (202 MHz, MeOD-d4, δ, ppm): -0.50, -0.71.  TMS-
alkyne groups were removed by dissolving polymers P22 and P23 in solutions of MeOH 
containing 0.5 M KF (4 molar equivalents KF relative to TMS-alkyne groups).  The 
solutions were stirred at 35 °C for 24 hours and then purified by dialysis against water.  
Lyophilization gave P22 and P23 as white solids in yields of 84 and 82%, respectively.  
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P23: 1H-NMR (500 MHz, MeOD-d4, δ, ppm): 0.78-1.03 (br), 1.03-1.26 (br), 1.82-2.16 
(br), 1.93 (s), 2.39-2.52 (br), 2.52-2.64 (br), 3.32 (s), 3.35-3.43 (br), 3.43-3.51 (br), 3.51-
3.58 (br), 3.58-3.68 (br). 3.68-3.82 (br), 3.82-3.91 (br), 3.91-4.04 (br), 4.04-4.16 (br), 4.16-
4.28 (br), 4.28-4.45 (br), 4.47-4.64 (br).  13C-NMR (125 MHz, MeOD-d4, δ, ppm): 17.60, 
21.52, 31.06, 45.92, 46.29, 54.65, 60.46, 64.15, 64.85, 64.89, 66.04, 67.29, 76.38, 76.51, 
76.54, 76.64, 82.17, 178.07, 178.94.  31P-NMR (202 MHz, MeOD-d4, δ, ppm): -0.50, -
0.72. 
 
• Crosslinking of P22 and P23 nanoparticles 
Shell-crosslinked nanoparticles were prepared from functional zwitteronics P22 and P23 
by thiol-yne coupling.  In 2 mL glass vials, aqueous suspensions containing Irgacure 2959, 
DTT, and alkyne-functionalized P22 or P23 were prepared at polymer concentration of 50 
or 100 mg/mL with [Irgacure 2959]0:[alkyne]0:[thiol]0 = 0.1:1:2.  The suspensions were 
degassed with bubbling nitrogen for 10 minutes and then irradiated at 365 nm (~3.5 
mW/cm2) in a UV box for 1 hour. 
 
• Preparation of nanoparticle-crosslinked hydrogels from P22 and P23 
Nanoparticle-crosslinked hydrogels were prepared from alkyne-containing zwitteronics by 
UV-initiated thiol-yne crosslinking.  Functional P22 or P23 were suspended in water at 
concentrations of 25, 50, or 100 mg/mL.  Tetrafunctional PEO thiol and Irgacure 2959 
were added at [Irgacure 2959]0:[alkyne]0:[thiol]0 = 0.1:1:1, and the suspensions were 
degassed with bubbling nitrogen for 10 minutes in 7 mL glass vials.  The degassed 
suspensions were irradiated at 365 nm (~3.5 mW/cm2) in a UV box for 1 hour. 
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• Rheology of nanoparticle-crosslinked hydrogels prepared from P22 and P23 
 Rheological characterization of functional zwitteronic nanoparticle-crosslinked 
hydrogels previously swelled in water for 18-24 hours and a Pluronic F127 thermogel was 
performed using a Malvern Kinexus stress-controlled rheometer operated in strain-
controlled oscillatory mode.  A 20 mm diameter stainless steel parallel plate fixture 
equipped with a solvent trap was utilized for rheological characterization of the Pluronic 
F127 thermogel.  Rheology of the 50 mg/mL P22 hydrogel was performed using a 50 mm 
2° cone-and-plate fixture.  P23 hydrogels and the 100 mg/mL P22 hydrogel were 
characterized using an 8 mm diameter stainless steel parallel plate.  For all gels, rheology 
was performed at 37°C, employing a frequency range of 1-100 rad/s. The strain amplitude 
used in the measurements was 0.1-1%, an amplitude range confirmed to be in the linear 
viscoelasticity region for all hydrogels using strain-sweep experiments; all frequency 
sweep measurements were thus performed under small amplitude oscillatory shear 
(SAOS). 
 For the Pluronic F127 thermogel, the 20 mm parallel plate fixture was mounted to 
the rheometer and allowed to equilibrate at 37°C. The gap was zeroed and then set to a 
value of 70 mm for sample loading. The Pluronic thermogel, previously prepared by 
heating a 200 mg/mL solution of Pluronic F127 in water at 37 °C, was transferred to the 
bottom plate of the rheometer using a stainless-steel spatula and taking care to prevent air 
bubble formation.  The reservoir around the plate was filled with Milli-Q water. This 
reservoir does not contact the sample but is enclosed with the sample under the solvent 
trap. The top plate was then lowered to a gap of 0.81 mm, and the sample was trimmed 
using a nylon edge and a razor blade. Once the sample was trimmed, the gap was lowered 
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to 0.80 mm and the solvent trap was put into place.  A similar procedure was used for the 
50 mg/mL P22 hydrogel, employing trimming and working gaps of 0.077 and 0.07 mm, 
respectively.  The system was then allowed to equilibrate at 37°C for approximately 5 
minutes before commencing rheological characterization.  For the 100 mg/mL P22 
hydrogel and the P23 hydrogels, the 8 mm parallel plate fixture was mounted to the 
rheometer and allowed to equilibrate at 37°C.  The gap was zeroed and then set to a value 
of 70 mm for sample loading.  After loading gels on the plate, the gap was adjusted 
gradually until the top plate made contact with the sample.  The top plate was lowered in 
0.1 mm increments until a normal force of 0.2-0.4 N was achieved; this protocol ensured 
that the top plate made homogenous contact with each hydrogel.  Two frequency sweeps 
were performed in series for each gel.  
 
• Synthesis of polyMPC by atom transfer radical polymerization (P24) 
 
 
PolyMPC P24 was prepared following a modified literature procedure.7  MPC (3.01 g, 10.2 
mmol) and EBiB (13.2 μL, 0.09 mmol) were dissolved in MeOH (6 mL) in a 2-neck, 25 
mL RB flask charged with a stir bar and the solution was degassed with nitrogen.  CuBr 
(13.2 mg, 0.09 mmol) and Bipy (28.0 mg, 0.18 mmol) were then added to the reaction 
vessel.  The resulting mixture was degassed with nitrogen and then was stirred at room 
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temperature for 16 hours.  The polymerization was quenched by exposure to ambient 
atmosphere, and residual copper was removed by the passing the solution through a plug 
of silica eluting with MeOH.  Polymer effluent was concentrated by rotary evaporation, 
and polymer was precipitated in THF.  Isolated polymer was dialyzed against water and 
lyophilized to give P24 as a white, granular solid in typical yields of 66-75%.  1H-NMR 
(500 MHz, MeOD-d4, δ, ppm): 0.64−1.15 (br, 3H), 1.67−2.13 (br, 2H), 3.27 (s, 9H), 3.71 
(br, 2H), 4.04 (br, 2H), 4.19 (br, 2H), 4.29 (br, 2H). 
 
• Synthesis of poly(MPC-co-hydrazine) (P25) 
 
Poly(MPC-co-hydrazine) random copolymer (P25) was synthesized as described 
previously and isolated in typical yields greater than 80%.8  Hydrazine content was 
estimated to be 22 mole percent using 1H-NMR spectroscopy by comparing signal 
intensities at 3.72 ppm (—CH2—N) (MPC) and 4.51 ppm (—CH2—CONHNH2).  1H-
NMR (500 MHz, MeOD-d4, δ, ppm): 0.70-1.20 (br, 3H), 1.70-2.30 (br, 2H), 3.28 (s, 9H), 
3.72 (br, 2H), 4.05 (br, 2H), 4.19 (br, 2H), 4.31 (br, 2H), 4.51 (br, 2H).  Mn, GPC = 25,000 
g/mole, PDI = 1.44. 
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• Synthesis of polyMPC-Dox prodrug (P26) 
PolyMPC-Dox (P26) was synthesized and purified as described previously.7,8  In an oven-
dried 25 ml RB flask charged with a stir bar, P25 (201.6 mg) and magnesium sulfate (204.6 
mg) were suspended in anhydrous MeOH (5 ml).  The suspension was acidified with glacial 
acetic acid (60 μL) and then DoxHCl (58.1 mg) was added.  The reaction vessel was 
sealed, and the red suspension was stirred under nitrogen, protected from the light, for 72 
hours.  The reaction mixture was passed through a column of Sephadex LH-20 size-
exclusion media eluting with MeOH to separate the conjugate from unreacted DoxHCl.  
The conjugate fraction was collected and concentrated by rotary evaporation.  Conjugate 
residue was then dissolved in minimal water (2-3 mL) and passed through a Sephadex G-
25 size-exclusion column eluting with pure water.  Prodrug fractions were combined and 
lyophilized to give P26 as a fluffy, red solid in yields over 84%. 
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• Synthesis of TMZ-carboxylic acid (TMZ-COOH) 
 
TMZ-carboxylic acid (TMZ-COOH) was prepared following a previously described 
procedure.10  In a round-bottom flask charged with a stir bar and fitted with an addition 
funnel, TMZ (2.29 g, 11.8 mmol) was dissolved in concentrated sulfuric acid (23.6 mL), 
and the resulting yellow solution was cooled to 0 °C under nitrogen atmosphere.  A solution 
of sodium nitrite (2.51 g, 36.4 mmol) in water (23.6 mL) was added dropwise over 45 
minutes, noting the evolution of a brown gas during the addition.  The mixture was allowed 
to warm to room temperature while protected from light.  After stirring for 17 hours, the 
mixture was cooled to 0 °C and quenched with ice (61 g).  Further stirring at 0 °C resulted 
in precipitation of a fine white solid, which was isolated by vacuum filtration, washed with 
cold water, and dried under vacuum to yield TMZ-COOH in 75% yield.  1H-NMR (500 
MHz, DMSO-d6, δ, ppm): 3.88 (s, 3H), 8.82 (s, 1H), 13.33 (br, 1H).  13C-NMR (125 MHz, 
DMSO-d6, δ, ppm): 36.32, 127.78, 129.09, 136.48, 139.10, 161.85.  HRMS-EI (m/z): [M]+ 
calculated for C6H5N5O3: 195.0392, found: 195.0395. 
 
• Synthesis of TMZ-methacrylate (TMZ-MA) 
In a round-bottom flask charged with a stir bar, TMZ-COOH (592.5 mg, 3.05 mmol) was 
suspended in DCM (20 mL).  HEMA (353 μL, 2.91 mmol) and catalytic DMAP (36.0 mg, 
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0.29 mmol) were added to the suspension, followed by EDC (674 mg, 3.51 mmol); the 
mixture became homogeneous and red.  After stirring under nitrogen at room temperature 
for 14 hours, the mixture was filtered, and the filtrate was diluted with DCM (30 mL) and 
washed with aqueous 0.1 M HCl (5 × 50 mL).  The organic layer was dried over sodium 
sulfate and concentrated by rotary evaporation.  The resulting white solid was dried under 
high vacuum, protected from light, to yield TMZ-MA in 71% yield.  1H-NMR (500 MHz, 
DMSO-d6, δ, ppm): 1.87 (s, 3H), 3.88 (s, 3H), 4.43 (t, J = 5Hz, 2H), 4.62 (t, J = 5Hz, 2H), 
5.68 (s, 1H), 6.04 (s, 1H), 8.85 (s, 1H).  13C (125 MH, DMSO-d6, δ, ppm): 17.93, 36.40, 
62.49, 62.51, 126.15, 126.20, 129.41, 135.60, 136.87, 138.93, 160.29, 166.41.  HRMS-
FAB (m/z): [M+H]+ calculated for C12H14N5O5: 308.0995, found: 308.0989. 
 
• General procedure for the synthesis of polyMPC-TMZ random copolymers (P27-
P30) 
MPC and TMZ-MA were dissolved in TFE at a total monomer concentration of 1 M in a 
20 mL vial charged with a stir bar.  ACVA and 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid were added as radical initiator (I) and chain-
transfer agent (CTA), respectively, targeting [monomer]0:[CTA]0:[I]0 of 102:1:0.2. The 
mixture was purged with nitrogen gas at 0 °C for 15 minutes, then stirred at 70 °C to initiate 
polymerization, judging monomer conversion by 1H-NMR spectroscopy.  At monomer 
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conversion >85%, the mixture was allowed to cool to room temperature then was quenched 
by exposure to air.  The crude reaction mixture was precipitated from TFE into THF (this 
was repeated three times) to remove unreacted monomer, and the polymer was isolated by 
centrifugation.  The isolated polymer was dissolved in aqueous 0.1 M HCl (10 mL), added 
to a centrifugal filter with a nominal molecular weight cutoff of 10 kDa, and centrifuged 
(4000 x g, 45 minutes, room temperature).  The filtrate was discarded and centrifugal 
dialysis was repeated twice.  The concentrated polymer was dissolved in aqueous 0.1 M 
HCl and lyophilization afforded polymers P27-P30 as pink solids.  Incorporation of TMZ-
MA into the copolymer structure was estimated by 1H-NMR spectroscopy by comparing 
relative signal intensities at 8.53 ppm (C—H in TMZ) and 2.86-3.29 ppm (N—(CH3)3 in 
MPC).  Copolymer yields were 60-74%.  1H-NMR (500 MHz, TFE-d3, δ, ppm): 0.12-1.14 
(br, 3H), 1.24-2.10 (br, 2H), 2.86-3.29 ppm (s, 9H), 3.60 (br, 2H), 3.92 (s, 3H), 4.01-4.26 
(br, 4H), 4.39 (br, 2H), 4.48-4.76 (br, 4H), 8.53 (s, 1H).  13C-NMR (125 MHz, TFE-d3, δ, 
ppm): 18.48, 20.22, 38.22, 46.59, 47.05, 55.94, 62.60, 64.46, 65.02, 65.91, 66.97, 68.04, 
128.44, 131.28, 138.79, 140.81, 162.60, 180.03.  31P-NMR (202 MHz, TFE-d3, δ, ppm): -
2.36. 
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• General procedure for the synthesis of a polyMPC macro-chain-transfer agent 
(macro-CTA) by RAFT (P31) 
 
In a 20 mL vial charged with a stir bar, MPC (3.9038 g, 13.2 mmol), 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid (74.3 mg, 0.27 mmol), and ACVA (15.6 mg, 
0.056 mmol) were dissolved in MeOH (13.2 mL).  The solution was degassed with 
bubbling nitrogen at 0 °C for approximately 20 minutes, and then was heated at 70 °C to 
initiate polymerization.  Upon achieving a monomer conversion <80%, as estimated by 1H-
NMR spectroscopy, the polymerization was terminated by exposure to air, and the solution 
was precipitated in THF.  The crude polymer was isolated by centrifugation (2000 rpm) 
and was dialyzed against water.  Lyophilization afforded P31 as a pink solid in yields 
>80%.  Mn of the polyMPC macro-CTA was estimated using 
1H-NMR spectroscopy by 
comparing signal intensities at 3.66-3.82 ppm (CH2—N) (PC methylene protons) to that of 
the terminal phenyl protons (7.40-7.96 ppm).  1H-NMR (500 MHz, MeOD-d4, δ, ppm): 
0.73-1.22 (br, 3H), 1.68-2.17 (br, 2H), 3.23-3.38 (s, 9H), 3.66-3.82 (br, 2H), 4.00-4.15 (br, 
2H), 4.15-4.29 (br, 2H), 4.29-4.41 (br, 2H), 7.40-7.95.  31P-NMR (202 MHz, MeOD-d4, δ, 
ppm): -0.45.  Mn, NMR = 15,100-19,800 g/mol, Mn, TFE GPC = 20,900-21,900 g/mol, PDI = 
1.05-1.13. 
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• General procedure for the synthesis of polyMPC-TMZ block copolymers (P32-
P34) 
In a 7 mL vial charged with a stir bar, polyMPC macro-CTA P31, TMZ-MA, and ACVA 
were dissolved in TFE ([TMZ-MA] = 0.25 M), targeting [ACVA]0:[P31]0: = 0.2:1 and 
[TMZ-MA]0:[P31]0 ranging from 17 to 37.  The mixture was purged with nitrogen gas at 
0 °C for 15 minutes, then stirred at 70 °C to initiate polymerization, judging monomer 
conversion by 1H-NMR spectroscopy.  At monomer conversion >90%, as judged using 1H-
NMR spectroscopy, the mixture was quenched in liquid nitrogen and was exposed to air.  
The crude reaction mixture was precipitated three times from TFE into THF, and the 
polymer was isolated by centrifugation.  The isolated polymer was dissolved in aqueous 
0.1 M HCl (10 mL), added to a centrifugal dialysis filter with a nominal molecular weight 
cutoff of 10 kDa, and centrifuged (4000 x g, 30 minutes, room temperature).  The filtrate 
was discarded and centrifugal dialysis was repeated twice.  The concentrated polymer was 
dissolved in aqueous 0.1 M HCl and lyophilization afforded polymers P32-P34 as pink 
solids in yields >50%.  Incorporation of TMZ-MA into the copolymer structure was 
estimated by 1H-NMR spectroscopy by comparing relative signal intensities at 8.72 ppm 
(C—H in TMZ) and 2.78-3.22 ppm (N—(CH3)3 in MPC).  1H-NMR (500 MHz, TFE-d3, 
δ, ppm): 0.00-1.07 (br, 6H), 1.25-2.13 (br, 4H), 2.78-3.22 ppm (s, 9H), 3.53 (br, 2H), 3.88 
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(s, 3H), 3.93-4.26 (br, 4H), 4.34 (br, 2H), 4.43-4.75 (br, 4H), 8.53 (s, 1H).  13C-NMR (125 
MHz, TFE-d3, δ, ppm): 18.47, 20.23, 38.51, 46.48, 46.95, 55.89, 62.81, 64.91, 65.94, 
67.36, 67.88, 126.34, 131.34, 138.27, 140.01, 161.35, 179.79, 180.62.  31P-NMR (202 
MHz, TFE-d3, δ, ppm): -2.79. 
 
• Synthesis of polyMPC-b-poly(butyl methacrylate) (polyMPC-BMA) (P35) 
A polyMPC-b-poly(butyl methacrylate) (polyMPC-BMA) copolymer (P35) was prepared 
by chain extension using polyMPC macro-CTA P31.  In a 7 mL vial charged with a stir 
bar, P31 (439.3 mg, 0.022 mmol), BMA (140 µL, 0.88 mmol), and ACVA (1.23 mg, 
0.0044 mmol) were dissolved in MeOH (1.76 mL).  The solution was purged with nitrogen 
gas at room temperature for approximately 15 minutes, and was heated at 70 °C to initiate 
polymerization.  After 18 hours, the solution was opened to ambient atmosphere and 
precipitated in THF (30 mL).  The crude polymer was isolated by centrifugation (3000 
rpm) and dialyzed against water.  Lyophilization afforded block copolymer P35 as a pink 
solid in 81% yield.  Incorporation of BMA into the copolymer structure was estimated by 
1H-NMR spectroscopy by comparing relative signal intensities at 1.37-1.74 ppm (CH2—
CH2 in BMA) and 3.66-3.84 ppm (N—CH2 in MPC).  1H-NMR (500 MHz, MeOD-d4, δ, 
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ppm): 0.73-1.21 (m, 7H), 1.37-1.74 (m, 4H), 1.74-2.20 (b, 2H), 3.32 (s, 9H), 3.76 (br, 2H), 
3.98 (br, 2H), 4.09 (br, 2H), 4.24 (br, 2H), 4.34 (br, 2H), 7.38-7.94.  31P-NMR (202 MHz, 
MeOD-d4, δ, ppm): -0.47.  Mn, TFE GPC = 29,400 g/mol, PDI = 1.16. 
 
• General procedure for the synthesis of fluorescent polyMPC-TMZ random 
copolymers (P36, P37) 
In a 7 mL vial charged with a stir bar, MPC and TMZ-MA were dissolved in TFE at a total 
monomer concentration of 0.75-1 M.  Fluorescein O-methacrylate, 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid (CTA), and ACVA were added to the solution, 
targeting [monomer]0:[fluorescein O-methacrylate]0:[CTA]0:[ACVA]0 of 102:1:1:0.2.  
The solution was degassed at 0 °C with nitrogen gas for approximately 15 minutes, and 
was heated at 70 °C, protected from light, to initiate polymerization.  Upon reaching 
monomer conversion >75% (estimated using 1H-NMR spectroscopy), the polymerization 
was quenched in liquid nitrogen and exposed to air.  The crude polymer was purified by 
precipitation from TFE into THF (6 times), isolated by centrifugation (2000 rpm), and dried 
under vacuum.  The polymer pellet was purified by centrifugal dialysis against 0.1 M HCl 
(aq) as described previously for polyMPC-TMZ copolymers P27-P30.  Fluorescein-
containing polymers P36 and P37 were isolated by lyophilization (protected from light) 
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and isolated as yellow and red solids, respectively, in yields of 55-59%.  Incorporation of 
TMZ-MA into the copolymer structure was estimated by 1H-NMR spectroscopy by 
comparing relative signal intensities at 8.58 ppm (C—H in TMZ) and 2.87-3.35 ppm (N—
(CH3)3 in MPC).  Fluorescein incorporation was estimated by fluorescence spectroscopy: 
P36 = 0.067 weight percent; P37 = 0.068 weight percent.  P36: Mn, TFE GPC = 37,300 g/mol, 
PDI = 1.19.  P37: Mn, TFE GPC = 37,000 g/mol, PDI = 1.20. 
 
• Synthesis of fluorescent polyMPC (P38) 
 
In a 7 mL vial charged with a stir bar, MPC (993.2 mg, 3.36 mmol), fluorescein O-
methacrylate (14.0 mg, 0.035 mmol), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid 
(18.7 mg, 0.067 mmol), and ACVA (3.6 mg, 0.013 mmol) were dissolved in TFE (4.46 
mL).  The solution was purged at room temperature with nitrogen gas, and was heated at 
70 °C, protected from light, to initiate polymerization.  A monomer conversion of 67% was 
achieved in 5.5 hours, and the polymerization solution was quenched in liquid nitrogen and 
was exposed to air.  The crude polymer was repeatedly precipitated into THF to remove 
unreacted monomer, and was isolated by centrifugation.  The polymer was dialyzed against 
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water, protected from the light, and isolated by lyophilization.  Fluorescent P38 was 
isolated as a light-yellow solid in 38% yield.  Mn of the polyMPC macro-CTA was 
estimated using 1H-NMR spectroscopy by comparing signal intensities at 3.64-3.84 ppm 
(CH2—N) (PC methylene protons) to that of the terminal phenyl protons (7.41-7.96 ppm).  
Fluorescein incorporation was estimated by fluorescence spectroscopy: P38 = 0.32 weight 
percent.  1H-NMR (500 MHz, MeOD-d4, δ, ppm): 0.65-1.62 (br, 3H), 1.66-2.20 (br, 2H), 
3.79-3.39 (s, 9H), 3.64-3.84 (br, 2H), 3.99-4.16 (br, 2H), 4.16-4.29 (br, 2H), 4.29-4.42 (br, 
2H), 7.41-7.96.  31P-NMR (202 MHz, MeOD-d4, δ, ppm): -0.47 ppm.  Mn, NMR = 24,500 
g/mol, Mn, TFE GPC = 21,000, PDI = 1.13. 
 
• General procedure for the synthesis of fluorescent polyMPC-TMZ block 
copolymers (P39, P40) 
 
In a 7 mL vial charged with a stir bar, fluorescent polyMPC macro-CTA P38, TMZ-MA, 
and ACVA were dissolved in TFE ([TMZ-MA] = 0.25 M), targeting [ACVA]0:[P38]0: = 
0.2:1 and [TMZ-MA]0:[P31]0 of 18 (P39) or 49 (P40).  The mixture was purged with 
nitrogen gas at 0 °C for 15 minutes, then stirred at 70 °C, protected from the light, to initiate 
polymerization.  At monomer conversion >85%, judged using 1H-NMR spectroscopy, the 
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mixture was quenched in liquid nitrogen and was exposed to air.  The crude polymers were 
then purified in similar fashion as block copolymers P32-P34.  Lyophilization afforded 
polymers P39 and P40 in yields of 45-66%.  Incorporation of TMZ-MA into the 
copolymer structure was estimated by 1H-NMR spectroscopy by comparing relative signal 
intensities at 8.64 ppm (C—H in TMZ) and 2.88-3.49 ppm (N—(CH3)3 in MPC).  
Fluorescein incorporation was estimated by fluorescence spectroscopy: P39 = 0.032 
weight percent; P40 = 0.021 weight percent.  1H-NMR (500 MHz, TFE-d3, δ, ppm): -0.33-
1.58 (br, 6H), 1.61-2.30 (br, 4H), 2.88-3.49 ppm (s, 9H), 3.62 (br, 2H), 3.95 (s, 3H), 4.05-
4.34 (br, 4H), 4.42 (br, 2H), 4.53-4.82 (br, 4H), 8.64 (s, 1H).  31P-NMR (202 MHz, TFE-
d3, δ, ppm): -2.61. 
 
• Critical micelle concentration (CMC) measurements of P7-P11 
Polymer solutions of varying concentrations were prepared in water with a total volume of 
1 mL.  5 µL of a stock solution of pyrene in acetone ([pyrene] = 1.2 x 10-4 M) was then 
added to each polymer solution (final [pyrene] = 6.0 x 10-7 M).  Solutions were incubated 
for approximately 18 hours at room temperature.  Excitation spectra were recorded from 
300 to 360 nm, at a scan rate of 100 nm/s, with emission set to 394 nm.  CMC values were 
determined by plotting that ratio of fluorescence intensities at 339 nm and 334 nm as a 
function of the log of the polymer concentration. 
 
• Critical aggregation concentration (CAC) measurements of P16-P20 
CAC values for PC-zwitteronics were estimated using a pyrene fluorescence assay.6  A 
pyrene solution (10 µL) with a concentration of 120 µM was added to serial dilutions of 
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block copolymers P16-P20 with concentrations ranging from 5 x 10-3 to 10 mg/mL and 
volumes of 2 mL.  The resulting suspensions, with a pyrene concentration of ~0.6 µM, 
were incubated at room temperature for 16-18 hours protected from light.  Using an 
excitation wavelength of 336 nm and a scanning rate of 600 nm/min, pyrene fluorescence 
emission spectra were recorded from 350-420 nm.  CAC values were determined by 
plotting the ratio of fluorescence intensities for the first (I1, λem ~ 374 nm) and third (I3, λem 
~ 385 nm) vibronic bands as a function of the log of the polymer concentration. 
 
• CAC measurements of P30 and P32-P34 
CAC values for polyMPC-TMZ copolymers were estimated using DLS.11  Polymer 
suspensions with concentrations of 0.001-5 mg/mL were prepared in pH 7.4 PBS and 
passed through 0.45 µm cellulose acetate membranes into disposable cuvettes.  The 
suspensions were analyzed by DLS at 37 °C using a fixed laser attenuator and position of 
9 and 3.00 mm, respectively.  Three measurements were made for each suspension, with 
each measurement consisting of 10 runs.  CAC values were estimated by plotting scattering 
intensity as a function of polymer concentration. 
 
• Pendant drop IFT measurements of zwitterionic polysiloxanes P7-P11 
1 mg/mL solutions of zwitterionic siloxane polymers in water were prepared and added to 
glass cuvettes.  For each polymer, a TCB droplet was dispensed into the solution using a 
syringe pump and the TCB droplet shape was recorded as a function of time.  Interfacial 
tension was measured every 60 seconds for 1,800 seconds, and equilibrium surface 
tensions (γeq) were obtained by averaging the values from 1,500 to 1,800 seconds. 
  159 
• Surface tensiometry of PC-zwitteronics P16-P20 
Equilibrium room temperature surface tension values (γeq) were measured for polymer 
suspensions prepared in Milli-Q® ultrapure water (18.2 MΩ • cm) at concentrations of 0.1-
10 mg/mL.  Suspensions of the PPO starting material and P16-P20 were cooled in an 
ice/water/sodium chloride bath prior to surface tension measurements to ensure complete 
polymer dispersion.  The polymer suspensions (~350 µL) were added to clean glass 
troughs, and changes in surface tension (γ) were measured using a metal probe (diameter 
= 0.51 mm) inserted into each suspension.  For each suspension, γ was allowed to 
equilibrate for at least 10 minutes and values were recorded every second.  Reported values 
of γeq are the average of γ values over the final five minutes of each experiment. 
 
• DLS of zwitterionic polysiloxanes P7-P11 
1 mg/mL aqueous solutions of the zwitterionic polysiloxanes were filtered through 0.45 
µm cellulose acetate membranes into clean, disposable cuvettes.  DLS measurements were 
performed at 20 °C with an equilibration time of 1 minute.  Solutions were measured three 
times, with each measurement consisting of 10 runs. 
 
• DLS of PC-zwitteronic block copolymers 
Zwitteronic block copolymer suspensions with concentrations of 1 mg/mL were cooled 
below their LCST in an ice/water/sodium chloride bath for 5 minutes to ensure complete 
polymer dispersion, and the cooled suspensions were quickly filtered through 0.45 µm 
membranes previously cooled at -20 °C into disposable cuvettes.  Hydrodynamic diameters 
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were then estimated by DLS at 25 °C; three measurements consisting of 10 runs were 
performed for each suspension. 
 
• DLS of polyMPC 24 and polyMPC-Dox P26 
2 mg/ml solutions of P24 and P26 in pH 7.4 PBS were filtered through 0.45 μm cellulose 
acetate membranes into disposable cuvettes.  These solutions were then analyzed by DLS 
at 25 °C, with an equilibration time of 1 minute.  The suspensions were measured three 
times, with each measurement consisting of 10 runs. 
 
• DLS of polyMPC-TMZ copolymers P27-P30 and P32-P34 
1 mg/mL suspensions of polyMPC-TMZ copolymers P27-P30 and P32-P34 were prepared 
in pH 7.4 PBS.  The suspensions were passed through 0.45 µm cellulose acetate filters into 
disposable cuvettes, and analyzed by DLS at 37 °C.  Three measurements were made for 
each suspension, with measurements consisting of 10 runs each. 
 
• Lower critical solution temperature measurements for PC-zwitteronics P16-P20 
The LCST miscibility of PC-zwitteronic (P16-P20) suspensions was probed by measuring 
changes in turbidity as a function of temperature.  Polymer suspensions with a 
concentration of 10 mg/mL were cooled in an ice/water/sodium chloride bath to ensure 
polymer dispersion and were added to glass cuvettes in a temperature-controlled holder.  
The suspensions were then cooled from 20 °C to -10 °C at a rate of 1 °C/min under a light 
nitrogen flow, and transmission at λ = 550 nm was recorded.  LCST values are reported as 
the onset of increasing transmittance. 
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• TEM of zwitterionic polysiloxanes 
Structures formed by the aqueous assembly of PC-containing siloxane block copolymers 
were visualized by TEM.  Block copolymer solutions in pure water (at > CMC) were 
dropcast onto 400 square mesh carbon-coated copper grids, and allowed to dry under 
ambient conditions. 
 
• TEM of crosslinked, functional zwitteronic nanoparticles 
Aqueous suspensions of crosslinked P22 and P23 nanoparticles, with concentrations of 1 
mg/mL, were dropcast onto PELCO® carbon-coated 300 mesh copper grids.  Excess 
suspension was wicked away with filter paper, and the resulting films were allowed to dry 
overnight under ambient conditions. 
 
• Cryo-TEM of polyMPC-TMZ block copolymer P34 
Nanoparticles formed from polyMPC-TMZ block copolymer P34 were visualized using 
cryo-TEM.  A suspension of P34 was prepared in pure water with a concentration of 1 
mg/mL and was filtered through a 0.45 µm cellulose acetate filter.  The suspension was 
cast onto a carbon-coated 400 mesh copper grid and blotted six times in a humidity 
controlled environment (~90% humidity) to remove excess suspension.  The grid was 
plunged into liquid ethane and the vitrified P34 nanoparticles were visualized at -180 °C 
using a liquid nitrogen cryo-transfer holder. 
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• Measurement of Dox loading in polyMPC-Dox P26 
Dox loading in P26 was determined using UV-Vis spectroscopy.  Absorbances of aqueous 
solutions of DoxHCl (0.01 mg/ml) and P26 (0.1 mg/ml) were measured at 480 nm.  Using 
the molar absorptivity of DoxHCl in water, Dox concentration in the polymer prodrug 
was calculated using Beer-Lambert analysis. 
 
• Cell culture of SKOV-3 cells 
Human ovarian adenocarcinoma SKOV-3 cells were maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 100U/mL penicillin, and 100μg/mL 
streptomycin at 37oC under 5% CO2. 
 
• Maximum tolerated dose of polyMPC P24 and polyMPC-Dox P26 
 
The maximum tolerated dose (MTD) is the greatest amount of drug that can be tolerated 
without evidence of toxicity.  The MTD of the polymer carrier, P24, and the polymer-Dox 
conjugate, P26, were evaluated in 7-week-old NOD SCID mice.  For polymer P24, three 
mice per treatment group were administered two lateral tail vein injections, at Day 0 and 
17, of polymer solutions in HBSS at doses of 50, 100, 200, 400 or 800 mg/kg.  Solutions 
of P26 in HBSS at Dox equivalent doses of 10, 20, 30, 40 or 50 mg/kg (3 mice per group) 
was administered via a single lateral tail vein injection.  Weight, appearance and behavior 
of the mice were monitored daily for a total of 35 days.  Symptoms of toxicity were defined 
as weight loss greater than 15% or evidence of distress in appearance or behavior; animals 
exhibiting these criteria were euthanized prior to the end of the study.  At the completion 
of the study, the remaining mice were euthanized.  Necropsy was then performed to collect 
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tissues for histologic evaluation, following which paraffin embedded tissue samples were 
stained with hematoxylin and eosin (H&E). 
 
• Biodistribution of polyMPC-Dox P26 
 
The uptake and accumulation of Dox within tumor tissue and off-target organs was 
evaluated in four-week-old NOD SCID mice for free Dox and prodrug P26.  SKOV-3 
ovarian human adenocarcinoma subcutaneous xenografts were established following 
injection of 1x107 cells in the right flanks of nine mice.  Following tumor establishment 
and growth to a volume of 100-500mm3 (calculated by length × width2 ⁄ 2), mice were 
administered HBSS (control), prodrug P26 (6 mg/kg Dox equivalent), or free Dox (6 
mg/kg) by lateral tail vein injection (3 mice per group).  Three days after the injections, the 
mice were euthanized and organs (liver, kidneys, spleen, heart, lungs) and tumor were 
resected, weighed, and then flash frozen in liquid nitrogen.  All tissues were stored at -
80°C prior to analysis. 
 Dox accumulation in the resected tissues was assessed by HPLC.  Tumor and 
organs were homogenized in a 3 mL solution of acidified isopropanol (90% isopropanol + 
75 mM HCl) using a BioSpec Tissue Tearor set at maximum speed.  The homogenized 
suspensions were incubated at 4°C for approximately 24 hours and then were centrifuged 
at 1,500 x g for 15 minutes.  50 μL of each isolated supernatant was evaporated overnight 
under a stream of nitrogen and the residue was resuspended in 50 μL of HPLC mobile 
phase (40/60 acetonitrile/water + 1% trifluoroacetic acid).  The suspensions were 
centrifuged at 12,000 rpm for 30 minutes at room temperature to precipitate residual 
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organic matter and the supernatants were analyzed by HPLC to determine Dox 
concentration. 
 
• Tumor Efficacy of polyMPC-Dox P26 
The therapeutic efficacy of prodrug P26 was evaluated using a human ovarian tumor model 
in NOD SCID mice.  Human ovarian tumors were established by injecting 1x107 SKOV-3 
cells subcutaneously in the right flanks of 24 four-week-old NOD SCID mice.  Mice 
identified to have intramuscular tumors were excluded from analysis. Once tumors reached 
a volume of 250-500 mm3, the mice were randomly divided into three groups (7-8 mice 
per group) and treated either with HBSS (control), half of the established MTD of free Dox 
(2 mg/kg),9 or half of the experimentally determined Dox equivalent MTD of P26 (5 
mg/kg).  Mice were treated via lateral tail vein injections every 7-8 days.  Treatment was 
withheld if the animals exhibited significant weight loss approaching 20% or excessive 
injection site scarring prohibited further injections.  The animals were evaluated every 24-
48 hours for overall health, tumor volume and weight.  Mice were removed from the study 
and euthanized if they experienced weight loss greater than 20%, exhibited signs of distress 
or if tumor volume exceeded 1,500 mm3.  At time of euthanasia, necropsy was performed 
and tumors and organs (liver, kidneys, spleen, heart and lungs) were collected for histologic 
evaluation, following which paraffin embedded tissue samples were stained with H&E. 
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• Statistical analysis of the in vivo evaluations of polyMPC-Dox P26 
Statistical analysis was performed using GraphPad Prism Software (Prism, GraphPad 
Software, Inc., San Diego, CA).  For the biodistribution study of, an unpaired T-test was 
used to compare Dox accumulation in the organs and tumors of mice treated with free Dox 
and polyMPC-Dox P26.  For the tumor efficacy study, log-rank comparison (Mantel-Cox 
test) was first employed to compare survival curves of the three treatment groups, 
following which, pairwise comparisons between treatment groups were performed.  Given 
the small sample sizes of the biodistribution and efficacy studies, α ≤ 0.10 was utilized as 
the threshold for statistical significance. 
 
• Measuring the solution stability of TMZ and polyMPC-TMZ copolymers P27-P30 
and P32-P34 
The stability of TMZ and polyMPC-TMZ copolymers was evaluated at physiological 
conditions using UV-Vis spectroscopy.  Solutions of TMZ and polyMPC-TMZ 
copolymers P27-P30 and P32-P34 were prepared in pH 7.4 PBS at a concentration of 1 
mg/mL.  The solutions were diluted to an approximate TMZ-equivalent concentration of 
0.013 mg/mL and transferred to quartz cuvettes charged with stir bars.  Solutions were 
incubated at 37 °C while stirring at 500 rpm in the UV-Vis spectrometer, and absorbance 
spectra (λ = 200-450 nm) were collected over a total of 6, 23, and 33 hours for TMZ, P27-
P30, and P32-P34, respectively.  The decrease in absorbance intensity at λ = 328-330 nm, 
corresponding to the urea of intact TMZ, was measured, and exponential decay curves were 
generated from plotting the normalized absorbance (A/A0).  Fitting these curves gave the 
decay constant, which was used to determine the t1/2 of free TMZ and polyMPC-TMZ 
copolymers. 
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• Cell culture of U87MG and T98G cells 
U87MG and T98G glioblastoma cells were cultured in DMEM supplemented with 10% 
FBS and 1x antibiotic-antimycotic solution at 37 °C under 5% CO2.  
 
• Cellular uptake of fluorescent polyMPC-TMZ copolymers P36, P37, P39, and P40 
in U87MG glioblastoma cells 
 
Cellular internalization of polyMPC-TMZ copolymers was evaluated in U87MG 
glioblastoma cells using confocal microscopy.  U87MG cells were plated on 35 mm dishes 
with glass microwells and incubate overnight.  The cells were then incubated at 37 °C with 
solutions of fluorescent polyMPC-TMZ copolymers (P36, P37, P39, P40) in DMEM 
containing 10% FBS at a 200 µM TMZ-equivalent concentration.  Cells were also treated 
with a 0.35 mg/mL solution of fluorescent polyMPC P38 in DMEM containing 10% FBS.  
After 3 hours, the cells were washed three times with pH 7.4 PBS and treated with 50 mM 
of Lysotracker® Red for 10 minutes to stain lysosomes.  The cells were washed three times 
with PBS, fixed with paraformaldehyde (4% in pH 7.4 PBS) for 15 minutes, washed three 
times with PBS, and treated with aqueous DAPI to stain nuclei.  The cells were visualized 
by fluorescence confocal microscopy using the following excitation and emission 
wavelengths: λex = 405 nm, λem = 450 nm (DAPI); λex = 488 nm, λem = 525 nm 
(fluorescein); λex = 561 nm, λem = 595 nm (Lysotracker® Red). 
 
• Flow cytometry 
Cellular internalization of polyMPC-TMZ copolymers by U87MG glioblastoma cells was 
quantified using confocal microscopy.  U87MG cells were grown in T-25 tissue culture 
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flasks and treated with solutions of fluorescein-labeled polyMPC-TMZ (P36, P37, P39, 
P40) at TMZ-equivalent doses of 200 µM in DMEM containing 10% FBS, or a 0.35 
mg/mL solution of polyMPC P38 in DMEM containing 10% FBS.  Cells were incubated 
for 2 hours at 37 °C, then trypsinised and washed with PBS.  Fluorescein fluorescence was 
then measured by flow cytometry. 
 
• In vitro cytotoxicity of polyMPC-TMZ copolymers P27-P30 and P32-P34 
The in vitro cytotoxicity of polyMPC-TMZ copolymers was evaluated in TMZ-sensitive 
U87MG and TMZ-resistant T98G glioblastoma cells.  Cytotoxicity assays were performed 
by seeding and incubating approximately 1-2 x 103 cells in 96-well plates overnight.  The 
cells were then incubated with solutions of TMZ (diluated from DMSO into a mixture of 
DMEM supplemented with 10% FBS) or polyMPC-TMZ copolymers in DMEM 
containing 10% FBS, respectively, at TMZ-equivalent concentrations ranging from 1 to 
20,000 µM.  As controls, cells were treated with a 25.9 mg/mL solution of polyMPC in 
DMEM containing 10% FBS.  For cytoxicity experiments utilizing O6-BG, O6-BG was 
added to cells from a concentrated DMSO stock solution.  After 6 days, cell viability was 
measured using a CellTiter-Glo® luminescence assay following manufacturer instructions.  
Luminescence was measured on a FLUOstar OPTIMA plate reader, and cell viability was 
calculated relative to untreated cells.  Dose response curves and IC50 values were calculated 
using GraphPad Prism 7 software. 
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